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ABSTRACT 
 
Accumulated molecular and clinical evidence indicate that human immune cells can 
support replication of hepatitis C virus (HCV).  The aim of this study was to investigate 
the ability of authentic, plasma-occurring HCV to infect human CD4+ and CD8+ T 
lymphocytes in vitro.  For this purpose, we adopted the previously established in vitro 
HCV replication system in total T cells derived from cultured normal human PBMC by 
employing affinity-purified CD4+ and CD8+ T lymphocytes as targets.  Using this system, 
we were able to demonstrate that molecularly intact HCV can infect and productively 
replicate in both CD4+ and CD8+ T lymphocytes, albeit at low levels, by documenting: 
(1) Presence of HCV positive and replicative (negative) strands in infected cells; (2) 
Intracytoplasmic localization of viral proteins; (3) Emergence of new HCV variants in the 
de novo infected cells, and (4) Release of HCV RNA-reactive particles from the infected 
cells with biophysical properties distinct from those of virions in inocula used to infect 
these cells. 
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CHAPTER ONE: INTRODUCTION 
1.1 Viral Hepatitis 
Hepatitis, coined from the ancient Greek word hepar (ἧπαρ), meaning liver and 
the suffix –itis, indicating inflammation, is an inflammatory liver disease characterized by 
hepatocyte injury, including necrosis, associated with lymphomononuclear cell 
infiltration. 
Viral infection is the most common cause of hepatitis. There are six viruses 
(hepatitis A through G viruses) capable of causing hepatitis.  Hepatitis A virus (HAV) is a 
small, non-enveloped, single-stranded RNA virus, member of the Picornaviridae family.  
HAV is transmitted by the faecal-oral route and, in most cases, causes acute, self-limiting 
infection.  An HAV vaccine has been available since 1992 and it is capable of conferring 
life-long protection (Orli and Arguedas, 2006). 
Hepatitis B virus (HBV) is a partially double-stranded DNA virus of the 
Hepadnaviridae family, which is carried in the blood and other bodily fluids (i.e., saliva, 
tears, semen, vaginal secretions) of the infected individuals.  Therefore, it can be 
transmitted via sexual intercourse, the parenteral route, or from the infected mother to the 
baby.  Acute hepatitis B (AHB) can progress to chronic hepatitis B (CHB) which, in up to 
10% of individuals infected during adulthood, can lead to life-threatening liver cirrhosis, 
hepatic decompensation, and hepatocellular carcinoma (HCC) (Ganem and Prince, 2004).  
HBV may also persist as occult, asymptomatic infection which is the consequence of 
resolved AHB or primary infection with very low virus doses (Michalak et al., 1994; 
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Michalak et al., 2004; Mulrooney-Cousins and Michalak, 2007).  More than 780,000 
individuals die every year due to the acute fulminant or chronic consequences of HBV 
infection (World Health Organization [WHO], 2014).  An effective vaccine against HBV 
has been available almost for thirty years; however, the present estimated global vaccine 
coverage is 69% (Zanetti et al., 2008).  Notably, an estimated 4.5 million individuals are 
infected every year worldwide (Goldstein et al., 2005). 
Hepatitis D virus (HDV) is a small, single-stranded, negative sense RNA virus of 
the genus Deltavirus, which has not yet been classified to a family.  HDV is a subviral 
RNA satellite virus that depends on HBV envelope for infection, virion assembly and 
transmission (Polish et al., 1993).  Therefore, it has a similar transmission route as HBV.  
HDV can be acquired as either a coinfection with HBV or superinfection of HBV-
infected individuals.  Vaccination against HBV also confers protection against HDV. 
Hepatitis E virus (HEV) is a small, non-enveloped, single-stranded RNA virus, 
member of the Hepeviridae family.  HEV is usually transmitted via the faecal-oral route. 
Acute HEV infection is a self-limited disease with a case-fatality rate lower than 0.1%.  
In pregnant women, HEV infection is more life threatening as it leads to fulminant 
hepatic failure and death in 15% to 20% of cases (Patra et al., 2007).  The first HEV 
vaccine, HEV 239 (Zhu et al., 2010) was approved in China in January 2012, but cost and 
its long term efficacy remain a concern. 
Hepatitis G virus (HGV), currently referred to as GB virus C (GBV-C), is an 
enveloped, single-stranded, positive RNA virus, member of the Flaviviridae family and 
the Pegivirus genus.  HGV is most commonly transmitted via the parenteral route and 
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generally causes a mild, self-limited infection.  HGV is primarily lymphotropic (Handa 
and Brown, 2000) and it is the human virus most closely related to hepatitis C virus 
(HCV), which is the virus studied in this thesis. 
 
1.2 HCV Infection 
1.2.1 Epidemiology  
 The global prevalence of HCV is not well known due to frequently asymptomatic 
nature of acute infection.  It is estimated by WHO that there are currently 130-150 million 
chronically infected individuals (WHO, 2014).  These individuals have a high risk of 
developing liver cirrhosis and HCC. 
Even though HCV is endemic worldwide, there is a great geographic variability in 
its distribution.  The lowest HCV prevalence is reported in industrialized nations in 
Western Europe, North America and Australia, whereas the highest prevalence is 
observed in countries located in Asia and Africa (Shepard et al., 2005) with Egypt having 
the highest reported seroprevalence rate of 22% (Frank et al., 2000).  This large reservoir 
of chronic HCV infection is believed to have been established during nationwide 
schistosomiasis parenteral treatment campaigns (Frank et al., 2000).  The second highest 
seroprevalence rate is reported in Pakistan, where it ranges between 2.4% and 6.5% of the 
population, and it is followed by China with a seroprevalence rate of 3.2% (Shepard et 
al., 2005).  In Canada, it is estimated that around 250,000 persons are chronically infected 
with HCV, with a prevalence rate of 0.78%, and at least 50,000 of them remain 
undiagnosed (Remis, 2007). 
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HCV is classified into six major genotypes (designated as 1-6), and more than 100 
subtypes (designated as a, b, c, etc.), on the basis of genomic sequence heterogeneity 
(Simmonds et al., 1993).  HCV genotypes are known to have unique patterns of 
geographical distribution.  In particular, genotype 1a is distributed widely in North 
America and Europe, genotype 3a is found commonly in Europe, while genotype 1b is the 
commonest worldwide and it is responsible for up to 73% of HCV cases in Japan (Takada 
et al., 1993; Simmonds, 2004).  Genotype 2 is mostly detected in Mediterranean 
countries, Western Africa and Far East (Mellor et al., 1995; Simmonds et al., 2004).  
Genotype 3 is endemic in South-East Asia, but is also distributed throughout India, the 
Far East and Australia (Tokita et al., 1994a, 1994b, 1995; Mellor et al., 1995; Simmonds, 
2004).  Genotype 4 is most widely distributed in Middle East and Africa, particularly 
Egypt, where it accounts for more than 90% of infections (Ramia and Eid-Fares, 2006).  
Infections caused by genotype 5 are common in South Africa (Cha et al., 1992).  Finally, 
genotype 6 is mainly distributed in South-East Asia and Australia (Simmonds, 2004).  
Determining HCV genotypes is of great clinical significance, as they play a role in 
disease pathology and response to treatment (see Sections 1.6.3. and 1.11.). 
 
1.2.2 Transmission Routes and Risk Factors 
HCV is most commonly transmitted parenterally (Conry-Cantilena et al., 1996).  
The primary risk factor for HCV transmission in the developed world is intravenous drug 
use (IDU).  In USA and Australia, 68% and 80% of current HCV infections, respectively, 
are caused by IDU (Alter, 2002; Dore et al., 2003).  IDU has been identified as the major 
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risk factor in several European countries as well (Elghouzzi et al., 2000; Dalgard et al., 
2003; Balogun et al., 2003).  The role of IDU in HCV transmission in developing 
countries remains unclear due to the very limited availability of relevant data, however, 
unsafe therapeutic injection practices constitute a major risk factor for HCV infection in 
these countries (Frank et al., 2000).  This is not the case for the developed world, with the 
exception of isolated outbreaks occurring mostly in nonhospital health care settings 
(Thompson et al., 2009; Fischer et al., 2010).  In these settings the presumed mechanism 
of infection is patient-to-patient transmission due to negligence of health care personnel 
to comply with basic principles of aseptic technique and infection control (e.g. syringe 
reuse).  
Another high risk factor for HCV infection, mostly in developing countries, is 
blood transfusion.  WHO’s Global Database on Blood Safety (GDBS) has estimated that 
47% of blood donations in low-income countries are not screened for transfusion-
transmissible infections (TTIs), including HCV (GDBS summary report, 2011).  In 
developed countries, blood transfusion was a high risk factor before 1992 when HCV 
screening of blood donations was introduced.  Since then, the risk of TTIs has been 
decreased so dramatically that classic methods of measurement of transfusion risk are no 
longer able to determine risk or identify transfusion-associated transmission events 
(Busch et al., 2003). 
HCV can also be transmitted via sexual contact (Alter et al., 1989), but far less 
efficiently than other sexually transmitted viruses, including HBV and human 
immunodeficiency virus type 1 (HIV).  More specifically, among people in long-term, 
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monogamous relationships, the risk of HCV acquisition ranges between 0-0.6% per year 
(Terrault, 2002) as determined by standard HCV RNA detection assays.  Regarding HCV 
vertical transmission, the rate ranges between 4-7% for pregnant women with high level 
of viremia (Ohto et al., 1994; Roberts and Yeung, 2002).  In the setting of HIV co-
infection, the rate of vertical transmission increases by 4 to 5-fold (Zanetti et al., 1995).  
Other risk factors for HCV transmission include accidental sticks with contaminated 
needles, hemophilia, hemodialysis, organ transplants conducted before 1992, intranasal 
cocaine use, body piercing, and tattoos (Villena, 2006). 
 
1.3 Flaviviridae Family 
 The Flaviviridae family of viruses is subdivided into the flavivirus, hepacivirus, 
pegivirus and pestivirus genera.  The Flaviviridae family was named after the yellow 
fever virus (flavus in Latin means yellow).  Viruses belonging to the Flaviviridae family 
are spherical with a diameter of 40-60 nm.  They contain a single, positive-strand RNA 
genome which is enclosed within a nucleocapsid contained in a host-cell derived lipid 
envelope (Petersen and Roehrig, 2001).  Their genome ranges between 9.5-12 Kilobases 
(Kb) in length, lacks both a 5’-cap structure and a 3’-poly-A tail, and it is flanked by 3’- 
and 5’-untranslated regions (UTR).  Following infection, the genome is translated into a 
large polyprotein which is modified and cleaved to generate 10 proteins (3 structural and 
7 nonstructural), common to all the flaviruses (Lindenbach et al., 2007).  The flaviruses 
are associated with great global health and economic burdens.  Other members of the 
Flavivirus genus include Dengue virus, Japanese encephalitis virus (JEV), Murray Valley 
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encephalitis virus (MVEV), St. Louis encephalitis virus (SLEV), West Nile virus (WNV) 
and yellow fever virus.  The Pestivirus genus includes bovine viral diarrhea virus 1 and 2, 
border disease virus, and classical swine fever virus.  HGV is a member of the Pegivirus 
genus which includes but is not limited to human hepegivirus-1 (HHpgV-1), simian 
pegivirus (SPgV), and equine pegivirus (EPgV).  HCV is a member of the Hepacivirus 
genus which also includes canine hepacivirus (CHV), equine hepacivirus (EHV), GB 
virus B (GBV-B), guereza hepacivirus (GHV), and Rodent hepacivirus (RHV). 
 
1.4 Hepatitis C Virus 
1.4.1 Genome Organization 
The HCV genome consists of a 9.6-Kb single-stranded, positive-sense RNA composed of 
a 5’-UTR, a long open reading frame (ORF), and a 3’-UTR (Figure 1.1) (Choo et al., 
1989).  The 341 nucleotide (nt)-long HCV 5’-UTR contains an internal ribosomal entry 
site (IRES) (Brown et al, 1992; Tsukiyama-Kohara et al., 1992), which is indispensable 
for cap-independent translation of HCV RNA (Honda et al., 1999) and is comprised of 
four highly structured domains (domains I-IV) (Brown et al., 1992).  Apart from playing 
an important role in viral protein translation, the HCV 5’-UTR also contains cis elements 
critical for HCV RNA replication (Friebe et al., 2001).  Furthermore, it has been found 
that the HCV 5’-UTR can bind to microRNA-122 (miR-122), leading in enhanced viral 
RNA translation and accumulation within infected hepatocyte-like Huh7 cells (Jopling et 
al., 2005; Wilson et al., 2011).  The long ORF is translated directly to a large polyprotein 
precursor of about 3,000 residues (Choo et al., 1991), which is co- and post-
 8 
 
translationally processed by viral and cellular proteases to produce 10 structural and 
nonstructural (NS) proteins.  The structural proteins include: core, envelope 1 (E1) and 
envelope 2 (E2), while the NS proteins are: NS2, NS3, NS4A, NS4B, NS5A and NS5B, 
and the peptide p7 which is not yet assigned to either category (Figure 1.1) 
(Bartenschlanger et al., 2004; Penin et al., 2004).  The 200-235 nt-long HCV 3’-UTR 
contains a short variable region, a poly(U/UC) sequence, and a practically invariable nt 
sequence, named the X-tail or 3’X region (Kolykhalov et al., 1996).  The X-tail together 
with part of the poly(U/UC) tract are essential for RNA replication, while the remainder 
of the 3’-UTR contributes to enhancement of replication (Friebe and Bartenschlager, 
2002; Yi and Lemon, 2003). 
 
1.4.2 Proteins and Their Function 
The HCV core protein is the first protein to be encoded by the HCV ORF.  After 
being cleaved from the polyprotein by host signal peptidases, it binds viral RNA 
(Santolini et al., 1994) and presumably assembles into HCV capsids at the cytoplasmic 
surface of the endoplasmic reticulum (ER) (Mizuno et al., 1995; Blanchard et al., 2002; 
Blanchard et al., 2003).  The HCV core protein is mostly found in the cytoplasm, in 
association with the ER, membranous webs (see below; Section 1.5.2.), lipid droplets and 
mitochondria.  However, in certain cases, it has also been detected in the nucleus (Suzuki 
et al., 1995).  In addition to its main role, which is the formation of the capsid that will 
store and protect HCV RNA, core protein most likely plays an important role in viral 
replication, virion maturation and pathogenesis (Polyak et al., 2006).  Furthermore, HCV 
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Figure. 1.1:  Schematic representation of the HCV genome and its polyprotein 
processing.  Image from Moradpour et al., 2007. 
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core protein modulates several host cell functions, such as gene transcription, lipid 
metabolism, apoptosis and various intracellular signaling pathways, by interacting with 
numerous cellular proteins (reviewed in Tellinghuisen and Rice, 2002).  
E1 and E2 are highly glycosylated, transmembrane proteins, cleaved from the 
polyprotein by host signal peptidases, which form non-covalent, heterodimeric complexes 
that constitute the building blocks of the virion envelope (Lavie et al., 2007).  E1 protein 
acts as the virion envelope-host membrane fusion subunit, while E2 recognizes and binds 
to various putative HCV cell receptors, as described in Section 1.4.3. The E2 protein 
sequence contains three highly variable regions: hypervariable region 1 (HVR1), HVR2, 
and the intergenotypic variable region (igVR) (Hijikata et al., 1991; McCaffrey et al., 
2011).   
The HCV p7 protein is a short protein, which is released from the polyprotein by 
host signal peptidases and possesses cation channel properties (Griffin et al., 2003; 
Pavlovic et al., 2003).  Those properties, together with predicted structural and 
topological features, suggest that p7 belongs to the viroporin family of proteins (Harada et 
al., 2000; Premkumar et al., 2004).  It has been shown that p7 is indispensable for 
productive infection in vivo (Sakai et al., 2003).  It also plays an important role in virus 
particle assembly and release of infectious virions (Steinmann et al., 2007; Atoom et al., 
2013).  Finally, p7 may play an important role in viral envelopment by protecting E2 
from premature degradation through an ion channel-like activity (Atoom et al., 2013).  
NS2 is a transmembrane protein encompassing part of the NS2-3 protease, also known as 
autoprotease, which is responsible for cis cleavage at the NS2-NS3 junction (Lorenz et 
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al., 2006; Santolini et al., 1995; Yamaga and Ou, 2002).  NS2 is dispensable for HCV 
RNA replication and appears to be essential for completion of the HCV replication cycle 
both in vivo and in vitro (Kolykhalov et al., 2000; Pietschmann et al., 2006).  
Furthermore, it has been shown that NS2 interacts with structural and other NS proteins 
to coordinate virus assembly (Ma et al., 2010; Popescu et al., 2011).  
NS3 is a multifunctional HCV protein with a serine protease activity located in its 
N-terminus and a NTPase/RNA helicase activity in its C terminus (Gallinari et al., 1998).   
The NS3 protease, with NS4A as a co-factor (Kim et al,, 1996), cleaves the HCV 
polyprotein at the NS3-4A, 4A-4B, 4B-5A and 5A-5B junctions (Bartenschlanger et al., 
1993).  The enzymatic activity of NS3 as a NTPase/RNA helicase renders NS3 
indispensable for RNA replication.  NS4B is an integral membrane protein that is co-
localized with other NS proteins at the ER membrane (Hugle et al., 2001).  The main role 
of NS4B is inducing the formation for the membranous web, a specialized membrane 
structure which is thought to be the HCV replication site (Egger et al., 2002; Gao et al., 
2004).  
The HCV NS5A protein is a membrane-anchored phosphoprotein which exists in 
several phosphorylation states.  NS5A plays an important role in viral replication.  
Numerous cell culture-adaptive mutations located in NS5A have been found to enhance 
HCV RNA replication (Blight et al., 2000; Krieger et al., 2001; Lohmann et al., 1999).  
Many of these mutations affect hyperphosphorylation of NS5A, denoting that HCV 
replication efficiency might be affected by NS5A phosphorylation status.  Furthermore, 
NS5A plays an important role in HCV infectious particle assembly (Appel et al., 2008).  
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In particular, domain III has been identified as the key determinant in NS5A for particle 
formation.  NS5A also contains two regions, called interferon (IFN)/ribavirin (RBV) 
resistance-determining region (IRRDR) and interferon-α (IFN-α) sensitivity-determining 
region (ISDR) thought to play a role in the response to IFN treatment (Enomoto et al., 
1996; Zeuzem et al., 1997; El-Shamy et al., 2008).  It has been postulated that high 
number of mutations in these areas correlates with lower resistance to IFN-α and, 
therefore, higher IFN treatment response rates.  NS5B is a tail-anchored protein, targeted 
post-transnationally in the cytoplasmic side of the ER.  NS5B acts as an RNA-dependent 
RNA-polymerase (RdRp) which drives HCV replication.  It is responsible for the 
synthesis of the negative (replicative) HCV RNA strand by using the genome as a 
template and the subsequent synthesis of the positive (genomic) RNA strand from this 
replicative intermediate (Behrens et al., 1996).  Due to its central role in HCV replication, 
NS5B constitutes a promising target for antiviral agents (Harper et al., 2005; Murakami et 
al., 2007).   
 
1.4.3 HCV Life Cycle 
The first step in the HCV replication cycle is attachment of viral proteins, mainly 
E2, to host cell receptors.  This interaction determines virus tissue tropism and will be 
discussed in detail in Sections 1.5.1. and 1.5.2.  Attachment to the target cell is followed 
by virion internalization via clathrin-mediated endocytosis (Blanchard et al., 2006).  
Acidification of the endosomes leads to HCV glygoprotein–cell membrane fusion, which 
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is followed by uncoating and release of the HCV RNA into the cytoplasm (Blanchard et 
al., 2006).  
Once inside the cell, the positive-sense HCV RNA is directly translated by a cap-
independent IRES-mediated process (Wang et al., 1993).  The translation process yields a 
large polyprotein which is co- and post-translationally cleaved by both host and viral 
proteases, as described in Section 1.4.2.  
HCV replicates via synthesis of a negative-strand HCV RNA which serves as a 
template for HCV RNA positive strand synthesis.  Thus, the detection of HCV RNA 
negative strand serves as an important marker of active replication.  As mentioned in 
Section 1.4.2, NS5B catalyzes HCV RNA synthesis (Lohmann, 1997) and, since it lacks 
stringent template specificity and proofreading activity, it is characterized by a high error 
rate contributing to the generation of large pool of HCV quasispecies found in each host 
(discussed in Section 1.4.5).  In human hepatoma Huh-7 cells bearing HCV subgenomic 
replicons, it was shown that the site of HCV RNA replication is an ER membrane 
alteration, called the membranous web (Gosert et al., 2003; Mottola et al., 2002).  Studies 
have also shown that HCV RNA replication is influenced by cholesterol and lipid 
metabolism (Ye et al., 2004; Kapadia and Chisari, 2005; Sagan et al., 2006). 
It has been suggested that HCV assembly and maturation takes place in the ER 
and post-ER compartments, and that virions exit through the secretory pathway.  Studies 
suggest that lipid droplets (intracellular organelles used for neutral fat storage) interact 
with HCV core and together they play a key role in assembly and production of infectious 
virions (Miyanari et al., 2007).  Furthermore, it was shown that HCV assembly and 
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maturation in Huh7 cells requires microsomal transfer protein (MTP) and apolipoprotein 
B (apoB), mimicking the synthesis of very low density lipoproteins (VLDL) (Gastaminza 
et al., 2007). 
 
1.4.4 Virion Ultrastructure and Biophysical Properties 
HCV particles are spherical ranging from 40-75 nm in diameter (Kaito et al., 
1994; Wakita et al., 2005; Gastaminza et al., 2010).  As previously mentioned, core 
together with E1 and E2 proteins constitute the main structural components of the HCV 
virion.  In particular, E1 and E2 proteins are anchored in the host cell-derived lipid 
envelope which encapsulates an isocathedral nucleocapsid composed by multiple copies 
of the core protein and the genomic viral RNA (Kaito et al., 1994).  HCV particles can 
circulate in various forms in sera of HCV-infected patients (reviewed in André et al., 
2005).  These forms include: free virions, virions bound to immunoglobulins, non-
enveloped HCV nucleocapsids (also known as naked cores) which are not infectious, and 
particles physically associated with low-density lipoproteins (LDL) and VLDL, both of 
which represent the infectious fractions.  This characteristic explains the great 
heterogeneity in HCV buoyant density.  For example, using patient plasma, it was shown 
that the buoyant density of the non-enveloped particles in a sucrose gradient ranges from 
1.23-1.27 g/mL, while the enveloped virions band at densities ranging from 1.05-1.11 
g/mL (Kaito et al., 1994) with peak infectivity in the fractions ranging from 1.09-1.11 
g/mL, as determined by challenging of chimpanzees with different gradient fractions 
(Bradley et al., 1985).   
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1.4.5 HCV Mutants and Quasispecies 
HCV is a highly diversified virus with genetic variability existing at different 
levels.  The genetic divergence is greatest between the 6 different genotypes which differ 
in 30% to 35% in nucleotide sequences (Simmonds et al., 1993).  The greatest levels of 
genetic diversity between genotypes are observed in the genomic regions encoding the 
two envelope glycoproteins and mainly in the E2 protein, as previously mentioned 
(Section 1.4.2.).  Areas, such as the core gene and the genes encoding the non-structural 
proteins, are more conserved.  The most conserved area of the HCV genome is the 5’-
UTR, which encompasses sequences and secondary structures necessary for the initiation 
of viral replication and translation (Bukh et al., 1995). 
Each of the 6 HCV genotypes encompasses a group of more closely related 
subtypes, showing a difference in nt sequence ranging between 20% and 25% (Simmonds 
et al., 1993).  Subtypes 1a, 1b and 3a, represent the major subtypes in the Western world 
(Simmonds et al., 2004).    
HCV continuously diversifies within the host, forming groups of related, but 
genetically distinct variants that share sequence similarity, named quasispecies (Martell et 
al., 1992).  With an RdRp that lacks proofreading (misincorporation frequencies 
averaging about 104 to 105 per nucleotide copied) and 1012 virions produced daily 
(Pawlotsky, 2003) every possible HCV mutant is produced several times a day within the 
infected host.  HCV quasispecies play a very important role in liver disease progression, 
response to IFN therapy, and resistance to direct acting antivirals (DAA).  More 
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specifically, patients who spontaneously resolve hepatitis C, harbor a more homogenous 
quasispecies population, while patients who progress to chronic hepatitis C (CHC) 
contain more diverse variant spectra (Farci and Purcell, 2000).  Furthermore, patients 
with minimal HCV diversity have less chances of harboring treatment-resistant 
quasispecies and, therefore, are more likely to achieve clinically apparent sustained 
virological response (SVR) than patients with greater HCV genome variant complexity 
(Pawlotsky, 2003; 2006).  Finally, all DDAs can select drug resistant variants.  Resistance 
refers to the selection of pre-existing HCV variants that are resistant to a specific drug 
and are caused by amino acid substitutions found within or close to the region targeted by 
a given drug (Strahotin and Babich, 2012).  As the nonresistant variants are eradicated by 
the use of a certain DAA, the resistant ones fill in the replication space.  
 
1.5 HCV Tissue Tropism 
1.5.1 HCV Hepatotropism 
The main target of HCV and site of its propagation is the hepatocyte (Fournier et 
al., 1998; Rumin et al., 1999; Castet et al., 2002; Lazaro et al., 2007).  However, in vitro 
infection of primary human hepatocytes (PHH) has been characterized by low levels of 
HCV replication.  It has been suggested that the differentiated status of hepatocyes in 
vitro could be affecting their ability to support HCV replication (Farquhar and 
McKeating, 2008).  As a result, the majority of studies have focused on the interactions 
between human hepatocarcinoma cell lines (mostly Huh-7 cells and their derivatives) and 
the HCV pseudoparticles (HCVpp) (described in Section 1.10.2.2) or the laboratory strain 
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Japanese fulminant hepatitis 1 (JFH-1) (described in Section 1.10.2.3) and JFH-1-derived 
clones.  Using these in vitro systems, it was proposed that HCV entry into the hepatocytes 
is a complex multistep process, mediated by several molecules.  Defined subgroups of 
these molecules possibly dictate HCV hepatotropism and host specificity in vivo. 
The dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin 
(DC-SIGN or CD209) and the liver/lymph node-specific intercellular adhesion molecule-
3 (ICAM-3)-grabbing integrin (L-SIGN or CD209L) are C-type lectins thought to 
contribute to HCV capture and its persistence in the liver (Koppel et al., 2005).  It was 
believed that binding of HCVpp to L-SIGN and CD-SIGN is mediated by interaction with 
the HCV E2 protein (Ludwig et al., 2004). 
Initial attachment of HCV to cells takes place via low-affinity interaction of the 
virion-associated apolipoprotein E (apoE) with low-density lipoprotein receptor (LDL-R) 
(Agnello et al., 1999) and glycosaminoglycans (GAGs) (Germi et al., 2002).  Even 
though LDL-R is dispensable for HCV entry, it might also be required for increased HCV 
replication (Albecka et al., 2012).  Moreover, it has been documented that upregulation of 
LDR–Rs in Daudi cells (B lymphoblast cell line) was followed by increased HCV RNA 
positive strand expression in these cells (Burlone et al., 2009).  With regards to the role of 
GAGs in HCV entry, it has been reported that HCV occurring in plasma binds GAGs 
expressed on the surface of African green monkey kidney Vero cells (Germi et al., 2002). 
CD81, a ubiquitously expressed tetraspanin, was shown to be indispensable for 
HCV entry based on neutralization of HCV transmission using anti-CD81 antibodies 
(Wakita et al., 2005; Zhong et al., 2005; Lindenbach et al., 2005).  The involvement of 
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CD81 in HCV entry was first hypothesized when it was found that it could bind to soluble 
E2 protein (Pileri et al., 1998).  Its role was later confirmed using both HCVpp and cell 
culture-derived HCV (HCVcc) and Huh7.5 cells as targets (Bartosch et al., 2003a; Hsu et 
al., 2003; Cormier et al., 2004; Zhang et al., 2004).  The role of CD81 in HCV entry 
requires interaction with another entry factor, claudin-1 (CLDN-1) (Harris et al., 2010).  
Furthermore, CD81 confers tropism of HCV for human cells as it was shown that mice 
expressing human CD81 in the liver were rendered permissive to HCV infection (Dorner 
et al., 2011; 2013).  However, CD81 occurs on many cell types and, therefore, cannot 
alone determine hepatocyte tropism. 
 Scavenger receptor-B1 (SR-B1) was identified as an HCV receptor in the HepG2 
hepatoma cell line due to its ability to bind recombinant HCV E2 via the HVR1 (Scarselli 
et al., 2002).  It was later confirmed as an entry factor for both HCVpp (Bartosch et al., 
2003b) and HCVcc JFH-1 (described in Section 1.10.2.3) (Catanese et al., 2010). 
Claudin-1 (CLDN-1), a tight junction protein (Evans et al., 2007), is thought to be 
working together with CD81 to mediate HCVcc entry into Huh7.5 cells (Farkuhar et al., 
2012). CLDN-6 and CLDN-9 were also found to play role in HCVpp entry into HEK-293 
T cells as expression of either of these molecules mediated entry of HCVpp into these 
cells (Zheng et al., 2007).  
Occludin (OCLN), another tight junction protein, has been identified as an HCV 
entry factor by rendering murine cells expressing human CD81, SR-B1 and CLDN1 
infectable with HCVpp (Ploss et al., 2009).  Together with CD81, OCLN confers HCV 
species tropism, as it was shown that mice engineered to express human CD81 and 
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OCLN1 in the liver were rendered susceptible to HCV infection (Dorner et al., 2011; 
2013).   
The iron uptake receptor, transferrin receptor 1 (TfR1), which is widely expressed 
in mammalian cells, including hepatocytes, has also been identified as an HCV entry 
factor (Martin and Uprichard, 2013).  Clinical observational data suggesting that an iron 
accumulation disorder often occured in the liver of patients with CHC (Fujita et al., 2007) 
prompted investigation for the role of TfR1 in HCV entry.   
Niemann-Pick C1–like 1 (NPC1L1) cholesterol uptake receptor has also been 
identified as an HCV entry factor (Sainz et al., 2012).  NPC1L1 is expressed in the apical 
canalicular surface of polarized hepatocytes (Jia et al., 2011).  Antibody-mediated 
blocking of NPC1L1 was shown to inhibit HCV entry to Huh7.5 cells in a way similar to 
that of CD81 antibodies (Sainz et al., 2012).  Furthermore, the use of Ezetimibe, an FDA-
approved NPC1L1-specific inhibitor used to treat hypercholesterolemia, was found to 
block HCV entry and cell-to-cell transmission in vitro (Sainz et al., 2012).  In the same 
study, the use of Ezetimibe in vivo delayed establishment of HCV genotype 1b infection 
in mice bearing human liver grafts.  
Two receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR) 
and ephrin type A receptor 2 (EPHA2) were also identified as molecules involved in 
HCV entry (Lupberger et al., 2011).  EGFR and EPHA2 promote CD81-CLDN1 
interaction (Lupberger et al., 2011).  Two anticancer compounds, erlotinib and dasatinib, 
which inhibit EGFR and EPHA2, respectively, were able to block HCV entry in 
hepatoma cells and PHHs.  Erlotinib was also shown to be effective at preventing HCV 
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infection in human liver chimeric, severe combined immunodeficient (SCID) mice which 
overexpress a urokinase-type plasminogen activator (uPA) transgene in the liver 
(Lupberger et al., 2011). 
Finally, serum response factor binding protein 1 (SRFBP1) was recently found to 
be involved in HCV cell entry (Gerold et al., 2015).  It is thought that SRFBP1 forms a 
complex with CD81 and coordinates host cell penetration.  
 
1.5.2 HCV Lymphotropism 
Even though HCV is considered to be mainly a hepatotropic virus, accumulating 
molecular and clinical evidence indicates that it also invades and propagates in the cells 
of the immune system, a property referred to as lymphotropism.  
Studies from different groups have shown that HCV replicates in the peripheral 
blood mononuclear cells (PBMC) of chronically infected patients, as evidenced by 
detection of HCV RNA positive, and its replicative intermediate, HCV RNA negative 
strand (Willems et al., 1994; Lerat et al., 1996; Blackard et al., 2006; Pham et al., 2008).  
Furthermore, detection of viral RNA in the immune compartment, was not limited to 
patients with CHC, but was also observed in patients who had achieved spontaneous or 
treatment-induced resolution of HCV infection (Pham et al., 2004; Radkowski et al., 
2005; Pham et al., 2005, 2008; MacParland et al., 2009; Pham et al., 2012).  
Immune cell subsets supporting HCV replication in vivo include CD4+ and CD8+ 
T cells, B cells, monocytes and possibly dendritic cells (Pham et al., 2004, 2008, 
Radkowski et al., 2005; Pal et al., 2006; Pawelczyk et al., 2013; Dai et al., 2015).  It is 
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worth noting that HCV infection, as evidenced by detection of both the negative stand 
and NS5A protein, was documented in CD4+, CD8+ T cells, monocytes and B cells of  
patients with both CHC and clinically resolved hepatitis C, called secondary occult HCV 
infection (OCI) (Pham et al., 2008).  In the same studies, it was found that overall loads 
of HCV were significantly higher in the patients with CHC than OCI, with monocytes 
carrying greatest virus loads.  
Further evidence of HCV lymphotropism is the detection of virus sequence 
variants in the PBMC and immune cell subsets that differ from those found in the serum 
and liver of HCV-infected patients (Maggi et al., 1997; Navas et al., 1998; Laskus et al., 
2002; Ducoulombier et al., 2004; Roque-Afonso et al., 2005; Di Liberto et al., 2006; 
Pham et al., 2008, 2012; MacParland et al., 2009; Durand et al., 2010, Chen et al., 2013, 
2015).  In one of these studies, it was uncovered that HCV variants residing in B cells of 
patients with OCI, exhibited different translational efficiency in B cells than in Huh7.5 
cells, suggesting that those B cell variants were better adapted to propagate in B cells 
(Durand et al., 2010).  Overall, these results indicate that either lymphotropism is a 
propensity of certain HCV variants or that infection of immune cells is a factor that favors 
selection of unique HCV variants.   
The lymphotropic nature of HCV is also in agreement with the greatest prevalence 
of certain lymphoproliferative disorders among HCV-infected patients, such as mixed 
cryoglobulinemia type II (MC type II), non-Hodgkins B cell lymphoma and mucosa-
associated tissue lymphoma (Agnello et al., 1992; Ferri et al., 1993; Tkoub et al., 1998).  
Evidence of HCV involvement in the aforementioned disorders will be summarized in 
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Section 1.8.2.  Apart from B cell dysfunction, there is evidence linking HCV with a 
number of functional abnormalities observed in other immune subsets which will be 
discussed in Section 1.8.2.3. 
 Taken together, the accumulated data indicate that the cells of the immune system 
constitute the site of active HCV propagation and can serve as a reservoir where the virus 
may persist indefinetely, and from where it can spread, as in the cases of reinfection 
following clinically apparent resolution of hepatitis C or after liver transplantation due to 
HCV-induced end-stage-liver-disease (ESLD).  Strong evidence supporting the immune 
cell origin of the variants reinfecting the transplanted liver is the detection of viral 
sequences in the plasma of transplanted patients that are identical to those harbored in the 
pretransplant PBMC (Laskus et al., 2002).  The ability of HCV to infect lymphocytes is 
further supported by data generated from numerous in vitro studies, which will be 
summarized in Section 1.10.2.5.  
Interestingly, lymphotropism is a propensity of naturally-occurring, patient-
derived HCV, but not laboratory constructed or Huh7 cell culture-adapted HCV clones, 
such as JFH-1 (further discussed in Section 1.10.2.3).  More specifically, it has been 
shown that the JFH-1 clone is unable to infect human lymphoid cells in vitro (Marukian 
et al., 2008; Murakami et al., 2008).  Recent studies completed in this laboratory, clearly 
documented that JFH-1 and related JFH1T clone were not able to establish in vitro 
infection in primary T cells, PBMCs, or T cell lines in contrast to authentic, patient-
derived HCV (Sarhan et al., 2012b).  
 24 
 
The increasing body of data on HCV lymphotropism generated interest on the 
mechanism and molecules used by HCV to infect human lymphocytes.  Another study 
performed in this laboratory, revealed that CD5, a glycoprotein that belongs to the 
scavenger receptor cysteine-rich (SRCR) family of receptors, is essential for infection of 
human T lymphocytes with naturally occurring HCV (Sarhan et al., 2012a).  It is of note 
that CD5 is a molecule displayed by T cells (Cantor et al., 1975; Ledbetter et al., 1979; 
and on a small population of B cells (Caligaris-Cappio et al., 1982; Antin et al., 1986).  
Therefore, it is the first HCV receptor identified that is target cell-specific.  This is in 
contrast to all other molecules identified as those potentially mediating HCV 
hepatotropism which are ubiquitously expressed on many cell types and not just on 
hepatocytes.  Further, studies were performed investigating association between T cell 
susceptibility and the molecules found to mediate infection of human hepatoma-derived 
Huh7 or Huh7.5 cell lines by HCV JFH-1 and HCVpp.  In this regard, expression of CD5 
and proposed HCV hepatocyte receptors, such as CD81, SR-B1, OCLN, CLDN1 and 
CLDN4 was evaluated in HCV-resistant and susceptible T cell lines, PBMCs, primary T 
cells, JFH-1-prone Huh7.5 and HCV-resistant HepG2 cell lines (Sarhan et al., 2013).  The 
results showed that: (1) Both CD5 and CD81 expression is concomitant with 
susceptibility of T lymphocytes to infection; (2) Susceptibility of HCV-prone T cell lines, 
but not primary T cells, coincides with high levels of OCLN expression, and (3) No 
association was found between SR-B1, CLDN-1 or CLDN-4 expression and T cell 
susceptibility to infection with authentic HCV (Sarhan et al., 2013). 
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1.6 Natural History of HCV Infection 
1.6.1 Acute Hepatitis 
The first 6 months (mo) after exposure to HCV are conventionally regarded as the 
acute phase of hepatitis C.  Acute hepatitis C (AHC) is rarely diagnosed due to its 
frequently asymptomatic nature.  The majority of newly infected individuals either do not 
experience any symptoms or develops mild, nonspecific signs of infection, such as 
fatigue, arthralgias, itch, anorexia and epigastric pain.  Only 15%-30% of acutely infected 
patients experience more severe symptoms (Busch and Shafer, 2005), usually starting 3 to 
12 weeks upon exposure (Alter and Seef, 2000).  Those symptoms typically last for 2-12 
weeks (Orland et al., 2002; Marcellin, 1999) and may include jaundice, low grade fever, 
and nausea.  Two to 8 weeks post-infection, serum alanine aminotransferase (ALT) 
begins to increase and may often reach levels 10-fold higher than normal (Chen and 
Morgan, 2006).  HCV RNA is detectable in serum/plasma 2 to 14 days post exposure 
with the use of modern nucleic acid testing (NAT) methods.  The sensitivity threshold of 
clinically available quantitative NATs is 10 to 15 International Units/mL (IU/mL) with 1 
IU ranging from 2 to 7 virus genomic equivalents (vge), depending on the assay 
(Pawlotsky 2000; Germer and Zein, 2001; Mulrooney-Cousins and Michalak, 2016).  
HCV genome load increases continuously and may reach 105 to 10 7 IU/mL immediately 
before serum ALT rise and symptoms appear.  Anti-HCV antibodies can be detected 
between 20-150 days post-infection (Busch and Shafer, 2005) using third-generation 
enzyme immunoassays (EIA).  Symptomatic AHC is associated with higher rates of 
apparent HCV clearance as measured by clinical laboratory assays and probably signify a 
 26 
 
more robust and effective immune response against the virus (Gerlach et al., 2003).  
Fulminant hepatic failure during AHC is rare and occurring at <1% of infected 
individuals (Farci et al., 1996).  
 
1.6.2 Spontaneous Resolution of Hepatitis C 
Spontaneous clinical resolution of hepatitis C, which is not equivalent with HCV 
molecular clearance (Pham et al., 2004; Chen et al., 2015), occurs only in 25% of acutely 
infected individuals (Grebely et al., 2007).  As discussed in detail in Section 1.8.2, 
vigorous and virus multispecific CD4+ and CD8+ T cell responses, accompanied by a type 
1 pattern of cytokine production, correlate with spontaneous resolution of hepatitis 
(Thimme et al., 2001).  Factors associated with a self-limiting course of AHC infections 
include female sex (Yamakawa et al., 1996), younger age at time of infection (Zhang et 
al., 2006), aboriginal ethnicity (Grebely et al., 2007), a history of jaundice (Gerlach et al., 
2003), and coinfection with HBV and HAV viruses (Piasecki, et al., 2004; Wietzke-
Braun et al., 2007).  A genetic factor associated with spontaneous resolution, that has 
attracted much attention is a polymorphism found in the region of the IL28B gene 
encoding IFN-lambda-3 (IFN-λ-3).  This single nucleotide polymorphism (SNP 
(rs12979860), defines two alleles C and T, from which the C-allele is associated with a 
greater likelihood of spontaneous clearance of hepatitis C and increased responsiveness to 
IFN/RBV therapy (Ge et al., 2009).  Recently, it was also revealed that polymorphic 
haplotypes in the interferon-induced helicase (IFIH1) gene, which encodes the melanoma 
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differentiation-associated protein 5 (MDA-5), strongly correlate with resolution of HCV 
infection (Hoffmann et al., 2015). 
 
1.6.3 Chronic Hepatitis C  
CHC develops in 75% to 85% of acutely infected individuals and is defined by 
persistence of HCV RNA in serum for at least 6 mo upon newly acquired infection (Chen 
and Morgan, 2006).  During CHC, in contrast to AHC, serum ALT and HCV RNA levels 
stabilize reaching 104 to 106  IU/mL and they rarely fluctuate more than 1 log10 (Fabrizi et 
al., 2000; Rehermann, 2009).  CHC can be asymptomatic for years with some people 
experiencing nonspecific signs, such as fatigue and arthralgia.  Lack of more severe 
symptoms can continue even after development of liver cirrhosis (replacement of liver 
tissue by scar tissue) and HCC.  Among patients with CHC, 5% to 20% will develop 
cirrhosis after 20 years.  Once cirrhosis is established, the risk of the development of 
HCC is 1% to 4% per year (Lauer and Walker, 2001).  
Liver injury in HCV infection is an immune-mediated process driven by 
continuous cycles of inflammation and necrosis, which lead to fibrosis and finally 
cirrhosis.  The rates of liver disease progression may vary greatly between patients (Lauer 
and Walker, 2001).  More specifically, female sex and younger age at time of HCV 
acquisition decrease the risk of progression to advanced liver disease, while increased 
alcohol consumption, obesity, African-American ethnicity, immunosuppression and other 
co-comorbidities (e.g., HBV, HIV co-infection) increase the risk of liver disease 
progression.  In addition, infection with HCV genotype 3 is associated with increased risk 
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of cirrhosis and HCC development compared to genotype 1, while patients infected with 
genotype 2 have a lower risk of cirrhosis and  HCC compared to those infected with HCV 
genotype 1 (Kanwal, et al., 2014).  Patients with a favorable risk profile may not develop 
serious liver disease even for 30 years after infection (Poynard et al., 1997).  Some of the 
consequences of liver cirrhosis are: (1) Portal hypertension which manifests by ascites, 
esophageal varices, encephalopathy; (2) Defective liver protein synthesis and metabolism 
in general, and (3) Development of HCC.  
 
1.6.4 Persistent Occult HCV Infection 
  OCI is defined as the presence of HCV RNA at low levels in plasma (typically < 
100 to 200 vge/mL, PBMC and/or liver (usually around 10 to 100 vge/μg of total RNA 
for both compartments), which are not detectable by the current clinical laboratory assays.  
This is accompanied by HCV replication in PBMC and liver for many years after having 
achieved clinically apparent SVR (Pham et al., 2004; Radkowski et al., 2005; Castillo et 
al., 2006; Ciancio et al., 2006).  This type of infection likely also occurs after an 
asymptomatic exposure to very small doses of HCV.  As previously indicated, HCV has 
been found to replicate in the same immune cell subsets in OCI as in CHC, with B cells 
carrying highest virus loads in OCI (Pham et al., 2008; Chen et al., 2013, 2015).  
Furthermore, it has been revealed that immune cells in OCI harbor HCV sequence 
variants that differ from those circulating in the plasma (Di Liberto et al., 2006; Pham et 
al., 2008).  Also, it was uncovered that OCI is characterized by immune cell cytokine 
expression profiles that differ from the ones observed in CHC, as well as in healthy 
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individuals (Pham et al., 2009), suggesting that OCI is not disregarded by the immune 
system.  Additionally, HCV-specific T cell responses have been identified in patients 
years after apparent recovery from HCV infection (Quiroga et al., 2006a; 2006b; Veerapu 
et al., 2011) and that was associated with HCV persistence in the liver (Quiroga et al., 
2006a; 2006b). 
OCI was discovered only after nucleic acid amplification assays of increased 
sensitivity were developed for the detection of the HCV RNA positive and negative 
strand.  The assays developed and used in this laboratory for detection of HCV RNA 
positive strand have a sensitivity level ≤ 10 vge/mL (≤ 3 IU/mL) or ≤ 5 vge/μg (≤ 1.5 
IU/μg) total RNA (Pham et al., 2004).  Factors contributing to the extremely intricate task 
which is the successful and consistent detection of OCI include: (1) Use of HCV RNA 
detection assays comprised by two rounds of cDNA amplification by PCR (direct and 
nested) after reverse transcription (RT), which are followed by detection of amplicons via 
nucleic acid hybridization (NAH) (i.e., RT-PCR/NAH assay); (2) Upregulation of HCV 
RNA expression in PBMC via ex vivo stimulation with mitogens (Pham et al., 2004, 
2005); (3) Analysis of greater volumes of plasma or higher numbers of cells; (4) Serial 
testing of samples of plasma and lymphocytes from patients examined; (5) Screening both 
PBMC and individual immune cell subsets isolated from these PBMC; (6) Extremely 
careful handling of samples  to avoid contaminations, and (7) The use of optimized RNA 
extraction protocols that guarantee isolation of a maximum amount of high quality HCV 
RNA (Pham et al., 2010).                                                                                                   
 The clinical consequences of OCI are not yet well defined, since, in most cases, 
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HCV RNA detection in patients who achieve SVR is not performed in the clinical setting 
using highly sensitive assays.  As a result, the persistence of HCV as OCI and its potential 
clinical implications await for verification.  However, the reactivation of virus persisting 
in the PBMC or liver of patients with clinically apparent SVR is entirely possible, 
especially in cases of immunosuppression either iatrogenic or related to comorbidities 
(reviewed in Pham et al., 2010).  It is worth mentioning cases of relapse of hepatitis C in 
patients who had received liver transplants following clinically apparent SVR (Zhou et 
al., 1996; Chartlton et al., 1998; Nudo et al., 2008).  There are also reports associating 
OCI with progressive liver disease. More specifically, one study showed that the 
percentages of patients with OCI (as evidenced by detection of HCV RNA in liver tissue) 
that had inflammation, fibrosis, or cirrhosis, were greater than the percentages observed 
in patients with the absence of HCV RNA detected in their livers (Castillo et al., 2004). 
Furthermore, there are reports associating OCI with development of lymphoproliferative 
disorders (Fowell et al., 2008; Youssef et al., 2012; Farahani et al., 2013).   
 Several studies implied association of OCI with HCC development.  It has been 
reported that 2.3-3.5% of patients with SVR developed HCC (Makiyama et al., 2004; 
Kobayashi et al., 2007).  Furthermore, HCC relapse has been documented in patients with 
SVR who have received curative hepatectomy (Sanefuji et al., 2009).  Also, development 
of well-differentiated HCC has been reported in a patient 13 years after achievement of 
SVR (Mashitani et al., 2009).  It is important to study the contribution of OCI to the 
perpetuation and reactivation of liver injury.  There is evidence, including data from this 
laboratory, implying that individuals with SVR should be regularly monitored even after 
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what appears to be successful virus elimination (Makiyama et al., 2004; Tsuda et al., 
2004; Kobayashi et al., 2007; Chen et al., 2013, 2015).  
With regards to the infectious potential of the virus persisting after clinically 
apparent SVR, a study performed in this laboratory demonstrated that traces of HCV 
which lingered in the PBMC of patients even 6 years post-SVR were able to productively 
infect naïve human T cells in vitro (MacParland et al., 2009).  In addition, trace amounts 
of HCV RNA detected in the plasma of patients with SVR was found capable of infecting 
HCV-naive chimpanzees (Veerapu et al., 2014). 
 
1.7 Immune Responses to HCV Infection 
1.7.1 Innate Immune Responses 
Innate immune responses constitute the first line of defense against pathogens.  
IFNs are key molecules in inducing an antiviral state in the cells exposed to virus and in 
activating as well as modulating the cells of the innate immune system. 
 Immediate and strong induction of type I IFNs in the liver is a predominant 
characteristic of acute HCV infection (Bigger et al., 2001; Su et al., 2002).  Innate 
immune defenses are triggered by recognition of viral macromolecular motifs known as 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) 
(Akira et al., 2006).  In HCV infection, the innate immune response is thought to be 
initiated by infected hepatocytes through two PRRs, toll-like receptor 3 (TLR3) and 
retinoic acid inducible gene-I (RIG-I).  TLR3 recognizes double stranded RNA (dsRNA) 
in the endosomes (Li et al., 2012), while RIG-I recognizes the 3’-NTR poly-U/UC region 
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in the cytoplasm (Saito et al., 2008).  Once activated, TLR3 recruits adapter molecule 
Toll-IL1-receptor domain-containing adaptor inducing IFN-β (TRIF), while RIG-I 
recruits the adapter molecule IFN-β promoter stimulator protein 1 (IPS-1) (Saito et al., 
2008).  These interactions activate a downstream intracellular signaling cascade resulting 
in activation of nuclear factor kB (NFKB) and IFN-β secretion.  Secreted ΙFN-β then 
induces an anti-viral state which expands to the uninfected neighboring cells by binding 
to the IFN-α/β receptor and activating the JAK/STAT pathway (Aaronson and Horvath, 
2002). Activation of this pathway leads to induction of the IFN-stimulated genes (ISGs) 
(Stark et al., 1998) and IFN-α subtype diversification (Gibbert et al., 2012).  In 
chimpanzees, transcriptome analysis revealed induction of ISGs early in the acute phase 
(Su et al., 2002).  Replicon-based studies have identified 4 of these ISGs as having an 
active role against HCV: protein kinase R (PKR), P56, 2’5’-oligoadenylate synthetase 
(OAS), and RNA-specific adenosine deaminase-1 (ADAR1) (Pflugherber et al., 2002; 
Hui et al., 2003; Guo et al., 2004; Taylor et al., 2005).  Furthermore, recent findings 
suggest that MDA-5 is involved in induction of IFN production from HCV infected cells 
(Israelow et al., 2014; Cao et al., 2015; Hiet et al., 2015).  As previously mentioned 
(Section 1.6.2), SNPs in the gene encoding MDA-5 strongly correlate with resolution of 
HCV infection (Hoffmann et al., 2015) implying that MDA-5 plays an important role in 
the natural course of HCV infection. 
Rapid induction of IFN-α/β in chimpanzees upon exposure does not, however, 
control the infection (Thimme et al., 2002), which is explained by the numerous strategies 
that HCV uses to attenuate the innate immune response.  In vitro studies have shown that 
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HCV NS3/4A protein blocks TLR3 and RIG-I signaling by cleaving adapter molecules 
TRIF (Li et al., 2005) and IPS-1 (Foy et al., 2003).  Furthermore, it was found that 
NS3/4A inhibits IFNα/β production, by binding to tank-binding kinase-1 (TBK1) and 
preventing it from phosphorylating and activating IFN-regulatory factor 3 (IRF3) 
(Breiman et al., 2005), an important molecule in the cascade leading to IFNα/β induction.  
In addition, it has been shown that HCV NS4B blocks IFN production by disrupting the 
stimulator of interferon genes (STING) interaction with mitochondrial antiviral-signaling 
protein (MAVS) and TBK1 (Nitta et al., 2013).  HCV core protein also plays an 
important role in compromising the innate immune responses by interfering with the 
JAK/STAT pathway in multiple ways: (1) It binds directly to STAT1 leading it to 
degradation (Lin et al., 2006); (2) It activates suppressor of cytokine signaling 3 
(SOCS3), a JAK/STAT signaling inhibitor (Bode et al., 2003); (3) It upregulates protein 
phosphatase 2A (PP2A) resulting in decreased transcriptional activity of ISG factor 3 
(ISGF3) (Heim et al., 1999), and (4) It inhibits binding of ISGF3 to IFN-stimulated 
response elements.  Further, NS5A inhibits PKR by direct binding (Gale et al., 1997) and 
interacts with 2’5’OAS leading to interleukin (IL)-8 induction, which attenuates ISGs 
overall expression (Polyak et al., 2001).  Finally, HCV E2 directly binds to and inhibits 
PKR activity (Taylor et al., 1999). 
Accumulating data indicate that type III IFNs (IL28 A/B and IL29, also known as 
IFN lambda 2, 3 and 1, respectively) play a very important role in HCV infection.  Type 
III IFNs are induced in response to TLR3 and RIG-I triggering and exert their antiviral 
activities by inducing ISGs via the JAK/STAT pathway (Balagopal et al., 2010).  They 
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bind, however, to receptors other than those of type I IFNs, which have different cellular 
distribution.  Published data suggest that type III IFNs are the major cytokines produced 
in the liver of HCV-infected humans and chimpanzees, as well as in PHH in vitro infected 
with JFH-1 (Thomas et al., 2012; Park et al., 2012).  Additionally, a polymorphism 
located in IL28B gene is associated with both spontaneous resolution of hepatitis C and 
response to IFN treatment (Ge et al., 2009), further highlighting the important role of 
IFN-III in innate immune responses against HCV.   
Important cellular components of the innate immune response again HCV are 
natural killer (NK) and NK T cells.  During acute infection, those key players are 
frequently found in the liver, where they recognize infected hepatocytes via an antigen-
independent manner and respond by exerting cytotoxicity and releasing large amounts of 
IFN-γ (Ahlenstiel et al., 2010; Amadei et al., 2010).  It has been suggested that NK and 
NK T cells play a more important role in HCV containment than HCV-specific T cells 
(Amadei et al., 2010).  It is worth mentioning that genetic studies of individuals exposed 
to HCV have shown that certain combinations of a killer cell immunoglobulin-like 
receptor (KIRs) genotype and HLA type correlate with resolution of hepatitis C (Khakoo 
et al., 2004).  Moreover, a recent study suggests that KIR2DL3+NKG2A- NK cells may 
control early HCV infection prior to seroconversion leading to a state of “natural 
resistance” in persons who inject drugs (Thoens et al., 2014).  Once NK and NK T cells 
are activated they produce IFN-γ which activates Kupffer cells and leads to production of 
proinflammatory molecules, such as TNF-α, galectin-9, IL-18 (Mengshol et al., 2010; 
Chattergoon et al., 2011). IL-18 seems to be the first cytokine produced in response to 
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HCV, marking the acute phase of HCV infection (Chattergoon et al., 2011).  Nonetheless, 
the role of IL-18 in HCV infection needs to be further studied.  SNPs in the promoter and 
the coding region of the IL-18 binging protein have been associated with resolution of 
infection in certain patient groups (An et al., 2008; Mosbruger et al., 2010).  
With regards to cellular innate immunity, the main producers of IFNs among the 
cells of the immune system are the plasmatocytoid and myeloid dendritic cells (pDCs and 
mDCs, respectively).  Both of these cell types contain high levels of interferon regulatory 
factor 7 (IRF7) and are, therefore, capable of rapid production of high levels of IFN-α.  
pDCs are highly specialized cells accumulating in the peripheral lymph nodes during an 
infection.  They express TLR7 and TLR9 as sentinels for viral infections and are capable 
of producing up to a 1000-fold more IFN-α than other cell types, driving the innate 
response.  It has been shown in vitro that short range exosomal transfer of HCV RNA 
from infected cells to pDCs triggers IFN-α production via TLR7 engagement (Dreux et 
al., 2012).  mDCs, on the other hand, migrate to the lymphoid tissue where they link the 
innate and adaptive immune response arms.  Studies have shown that the frequency of 
DCs in the circulation during HCV infection is lower and that their function is 
compromised (Decalf et al., 2007; Dolganiuc et al., 2006).   The HCV-mediated 
impairment of DC functions, as well as NK and NK T cells, will be discussed further in 
Section 1.9.1. 
 
 36 
 
1.7.2 Adaptive Immune Responses 
1.7.2.1 Humoral Immune Responses 
HCV-specific antibodies are detectable 8-20 weeks upon infection (Thimme et al., 
2001 and 2002).  A defect in the priming of HCV-specific B cells has been suggested as 
the reason underlying this delay, as there is no general immunosuppression observed in 
HCV acute infection (Rehermann, 2009).  Other effects of HCV infection on B cell 
number, function and phenotype leading to the development of certain extrahepatic 
disorders (e.g., type II MC) will be discussed in Section 1.8.2.1.  Doubts for the 
importance of the role of humoral response in resolution of hepatitis C have stemmed 
from reports of immunocompromised patients clearing HCV infection (Christie et al., 
1997), as well as patients clearing infection before emergence of neutralizing Abs (nAbs).  
Earlier studies suggested that HCV-specific antibodies emerge during the acute phase at 
low titers and they are virus isolate-specific, while their titers and breadth of specificity 
increases with progression to CHC (Logvinoff et al., 2004; Cox et al., 2005).  Another 
study, however, showed that nAbs emerging during the acute phase exert pressure on 
viral variants, driving their sequence evolution (Dowd et al., 2009).  In the same study, it 
was reported that spontaneous resolution of hepatitis C was accompanied by high levels 
of nAbs which peaked at the time of clearance.  On the same note, a strong nAb response 
developed in a patient with CHC led to a decrease in serum HCV RNA to undetectable 
level by a clinical assay and overturning of T-cell exhaustion (Raghuraman et al., 2012).  
Several other studies also suggest that B cells and neutralizing antibodies play a 
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significant role in spontaneous resolutions of HCV (Giang et al., 2012; Osburn et al., 
2014).   
 
1.7.2.2 T Cell Responses  
HCV-specific T cells are considered to be the major mediators of HCV clearance 
(Lechner et al., 2000; Thimme et al., 2001).  This is evident by the fact that decrease in 
viral load is concomitant with emergence of HCV-specific T cells and IFN-γ detection in 
the liver (Shin et al., 2011).  T cell responses are detectable 5-9 weeks post-infection 
(Thimme et al., 2002).  As with humoral immunity, this delayed onset has been related to 
defective priming (Rehermann, 2009).   
  Spontaneous resolution of acute hepatitis C is characterized by the presence in the 
circulation of robustly proliferating HCV-specific CD4+ T cells (Diepolder et al., 1995; 
Missale et al., 1996) that produce high levels of type I cytokines, such as IFN-γ, IL-2 and 
TNF-α (Gerlach et al., 1999).  On the contrary, HCV-specific CD4+ T cell responses are 
undetectable or weak during the acute phase of hepatitis in patients who progress to CHC.  
Additionally, retreat of originally robust HCV-specific CD4+ T cell responses is 
correlated with loss of viral control and relapse of viremia (Gerlach et al., 1999; 
Nascimbeni et al., 2003).  
On the other hand, HCV-specific CD8+ T cells are present in the blood of acutely 
infected patients, independently of the disease outcome (Kaplan et al. 2007).  Until the 
appearance of HCV-specific CD4+ T cells, CD8+ T lymphocytes exhibit a stunned 
phenotype, i.e., decreased proliferation, IFN-γ production and cytotoxicity, and increased 
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expression of programmed death-1 (PD1) molecule (Thimme et al., 2001; Lechner et al., 
2000; Urbani et al., 2002; Kasprowicz et al., 2008).  The functional impairment of CD8+ 
T cells is reversed and memory CD8+ T cells emerge upon appearance of HCV-specific 
CD4+ T cells and reduction in viral load (Urbani et al., 2006).  The timing between 
emergence of HCV-specific CD8+ T cells and a decrease in virus load to levels 
undetectable by clinical laboratory assays highlights the important role of CD8+ T cells in 
containing HCV infection (Shoukry et al., 2003; Neumann-Haefelin and Thimme, 2011). 
Activation of both HCV-specific CD4+ and CD8+ T cells is indispensable for resolution 
of hepatitis C.  The requirement for CD4+ T cells was demonstrated in the study in which 
chimpanzees were reinfected with HCV after antibody-mediated depletion of this cell 
subset.  However, in spite of the presence of functional memory CD8+ T cell responses, 
viral control was incomplete (Grakoui et al., 2003).  Similarly, the role of CD8+ T cells 
was shown in chimpanzees which were exposed to HCV after in vivo depletion of CD8+ 
T cells.  Again, the presence of memory CD4+ T cells was not enough to contain viral 
infection, which was inhibited only upon CD8+ T cell restoration (Shoukry et al., 2003). 
  With regards to memory T cell responses in HCV infection, studies have shown that, 
they do not confer sterilizing immunity.  Studies of chimpanzees that were re-exposed to 
HCV after spontaneous resolution of hepatitis C revealed that the majority of reinfected 
animals exhibited a vigorous proliferation of T cells, accompanied by clinical resolution 
of infection (Bassett et al. 2001).  Furthermore, a study on reinfection in IDUs showed 
that the rates of HCV infection were lower in those who had been re-exposed to the virus 
in the past (Grebely et al., 2006).  Finally, another study analyzing memory immune 
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responses in re-infected IDUs, showed that protective immunity was characterized by 
increased proliferation of HCV-specific T cells, as well as increased breath of T cell and 
nAb responses, followed by rapid decrease of viral load (Osburn et al., 2010). 
In CHC, HCV-specific T cells are constantly stimulated, yet all their effector 
functions are compromised.  CD4+ T cells produce less IL-2 and IFN-γ and this decrease 
correlates with cytotoxicity impairment and overall dysfunction of CD8+ T cells 
(Francavilla et al., 2004).  In the absence of CD4+ T cell help, CD8+ T cells exhibit an 
exhausted phenotype characterized by increased levels of PD-1 and T-cell 
immunoglobulin and mucin domain-containing molecule 3 (Tim-3; a negative immune 
regulator), and low levels of CD127 (Golden-Mason et al., 2009; Kroy et al., 2014).  
Overall, exhaustion of T cells seems to be conferred by expression of a panel of several 
different inhibitory receptors, rather than a single one (Bengsch et al., 2010), which 
explains the reason behind the limited efficacy of anti-PD-1 immunotherapy in both 
humans and chimpanzees with CHC (Fuller et al., 2013; Gardiner et al., 2013).  Failure of 
CD8+ T cells to control HCV replication is accompanied by appearance of resistant HCV 
variants bearing mutations in HLA class I-restricted virus epitopes (Grakoui et al., 2003).  
As a result, CD8+ T cells in CHC are either unable to recognize newly emerged epitopes 
or, even when their cognate epitopes are present and unaltered, they are unable to exert 
their effector functions as a result of expression of several different inhibitory receptors. 
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1.8 Extrahepatic Manifestations of HCV Infection 
1.8.1 Non-Lymphatic System Manifestations 
Even though the liver is the main source of clinical manifestations, HCV infection 
coincides with a number of non-hepatic symptoms and disorders.  Some of these 
manifestations have a strong and/or well documented association with hepatitis C, for 
example: porphyria cutanea tarda, lichen planus, certain types of nephropathy, while 
others, for example: thyroid disorders, diabetes mellitus type 2, need to have their 
association with HCV infection further confirmed and documented.  
Porphyria cutanea tarda (PCT) is caused by decreased activity of the enzyme 
uroporphyrinogen decarboxylase, leading to defective porphyrine metabolism and, as a 
result, to the induction of development of skin erythema, vesicles and bullae due to sun 
exposure. A strong correlation between sporadic PCT and HCV infection was uncovered 
when several studies showed the prevalence of chronic HCV infection in about 50% of 
patients with sporadic PCT (Piperno et al., 1992; Ferri et al., 1993).  Since no significant 
defect was found in the porphyrine metabolism in patients with CHC not suffering from 
PCT, it is possible that HCV infection acts as an accelerator, rather than a causal factor 
for the emergence of PCT (Hussain et al., 1996; O’Reilly et al., 1996). 
Oral lichen planus (OLP) is a skin disorder characterized by degeneration of the 
skin deep basal epithelium mediated by inflammatory infiltrates, mainly CD4+ T cells. It 
is affecting 1% of the general population.  An association between HCV infection and 
OLP has been established by studies estimating the prevalence of HCV infection among 
these patients at 27% (Carrozo et al., 1996; Bagan et al., 1998).  This association was 
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further solidified by detection of HCV RNA positive and negative strands in biopsies of 
oral mucus membrane from OLP patients (Arrieta et al., 2000) and by reports showing 
OLP improvement in HCV-infected patients receiving IFN-α therapy (Nagao et al., 
1999). 
The association between HCV infection and glomerulonephritis (GN) has been 
well documented (Johnson et al., 1994; Daghestani and Pomeroy, 1999).  Amongst the 
different types of nephropathy associated with HCV infection, a clear association has 
been established for cryoglobulinaemic or MC-related nephropathy.  Involvement of 
HCV in the pathogenesis of this disease has been proven by the detection of 
immunocomplexes of HCV antigens with anti-HCV antibodies.  Deposition of 
immunocomplexes in glomerular basement membranes is known to induce damage of 
glomeruli (Horikoshi et al., 1993).  
Several thyroid disorders (i.e., hypo- or hyperthyroidism, Hashimoto’s thyroiditis 
coinciding with the presence of anti-thyroid autoantibodies), often accompany chronic 
HCV infection, particularly in female subjects of older age (Preziati et al., 1995; 
Fernandez-Soto et al., 1998; Huang et al., 1999).  Detection of anti-thyroid peroxidase 
Abs is the most common in patients with CHC and it is observed in around 14% of 
women with CHC (Marazuela et al., 1996).  Therapy with IFN-α has been associated with 
the development of thyroid disorders in HCV-infected patients (Preziati et al., 1995; 
Fernandez-Soto et al., 1998) and also with the induction, precipitation and aggravation of 
thyroid disorders in individuals treated for  hepatic diseases other than CHC (Hsieh et al., 
2000). Taken together, these data suggest a synergistic effect between HCV infection and 
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treatment with IFN-α in the induction of thyroid gland diseases.  Finally, cancer of 
thyroid gland is often observed in patients chronically infected with HCV (Antonelli et 
al., 2007). 
Higher prevalence of type-2 diabetes mellitus has been shown in patients with 
CHC (Simo et al., 1996).  It is thought that this disorder is associated with high insulin-
resistance (Petit et al., 2001), which has been found to be likely induced by HCV core 
protein (Shintani et al., 2004).  It has been postulated that diabetes mellitus can increase 
the risk of development of HCC and overall rate of mortality (El-Serag et al., 2004). 
 
1.8.2 Lymphatic System Manifestations 
1.8.2.1 Mixed Cryoglobulinemia  
Type II MC is the most documented extrahepatic manifestation of HCV infection.  
Type II MC is characterized by accumulation of immunocomplexes which consist of a 
monoclonal IgM-rheumatoid factor plus polynclonal IgG.  These immunocomplexes are 
called cryoglobulins since they typically precipitate below normal body temperature.  
Circulating cryoglobulins are deposited in small and medium size vessels causing 
vasculitis in 2-3% of HCV-infected patients with cryoglobulinemia (Sansonno et al., 
1996; Adinolfi et al., 1996; Mazzaro et al., 2005).  
Up to 80% of patients with type II MC can be infected with HCV (Agnello et al., 
1992), while the prevalence of this disorder among patients chronically infected with 
HCV ranges between 19% and higher than 50% (Lunel et al., 1994; Wong et al., 1996).  
The involvement of HCV in the pathogenesis of this disorder is further supported by 
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detection of both HCV RNA and anti-HCV Ab in the cryoprecipitates, and also from the 
effect of antiviral treatment on the course of this disease.  More specifically, regression of 
MC is strongly associated with a decrease in serum HCV RNA load and recurrence of the 
disease coincides with a relapse of HCV infection (Martyak et al., 2009).  
The mechanism underlying pathogenesis of HCV infection-associated MC is 
complex and seems to be related with unregulated B cell proliferation.  More specifically, 
it has been shown that there is an expansion of CD5+ B cells, known to produce low-
affinity IgM, in the peripheral blood of patients with CHC (Curry et al., 2000).  
Expansion of CD5+ B cells expressing high levels of the HCV co-receptor CD81 was 
reported in the HCV-infected livers of patients with CHC (Curry et al., 2003).  It was also 
reported that binding of a combination of HCV E2 protein and anti-CD81 mAb to CD81 
on human B cells induced proliferation of naïve B cells and that E2-CD81 binding lead to 
phosphorylation of protein tyrosine and hupermutation of the immunoglobulin genes in B 
cell lines (Cocquerel et al., 2003; Rosa et al., 2005; Machilda et al., 2005).  Furthermore, 
it was shown that CD5+ B cells are more resistant to apoptosis than CD5- B cells in 
patients with CHC but not in healthy individuals, and that increased levels of anti-
apoptotic cytokines in the serum of patients with CHC protected CD5+ B cells from 
apoptosis (Mizuochi et al., 2009).  It has also been demonstrated that E2-CD81 
interaction protects human B lymphocytes from Fas (CD95)-mediated apoptosis (Chen et 
al., 2010).  Finally, a recent collaborative study between the Department of Medicine, 
University of Maryland, USA and this laboratory showed that HCV NS3/4A induced 
upregulation of host B-cell receptor (BCR) signaling in HCV-infected B cells (Dai et al., 
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2015), thus revealing a putative molecular mechanism underlying HCV-associated B-cell 
lymphoma.  
 
1.8.2.2 Non-Hodgkins B Cell Lymphoma 
 HCV infection is also strongly associated with non-Hodgkins B cell lymphoma 
(NHL).  HCV infection of PBMC has been reported in the majority of HCV-positive 
patients with NHL (Ferri et al., 1997). This lymphoproliferative disorder is characterized 
by an unregulated proliferation of B lymphocytes leading to an increased number of 
monoclonal B cells in the circulation.  The suggested mechanisms underlying HCV 
induced-unregulated proliferation of B cells are outlined in Section 1.8.2.1. 
 
1.9 Alterations in Immune Cell Function Coinciding with HCV Infection 
1.9.1 NK and NK T Cell Function Disfunctions 
A number of reports have shown that HCV directly targets NK cell functions, 
although the possibility of HCV replication in these cells has not yet been investigated.  
With regards to NK cells, in vitro studies have shown that binding of HCV E2 to CD81 
leads to direct inhibition on NK cell function (Tseng and Klimpel, 2002; Crotta et al., 
2002), however, this is not the case when E2 is part of complete virions (Yoon et al., 
2009).  In vitro studies have also revealed that HCV core protein upregulates major 
histocompatibility complex (MHC) class I expression on hepatocytes and that it stabilizes 
expression of human leukocyte antigen (HLA)-E by DCs leading to impaired NK cell 
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cytolytic activity (Herzer et al., 2003; Natterman et al., 2006).  Furthermore, it was shown 
that NK cells exhibited decreased cytotoxicity and cytokine production concomitant with 
a downregulation in NKp30 cell surface expression, in the presence of HCV-infected 
cells (Holder et al., 2013).  In Addition, it has been reported that decreased expression of 
MHC class I polypeptide-related sequence A and B (MICA and MICB, respectively) on 
DCs in the setting of CHC further lowers NK cell levels of activation (Jinushi et al., 
2003).  Furthermore, it has been observed that the absolute number and percentage of 
peripheral blood NK cells are decreased in patients with CHC compared to healthy 
individuals (Meier et al., 2005).  It was shown that this abnormality is connected with 
decreased levels of IL-15 (i.e., an important cytokine in NK cell maturation, frequency 
and function) in patients with CHC (Meier et al., 2005).  Since it has been documented 
that DCs have impaired ability to produce IL-15, it is possible that a decreased number of 
NK cells in those patients is a downstream effect of DC impairment (Jinushi et al., 2003).  
Additionally, it has been reported that NK cells in patients with CHC are impaired in their 
ability to produce IFN-γ (Dessouki et al., 2010) and produce more Th2 cytokines, such as 
IL-10 and TGF-β and the chemokine IL-8 (Crotta et al., 2010).  This abnormal NK cell 
cytokine profile leads to polarization of T cell differentiation towards a Th2 response, 
which is associated with HCV persistence, and further compromises DC functions 
(Zignego, 2004).  A recent report (Serti et al., 2014) suggests that the attenuated IFN-γ 
production by NK cells in the setting of CHC is caused by the decreased ability of 
monocytes to respond to HCV infected cells by producing IL-18 which would in turn 
stimulate NK cell cytokine production.  
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The impairment of NK T cells function in the context of HCV infection needs to 
be further investigated.  So far, it has been reported that the frequency of invariant NK 
(iNK) T cells is comparable between healthy individuals and patients infected with HCV.  
However, iNK T cells in CHC produce higher levels of Th2 cytokines upon activation 
contributing to a cytokine milieu that promotes virus persistence (Kanto and Hayashi, 
2007).   
 
1.9.2 Alterations in DC Function 
 As far as pDCs are concerned, it has been shown that their frequency in the 
circulation of patients with CHC is reduced (Decalf et al., 2007) and that there is a 
decreasee in their ability to produce IFN-α after in vitro stimulation (Dolganiuc et al., 
2006).  In vitro studies have shown that HCV core and NS3 proteins trigger TNF-α 
production via TLR-2 engagement, leading to inhibition of IFN-α production and to pDC 
apoptosis (Dolganiuc et al., 2003).  Additionally, it has been reported that HCV JFH-1 
inhibits TLR7 ligand-induced pDC CD40 expression, which in turn impairs the cell 
ability to activate naïve CD4 T cells (Liang et al., 2009). 
 With regards to mDCs, it has been reported that in the setting of HCV infection 
they are characterized by defective maturation and functional differentiation accompanied 
by decreased production of IL-12 and increased release of IL-10 (Auffermann-Gretzinger 
et al., 2001; Dolganiuc et al., 2003).  In vitro studies have demonstrated that HCV core 
binding to complement receptor of macrophages and DCs lead to decreased production of 
IL-12 (Eisen-Vandervelde et al., 2004).  Data regarding the effect of HCV on the 
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allostimulatory capacity of DCs are so far contradictory (Wedemeyer, et al., 2002; Bain et 
al., 2001; Longman et al., 2004).  
 
1.9.3 Alterations in T Cell Functions 
The alterations of T cell functions in the context of HCV infection will be 
discussed in Chapter 5. 
 
1.10 Models for Study of HCV Infection 
1.10.1 Animal Models 
1.10.1.1 The Chimpanzee Model 
Chimpanzees have played a pivotal role in the discovery of HCV, the study of 
HCV infection and characteristics of the elicited innate and adaptive immune responses.  
The major contributions of the chimpanzee model to HCV and hepatitis C research 
include: (1) Discovery of HCV (Choo et al., 1989).  Molecular clones of HCV were first 
isolated from a cDNA expression library prepared with mRNA from a chimpanzee 
challenged with non-A, non-B hepatitis (NANBH)-infected serum; (2) Testing the 
infectivity of different HCV clones (Kolykhalov et al., 1997; Yanagi et al., 1997; 
Shimizu et al., 1998; Sakai et al., 2007); (3) Defining the role of CD4+ (Skoukry et al., 
2003) and CD8+ T cells (Grakoui et al., 2003) in control of HCV; (4) Uncovering the role 
of memory T cells (CD4+ and CD8+) in re-infection with HCV (Farci et al., 1992; 
Nascimbeni et al., 2003; Bassett et al., 2001); (5) Testing efficacy of potential vaccines 
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against HCV (Esumi et al., 1999; Puig et al., 2006; Rollier et al., 2007), and (6) Testing 
the anti-HCV efficacy of antiviral agents (Olsen et al., 2004; 2011; Carroll et al. 2009).  
In many countries, invasive research in chimpanzees has been banned.  A report 
published in 2011 from the Institute of Medicine (IOM) addressing the guidelines for use 
of the chimpanzees, concluded that most research performed on chimpanzees is 
unnecessary.  In 2015, the National Institutes of Health (NIH) announced that it would no 
longer support biomedical research on chimpanzees. 
 
1.10.1.2 The Scid-Alb/uPA Mouse Model 
The Scid-Alb/uPA mice are SCID mice which overexpress a uPA transgene in the 
liver under the control of the albumin promoter (Alb) leading to degeneration of their 
hepatocytes (Mercer et al., 2001).  Being SCID, their livers can be repopulated with PHH 
and can subsequently be infected with HCV.  Scid-Alb/uPA mice have been used 
extensively to study anti-HCV treatments, such as IFN-2α and DAAs, including anti-NS3 
and anti-NS5B proteases (Kneteman et al., 2006; Kneteman et al., 2009).  The antiviral 
effects of telaprevir were studied by utilizing this model (Kamiya et al, 2010).   A major 
disadvantage of the Scid-Alb/UPA model, as with any immunodeficient animal model, is 
the inability to study the host’s immune responses, which are of pivotal importance to the 
pathogenesis and outcome of liver disease in HCV infection.   
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1.10.1.3 The Fah-/-Rag2-/-IL2rg-/- (FRG) Mouse Model 
The FRG mice lack the fumaryl acetoacetate hydrolase gene (Fah), the 
recombination activating gene 2 (Rag2), and the γ-chain of the receptor for IL-2 (Il-2rγ) 
(Bissig et al., 2010).  Lack of Fah causes degeneration of their hepatocytes.  Being 
severely immunocompomised their livers can be repopulated by PHH which can be 
subsequently infected with HCV.  Advantages of this model are that the liver can be 
engrafted up to 95% with human hepatocytes and that degeneration of the hepatocytes 
can be inhibited by an orally administrated drug.  A major contribution of this model was 
its use for testing the efficacy of Debio 025, an HCV inhibitor targeting the host factor 
cyclophilin A (Bissig et al., 2010).  
1.10.1.4 The SCID-BNX Trimera Mouse Model 
 For the generation of this model, mice of a beige/nude/X-linked (BNX) 
immunodeficient background were reconstituted with SCID mouse bone marrow cells 
after total body irradiation.  The mice were then grafted at extrahepatic sites with ex vivo 
infected liver tissue fragments (Galun et al., 1995). The trimera mouse model was used 
for evaluation of a DAA and a anti-HCV putative monoclonal Ab (Ilan et al., 2002).  
Major drawbacks of the system include low levels of viremia as well as a high frequency 
of graft loss. 
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1.10.1.5 The AFC8-hu HSC/Hep Mouse Model 
In this model, liver cell death is induced by expression of a fusion protein of the 
FK506 binding protein (FKBP) and caspase 8, which is driven by the albumin promoter 
(AFC8) (Washburn et al., 2011).  Subsequently, CD34+ human hematopoietic stem cells 
and hepatocyte progenitors are transplanted simultaneously, leading to immune 
reconstitution with human leukocytes and liver repopulation with human hepatocytes.  
The mice can then be infected with sera from HCV-infected patients.  This model allows 
study of HCV-specific T cell responses and liver pathogenesis; however, limitations 
include lack of detection of HCV RNA in the blood and impaired generation of HCV-
specific Abs.   
 
1.10.1.6 Mouse Models Expressing Proposed Human HCV Receptors 
In these mouse models, immunocompetent mice were genetically engineered in 
order to express the human CD81, OCLN, SR-B1 and CLDN1 (Dorner et al., 2011).  The 
HCV genome used for infection of these mice was also genetically modified in order to 
induce luciferase expression in the infected mice.  Since the mice used were 
immunocompetent, HCV replication was very low and transient.  However, that model 
was used to study passive immunization against HCV using anti-CD81 and anti-E2 
antibodies, as well as the efficacy of a recombinant vaccine eliciting anti-HCV nAbs.  
Building on this work, mice expressing human CD81, OCLN, SR-B1 and CLDN1, were 
crossed with mouse strains deficient in several genes involved in innate immunity 
(Dorner et al., 2013).  Blunting innate immune pathways resulted not only in measurable 
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persistent viremia, but also in production of de novo infectious viral particles from the 
liver of infected mice providing evidence for recapitulation of the entire HCV life cycle in 
this mouse model.   
In a similar approach, mice with intact immune system and expressing both 
human CD81 and OCLN genes, were shown to be permissive to infection by HCVcc and 
HCV positive sera (Chen et al., 2014).  In this mouse model, the full HCV life cycle was 
recapitulated, and viremia persisted for more than 12 months accompanied by fibrotic and 
cirrhotic progression.  
 
1.10.1.7 The Tupaia Belangeri (Tree-shrew) Model  
Tupaia belangeri are small mammals native to Southeast Asia.  Initially, it was 
shown that in vitro infection of tupaia primary hepatocytes with serum or plasma from 
HCV-infected humans resulted in productive infection and release of virions capable of 
infecting naïve tupaia hepatocytes (Zhao et al., 2002).  Later on, it was also shown that 
HCV-infected tupaia developed liver pathology and that their serum could be used as 
inoculum inducing HCV infection in HCV-naïve tupaia (Amako et al., 2010).  More 
recent studies showed that transfection of the four tupaia orthologs of CD81, CLDN-1, 
OCLN and SR-B1 in HCV-resistant mouse cell lines rendered them susceptible to 
HCVpp or HCVcc (Tong et al., 2011).  Low HCV viremia is a major limitation for this, 
otherwise, promising animal model. 
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1.10.2 Cell Culture Models 
1.10.2.1 Replicon System 
The replicon system, developed in 1999, is a cell-culture system based on the 
selection of cells supporting stable replication of cloned, sugbenomic, autonomous 
replicating HCV RNAs.  The original subgenomic replicon consisted of a genetically 
modified, self-replicating genotype 1b HCV RNA, which contained a selection marker 
(neo) under the control of HCV 5’-UTR-IRES, and the HCV non-structural genes (NS2-
NS5 or more often NS3-NS5) under the control of an IRES from encephalomyocarditis 
virus that directed replication and polyprotein cleavage (Lohmann, 1999).  Over the past 
years, it became clear that certain cell culture adaptive mutations dramatically enhanced 
RNA replication.  These mutations are mostly located in the center of NS5A encoding 
region (Krieger, 2001).  Since the first generation of replicons, a number of different 
replicon constructs have been created, including subgenomic or genomic, bi- or 
monocistronic, replicons expressing luciferase, subgenomic replicons of genotypes 1a, 2a, 
and, more recently, 3a and 4a (Saeed et al., 2012).  The replicon system enabled the study 
of the HCV replication process, the role of viral proteins, and facilitated discovery of anti-
HCV drugs by allowing high throughput screening of HCV inhibitors that target either 
viral genes or host factors (e.g. cyclophilins).  An example is the discovery of telaprevir 
(VX-950) (Lin et al., 2006) using Huh7 cells bearing the subgenomic replicon as targets.  
The replicon system, however, does not recapitulate the entire HCV life cycle and, 
therefore, it cannot be used to study viral entry, assembly or egress.  More importantly, 
the majority of research using the replicon system has been conducted in Huh7 cells, a 
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hepatocyte-like cell line derived from HCC with many unique features that do not occur 
in PHH. 
 
1.10.2.2 HCV Pseudoparticles (HCVpp) 
The HCV pseudoparticles are lenti- or retroviral core particles expressing the 
HCV glyproteins E1 and E2 on their surface (Bartosch et al., 2003a; Drummer et al., 
2003).  Originally, HCVpp expressed chimeric HCV E1 and E2 proteins, but a second 
generation of HCVpp has been developed using the unmodified HCV glycoproteins.  The 
development of HCVpp allowed studies on HCV entry that started by confirming that 
both E1 and E2 proteins are required in this step (Bartosch, et al., 2003b).  It has since 
been used to identify and confirm HCV candidate receptors and co-receptors, as well as 
host factors affecting HCV infectivity (reviewed in Wilson and Stamataki, 2012).  
Furthermore, studies employing HCVpp confirmed the hypothesis that HCV enters the 
cells via clathrin-mediated endocytosis (Hsu et al., 2003).  The development of HCVpp 
bearing envelope proteins of genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a have enabled studies 
on cross- and genotype-specific neutralization (Bartosch et al., 2003a; Meunier et al., 
2005).  An important drawback of this system is the fact that it does not give information 
on entry for viral particles associated with either lipoproteins or immunoglobulins which 
represent the majority of particles circulating in patient sera, and whether the entry 
facilitated or not productive virus replication.  Finally, the use of Huh7 cells as targets in 
this system limits the in vitro to in vivo correlation and translation. 
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1.10.2.3 Cell Culture-Derived HCV (HCVcc) 
In 2005, it was reported that an HCV strain could replicate and release infectious 
particles (HCVcc) upon transfection of Huh7 cells (Zhong et al., 2005; Lindenbach et al., 
2005; Wakita, 2005).  That strain was cloned from a genotype 2a virus isolated from a 
Japanese patient with fulminant hepatitis and was, therefore, referred to as JFH-1.  A 
unique feature of JFH-1 is that it can replicate efficiently (50-fold more efficiently than 
adapted subgenomic replicons) in Huh7 cells without adaptive mutations (Kato et al., 
2003).  Furthermore, hepatoma cells infected with JFH-1 released viral particles that 
infect naïve Huh7 cells de novo.  JFH-1 is also capable of infecting PHH (Molina et al., 
2008; Helle et al., 2013).  Another important characteristic of JFH-1 is that it can infect 
chimpanzees, although at very low efficiency, as well as, although with significant 
difficulty, mice transplanted with human hepatocytes (Lindenbach et al., 2006; Kato et 
al., 2008).  It is incapable, however, to infect human primary lymphocytes and T cell lines 
unlike authentic, plasma-derived virus (Sarhan et al., 2012b).  Further advancements of 
the HCVcc include the generation of HCVcc inter-genotypic chimaeras (Scheel et al., 
2008) and the JFH1T strain (Russell et al., 2008).  The JFH1T was generated by cell-
culture adaptive mutations and is characterized by a 100- to 1000-fold greater production 
of virus particles compared to the parental JFH-1 (Russell et al., 2008).  A fully 
replicating genotype 1a strain (H77-S) was also generated, but it was found to be of very 
low infectivity to Huh7 cells (Yi et al, 2006).   The HCVcc system enabled extensive 
research in HCV biology and allowed screening for drugs targeting every aspect of HCV.  
Those drug screens, however, only provide information for genotype 2a, which is a rare 
 55 
 
and easy genotype to treat, and reflect virus drug susceptibility in hepatoma Huh7.5 cells 
which may not necessarily mirror susceptibility of hepatocytes infected in situ with 
naturally occurring HCV. 
 
1.10.2.4 In Vitro Infection of Primary Human Hepatocytes (PHH) 
  Some studies have documented successful in vitro infection of PHH with HCV-
positive patient serum (Fournier et al., 1998; Rumin et al., 1999; Castet et al., 2002; 
Lázaro et al., 2007; Gondeau et al., 2014) and release of infectious virus capable of de 
novo infection of virus-naïve PHH (Lázaro, 2007).  The later represents the closest model 
of HCV replication in the liver studied so far.  Infection of PHH with patient serum 
represents a most physiologically relevant system that has provided researchers a great 
insight on the interactions between native HCV and hepatocyte lipoprotein receptors 
(reviewed in Farquhar, 2008).  Furthermore, this system allowed testing PHH 
susceptibility to different HCV genotypes (Lázaro, 2007).  However, PHH are extremely 
hard to establish and maintain in culture, and the cells only show low level, inconsistent 
HCV replication, which has led researchers to explore other alternatives, such as 
micropatterned cocultures (MPCCs) of PHH (Ploss et al., 2010) and hepatocyte-like cells 
derived from human induced pluripotent stem cells (iPSCs) (Schwartz et al., 2012; Wu et 
al., 2012). 
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1.10.2.5 In Vitro Infection of Primary Human T Lymphocytes and T Cell Lines 
The first in vitro infection system using wild-type, plasma-occurring HCV and 
primary human T lymphocytes was developed in this laboratory (MacParland et al., 
2006).  This system was based on the previous studies demonstrating that 
phytohaemagglutinin (PHA), as well as other mitogens, can induce upregulation of HCV 
replication in human lymphocytes (Pham et al., 2004, 2005).  Subsequently, PHA-
pretreatment of primary T cells was used to increase their susceptibility to patient-
derived, native HCV.  Utilizing this system, it was found that HCV can infect PBMC-
derived T cells, as evidenced by expression of HCV replicative strand, non-structural 
proteins and the identification of unique HCV variants in the target cells.  In addition, it 
was shown that the virions secreted by the in vitro infected T cells were able to de novo 
infect mitogen-induced, HCV-naïve lymphocytes.  The biophysical properties of the 
produced virions were characterized by sucrose gradient centrifugation and immune 
electron microscopy (IEM).  The results showed that the viral particles released by the in 
vitro infected cells had similar physical and structural properties to those of complete 
HCV virions.  Furthermore, using this in vitro infection system, CD5 was found to be 
essential for infection of human T lymphocytes with naturally occurring HCV (Sarhan et 
al., 2012a).  
Other in vitro studies have shown that authentic, patient-derived HCV can 
propagate in human T cell lines (Shimizu et al., 1992; Sarhan et al., 2012a, 2012b).  
Importantly, the virus produced by the in vitro infected T cell lines was also found to be 
infectious to chimpanzees (Shimizu et al. 1998).  Finally, it has been documented that 
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HCV secreted from a B-cell line (SB cells) was able to infect primary human CD4+ T 
lymphocytes in vitro (Kondo et al., 2010).  
 
1.10.2.6 In Vitro Infection of Other Immune Cell Types 
Numerous studies have documented the ability of HCV to infect immune cell 
types other than T lymphocytes in vitro.  A study published by Bertolini et al. in 1993 
documented the ability of wild-type, plasma-occurring HCV to infect the human bone-
marrow-derived B-cell line CE in vitro.  Furthermore, it has been shown that, TOFE, a 
human lymphoblastoid B cell line (LCL), supports long-term viral replication of wild-
type, plasma-occurring HCV (Valli et al., 1995; Iacovacci et al., 1997; Serafino et al., 
2003).  Sung et al., 2013 established three in vivo HCV-infected B-cell lines directly from 
patients with CHC.  One of these B-cell lines (SB) persistently produced HCV virions in 
culture and was able to infect PBMC and Raji B-cell line in vitro.  Apart from B cells, 
human monocyte/macrophages were also found to be susceptible to in vitro infection with 
wild-type HCV (Caussin-SchwemLing et al., 2001; Radkowski et al., 2003), as well as 
DC (Navas et al., 2002). 
 
1.11 Therapy of HCV Infection 
1.11.1 Standard Anti-HCV Therapy 
The goal of treatment for hepatitis C patients is SVR, which is defined by clinical 
assays as undetectable serum or plasma HCV RNA 6 months after completion of therapy.  
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This status is associated with less than 5% chance of recurrence of a symptomatic disease 
(Shiffman, 2006).  The first treatment option for patients with CHC was IFN-α 
(Hoofnagle et al., 1986).  The success rates of which ranged between 6-12%.  When IFN-
α was combined with ribavirin (RBV) treatment success rates increased to 38% and 
reached 55% when pegylated-IFN-α (PEG-IFN-α) and RBV were employed (Poynard et 
al., 1995; McHutchinson et al., 1998; Manns et al., 2001; Fried et al., 2002).  PEG-IFN-α 
and RBV is the standard of care since 2002 (Poynard et al., 1995; McHutchinson et al., 
1998; Manns et al., 2001; Fried et al.,, 2002).  The response to PEG-IFN/RBV depends 
greatly on the HCV genotype with the SVR rates for patients infected with HCV 
genotype 1 ranging between 41-52% in comparison to 76-84% for genotypes 2 and 3 
(Manns et al., 2001; Fried et al., 2002; Shiffman et al., 2007).  Genotype 4, 5 and 6 on the 
other hand are associated with lower responsiveness, but still higher than that of genotype 
1 (Manns et al., 2001; Fried et al., 2002; Jacobson et al., 2007; Shiffman et al., 2007).  
More specifically, the SVR rates for genotype 4 range between 65% and 72% (Alfaleh et 
al., 2004; Hasan et al., 2004; Khuroo et al., 2004.  Thus, determining genotype prior to 
treatment is of great clinical importance.  It defines treatment duration which for patients 
with HCV genotype 2 and 3 receiving PEG-IFN/RBV is 24 weeks, in contrast to patients 
infected with HCV genotype 1, 4, 5 and 6 who are being treated for a total of 48 weeks. 
 In 2011, the first DAAs, boceprevir and telaprevir, both protease inhibitors, were 
approved by the Food and Drug Administration (FDA) and Health Canada and have since 
been a part of the standard of care for the treatment of genotype 1.  More specifically, 
administration of boceprevir begins 4 weeks after PEG-IFN/RBV treatment initiation and 
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continues for the remainder of the 44 weeks, while telaprevir administration is initiated 
with the start of PEG-IFN/RBV and ends 32 weeks prior to PEG-IFN/RBV completion.  
Incorporation of either of these protease inhibitors in triple therapy has brought the SVR 
rates up to 70-80% for HCV genotype 1 patients, both treatment naïve and those who had 
previously failed to achieve SVR with IFN/RBV treatment (Shiffman, 2011).   Those two 
protease inhibitors have, therefore, revolutionized HCV therapy, making for the first time 
CHC cure more likely for patients infected with genotype 1.  Unfortunately, triple therapy 
as well as PEG-IFN/RBV alone is accompanied by numerous side effects, such as 
anemia, insomnia, anxiety, depression, IFN-thyroid disease, nausea, diarrhea, anal-rectal 
discomfort, rash, pruritus and others, making adherence to therapy extremely challenging. 
In 2013, two new DAAs were approved by FDA and Health Canada, simeprevir 
(TMC435) and sofosbuvir (PSI-7977).  Simeprevir is a NS3/4A protease inhibitor 
(Raboisson et al., 2008) which is taken orally once a day and is generally well tolerated.  
Phase III trials have demonstrated that it is much superior compared to PEG-IFN/RBV 
alone and that it exhibits high efficacy in treating genotype 1a and 1b infections in 
treatment-naïve patients and in patients who have been previously treated with IFN-based 
therapies (You and Pockros, 2013).  Overall, up to 80% of clinical trial participants with 
HCV genotype 1 infection achieved SVR upon completion of therapy that included 
simeprevir (Traynor, 2014).  For patients with HCV genotype 1 without cirrhosis and 
without HIV-1 co-infection, 12 weeks of dual therapy with simeprevir and sofosbuvir is 
recommended.  For cirrhotic patients infected with HCV genotype 1 and without HIV-1 
co-infection, duration of dual therapy with simeprevir and sofosbuvir is extended to 24 
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weeks.  Finally, for patients infected with HCV genotype 1 or 4, with or without cirrhosis, 
the recommended treatment is simeprevir in combination with PEG-IFN/RBV for 12 
weeks, followed by an additional 12 or 36 weeks of PEG-IFN/RBV depending on prior 
response status and presence of HCV-1 co-infection. 
Sofosbuvir is a prodrug acting as an NS5B polymerase inhibitor (Murakami et al. 
2010; Sofia et al. 2010).  It is taken orally once a day and it is generally well tolerated.  
Clinical trials have shown that 90% of patients with HCV genotype 1a infection receiving 
sofosbuvir in combination with PEG-IFN/RBV achieve SVR 12 weeks after treatment 
discontinuation (Koff, 2014).  Patients with HCV genotype 2 infection receiving 
sofosbuvir with RBV alone also achieve SVR 12 weeks after treatment discontinuation at 
a rate of at least 90% with little effect from coinciding cirrhosis.  For HCV genotype 3 
infected patients 24 weeks of dual therapy with sofosbuvir and RBV is recommended 
(Koff, 2014).  Patients with HCV genotype 4 infection receiving sofosbuvir in 
combination with PEG-IFN/RBV achieve SVR in 12 weeks at a rate of 96% (Lawitz et 
al., 2013).  The efficacy of sofosbuvir in combination with PEG-IFN/RBV or with RBV 
alone signifies a new era in HCV treatment.  In 2014, FDA approved the use of 
sofosbuvir in combination with ledipasvir, an NS5A inhibitor (previously GS-5885) (Link 
et al., 2014).  The sofosbuvir and ledipasvir combination product, called Harvoni, is 
indicated, with or without RBV, for the treatment of genotype 1, 4, 5 or 6 CHC infection. 
In 2014, FDA approved Viekira Pak which includes ombitasvir (ABT-267) an NS5A 
inhibitor, paritaprevir (AB-450), an NS3/4A protease inhibitor, ritonavir (ABT-450/r) a 
CYP3A inhibitor and dasabuvir (ABT-333), a non-nucleoside NS5B palm polymerase 
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inhibitor (Deeks et al., 2015).  Viekira Pak, with or without RBV, is indicated for the 
treatment of patients with genotype 1 CHC infection, including those with compensated 
cirrhosis.  In 2015, ombitasvir, paritaprevir and ritonavir were approved by the FDA for 
the treatment of patients with genotype 4  CHC infection without cirrhosis, used in 
combination with RBV, providing the first IFN-free treatment option for patients with 
genotype 4 infection.  
Daclatasvir (BMS-790052), an NS5A inhibitor (Lemm et al., 2011), was approved 
by the FDA in 2015 for use, in combination with sofusbuvir, for the treatment of HCV 
genotype 3 infections.  In 2016, its use in combination with sofusbuvir, with or without 
RBV, was expanded for the treatment of HCV genotypes 1 and 3.  
 Finally, in 2016, FDA approved elbasvir (MK-8742), an NS5A inhibitor (Coburn 
et al., 2013), in combination with grazoprevir (MK-5172), an NS3/4A protease inhibitor 
(Harper et al., 2012), for the treatment of genotype 1 or 4 chronic HCV infections, with or 
without the use of RBV.  
When treatment has failed or emergence of decompensated liver disease has 
preceded CHC diagnosis, orthotopic liver transplantation (OLT) is performed as the last 
resort.  In the United States, decompensated cirrhosis from CHC is the main reason for 
OLT with 40-45% of all OLT performed because of HCV-induced ESLD (Davis et al., 
2003; El Serag, 2004).  Recurrence of HCV infection is nearly universal in pre-OLT 
viremic patients, leading to diminished graft and patient survival (Féray et al., 1992; 
Wright et al., 1992; Rosen et al., 1998).  In fact, within days post-OLT, serum HCV RNA 
titers may reach levels similar to those observed before operation and peak 1-3 months 
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later, reaching levels several-fold higher than prior to transplant (Wiesner et al., 2003; 
Charlton et al., 2003).  As a result, there is acceleration of histological progression of 
hepatitis, which can lead to rapid development of cirrhosis and graft failure (Gane et al., 
1996; Forman et al., 2002; Chopra et al., 2003).  Therefore, it is critical to continuously 
treat these patients with highly effective antiviral agents. 
 
1.11.2 Factors Affecting and Predicting Antiviral Therapy Outcome 
Close monitoring of viral kinetics throughout anti-HCV therapy have revealed 
various treatment outcomes in CHC patients.  As previously mentioned, SVR  is defined 
as undetectable HCV RNA by the current laboratory assays, up to 24 weeks after 
completion of therapy.  However, SVR is very rarely achieved as shown when assays of 
enhanced sensitivity are being used for HCV RNA detection (reviewed in Pham et al., 
2010; Chen et al., 2013).  Rapid virologic response (RVR) is defined as an undetectable, 
by the current assays, serum HCV RNA at treatment week 4.  Early virologic response 
(EVR) consists of an HCV RNA reduction > 2 log in comparison to baseline viral titers 
by 12 weeks of therapy.  Nonresponse is defined as < 2 log reduction of HCV RNA levels 
after 12 weeks of therapy compared to baseline titers, while partial response consists of 
an EVR which is not followed by viral titer decrease to undetectable levels at week 24 of 
therapy. 
` Predicting probable treatment outcomes is of critical significance for identification 
of ideal duration of treatment and optimization of therapy in general.  Several HCV and 
host factors can predict treatment response.  Among viral factors, HCV genotype is a 
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critical baseline predictor for response to PEG-IFN/RBV, with genotype 1 patients 
showing the poorest response to treatment and patients infected with genotype 2 and 3 
achieving the highest response rates. 
HCV quasispecies variation can also predict treatment outcome, even though this 
factor is not routinely used as a predictor in a clinical setting.  Patients with minimal HCV 
genomic variant complexity have less chances of harboring treatment-resistant 
quasispecies and, therefore, are more likely to achieve SVR (Pawlotsky, 2003 and 2006).  
Additionally, mutations within certain HCV genomic regions (i.e., NS5A region; see 
Section 1.4.2) have been found to be associated with higher SVR rates. 
HCV plasma baseline viral load is another important viral pre-treatment predictor 
of response to therapy.  Patients with low baseline HCV load (i.e., <600,000 – 800,000 
IU/L) have increased chances of achieving SVR, regardless of HCV genotype (Poynard et 
al., 1998; Manns et al., 2001; Zeuzeum et al., 2006), while patients with high pre-
treatment viral load (i.e., >800,000 IU/L) are more resistant to therapy and generally have 
worse long-term outcomes.  In this regard, it has been documented that pre-treatment 
HCV RNA loads in PBMC of non-responders to PEG-IFN/RBV were significantly higher 
than those of responders (Pham et al., 2013). 
 Viral kinetics during PEG-IFN/RBV therapy is also considered valuable indicator 
of treatment outcome.  Patients presenting an RVR have >85% chances of achieving SVR 
(Martinot-Peignoux et al, 2009), while not achieving EVR by week 12 is associated with 
97-100% chances of failure to secure SVR (Davis et al., 2003; Ferenci et al., 2005).  
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Finally, no viral titer decrease throughout treatment means that patients will not be able to 
respond to therapy (Martinot-Peignoux et al., 1998; 2009).  
With regards to host predictors of treatment outcome, advanced age (Manns et al., 
2001), male gender (Poynard et al. 2007) and African-American ethnicity (McHuthchison 
et al., 2000; Jeffers et al., 2004) are factors associated with poor response to PEG-
IFN/RBV.  Lower SVR rates are also associated with obesity (body mass index (BMI) > 
25 kg/m2) (Ortiz et al., 2002), insulin resistance (Romero-Gomez, 2005), as well as 
certain liver histological parameters (i.e., advanced fibrosis, cirrhosis and steatosis, 
Poynard et al., 2000; Everson et al., 2006; Leandro et al., 2006). Comorbidities, such as 
HIV or HBV co-infection, excessive alcohol consumption, and drug use also compromise 
response to IFN/RBV treatment (Alberti et al. 2009). 
Furthermore, ISG baseline expression pattern has been shown to predict treatment 
outcome.  More specifically, in studies with HCV-infected chimpanzees, it was reported 
that high levels of ISGs in the liver correlate with IFN treatment failure (Lanford et al., 
2007).  In studies conducted in liver biopsies of individuals with CHC, it was found that 
high ISG expression in hepatocytes is associated with poor response to treatment, while 
high ISG expression in liver infiltrating monocytes correlates with improved treatment 
response (McGilvray et al., 2012).  To this regard, a study reported in 2013 by Pham et 
al. showed that the baseline expression levels of IL-8, ISG15, OAS and TLR-4, -5, and 7 
in the PBMC of non-responders to treatment were 3- to 10-fold higher than those of 
responders.  After treatment, non-responders persistently expressed 6- to 20-fold higher 
levels of IL-8, ISG15 and OAS in their PBMC compared to responders.  In the same 
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study, it was documented that the expression levels of IFN-α, ΙFN-γ and IFN-λ in the 
PBMC of responders were higher before and after treatment compared to those of non-
responders. 
Finally, a polymorphism found in the region of the IL28B gene is a strong 
predictor of treatment outcome with IFN-α/RBV as summarized in Section 1.6.2.  This 
SNP (rs12979860) is located near the IL28B gene, encoding IFN-λ-3, and defines 2 
alleles C and T.  The C allele is associated with an almost two-fold increase in response to 
IFN/RBV treatment, among patients of European ancestry and African-Americans. 
Furthermore, the C-allele is associated with a greater likelihood of spontaneous resolution 
of hepatitis C (Ge et al., 2009).  
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CHAPTER TWO: HYPOTHESIS AND AIMS OF THE 
STUDY 
 
 The ability of HCV to replicate in CD4+ and CD8+ T cells in vivo has been shown 
by a study where HCV RNA positive and negative strands as well as HCV NS5A protein 
were detected in the immune cell subsets of patients with CHC and OCI (Pham et al., 
2008).  In the same study, it was shown by clonal sequencing that HCV variants harbored 
in the in vivo infected cells differed from those carried in the plasma of these patients, 
providing supporting evidence of active HCV replication in these immune cells. 
  Furthermore, an in vitro HCV replication system was previously established in 
which mitogen-induced total T cell cultures derived from PBMC served as targets for 
plasma occurring, wild-type HCV (MacParland et al., 2006), as summarized in Section 
1.10.2.5.  However, it remained unidentified if both CD4+ and CD8+ T cells were 
susceptible to infection with native HCV.  It was expected that a significantly different 
intracellular anti-viral cytokine milieu in CD4+ and CD8+ T lymphocytes may predispose 
them to different susceptibility to HCV infection. 
 To investigate the ability of authentic HCV to infect CD4+ and CD8+ T 
lymphocytes in vitro and to characterize the molecular and biophysical properties of the 
virus propagating in these subsets, we adopted the previously established in vitro HCV 
replication system in total T cells derived from normal human PBMC by employing 
affinity-purified, normal human CD4+ and CD8+ T lymphocytes as targets.  Thus, the 
aims of our study were: 
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 1. To establish, based on the previous acquired expertise, an in vitro infection 
model in which patient-derived HCV infects normal human primary CD4+ and CD8+ T 
lymphocytes. 
 2. To determine whether productive replication of HCV takes place in the in vitro 
infected CD4+ and CD8+ T cells by detecting HCV RNA negative (replicative) strand and 
intracellular localization of HCV structural and non-structural proteins. 
 3. To characterize the biophysical properties of HCV RNA-reactive particles 
released by de novo infected CD4+ and CD8+ T cells and compare them to those of 
virions occurring in the plasma serving as HCV inocula to infect these cells. 
 4. To assess the existence of HCV variant sequences in the de novo infected CD4+ 
and CD8+ T cells and determine if they differ from those occurring in the plasma used as 
HCV inocula.   
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CHAPTER THREE: MATERIALS AND METHODS 
 
3.1 Donors of HCV Inocula 
 The expertise previously gained in this laboratory that applied the HCV 
replication system in T cells revealed that the following conditions can lead to the 
identification of HCV inocula most suitable for infection experiments: (1) Treatment-
naïve patients with CHC should serve as donors; (2) Their plasma should carry a high 
HCV RNA load, preferable more than 104-105 vge/mL; (3) HCV RNA should be 
detectable in the donors PBMC, and (4) Their plasma should be capable of in vitro 
infecting normal PBMC-derived T cells using the conditions previously established in 
this laboratory (MacParland et al., 2006).  Therefore, identifying donors of HCV inocula 
for the in vitro infection of affinity-purified CD4+ and CD8+ T cells in this study was a 
three-step process (see Figure 3.1).  At step one, the HCV RNA load in the plasma of 16 
patients with clinical diagnosis of CHC was evaluated by real-time RT-PCR.  At the 
second step, real-time RT-PCR was used again to examine the presence of HCV RNA in 
the PBMC of patients with detectable HCV RNA in their plasma.  In cases where HCV 
RNA in the PBMC was undetectable by real-time RT-PCR, we employed the nested-RT-
PCR/NAH assay the sensitivity of which is approximately 10-fold greater than that of the 
former (Pham et al., 2004).  At the final step, plasma carrying high HCV RNA load from 
patients with detectable HCV RNA in their PBMCs were used for in vitro infection 
experiments of PBMC-derived T cells using the cell culture conditions established 
previously (MacParland et al., 2006).  Plasma found capable of in vitro infecting PBMC-
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Figure 3.1.  Overall approach to selection of HCV-positive inocula for T lymphocyte 
infection experiments and the numbers of the inocula examined at each stage. 
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derived T cells, as evidenced by detection of HCV RNA positive and negative strands, 
served as inocula for the in vitro infection experiments with affinity-purified CD4+ and 
CD8+ T cells as targets. 
 
3.2 HCV Immune Cell Targets 
 Monocyte-depleted PBMC (see Section 3.5), as well as CD4+ and CD8+ T cells 
affinity-purified from PBMC of two healthy individuals (A/M and B/F) served as targets 
for HCV in vitro infection experiments.  As indicated in Section 3.1, monocyte-depleted 
PBMCs were used as targets for HCV infection experiments aiming to identify the most 
infectious and suitable inocula used in the main infection experiments with affinity-
purified CD4+ and CD8+ T cells.  The donors of PBMC had no clinical history of HCV 
exposure and their sera was negative for HCV RNA, as evidenced by RT-PCR/NAH 
assay (sensitivity ≤ 10 vge/mL or 3 IU/mL) (Pham et al., 2004) and for anti-HCV 
antibodies (enzyme immunoassay; Abbott Molecular, Mississauga, Ontario, Canada).  
Affinity-purified CD4+ and CD8+ T cells from healthy controls were also exposed, in 
some experiments, to healthy donor plasma (HDP), as controls.  
 
3.3 Plasma Collection and PBMC Isolation 
 Blood between 20 and 130 mL, depending on the type of experiment, was 
collected in Vacutainer tubes containing acid-citrate-dextrose anticoagulant, solution A 
(ACD-A) (Becton Dickinson, Franklin Lakes, New Jersey).  PBMC isolation was 
performed immediately after blood collection to avoid potential RNA degradation.  
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Initially, the blood was centrifuged at 800 x g for 30 minutes (min) at ambient 
temperature (AT).  The supernatant was then carefully removed, aliquoted in 1.8 mL 
poly-propylene precooled tubes (Nunc CryoTubes; Sigma-Aldrich, Oakville, Ontario, 
Canada) and stored at -80˚C.  Following plasma removal, the remainder blood was 
diluted with phosphate-buffered saline (PBS) containing 2 mM 
ethylenediaminetetraacetic acid (EDTA) (1:1 final dilution), carefully layered over Ficoll-
Paque PLUS (GE Healthcare Life Sciences, Little Chalfont, United Kingdom) in a 1:1 
ratio, and centrifuged at ~400 x g for 30 min at AT.  The buffy coat (thin white interface 
containing PBMC) was carefully collected, diluted with PBS-EDTA in a ~ 1:1 ratio, and 
centrifuged at 200 x g for 10 min at AT.  The supernatant was collected and the cell pellet 
was treated with 5-10 mL of ammonium-chlorate-potassium (ACK) buffer for 15 min to 
lyse contaminating red blood cells.  After ACK treatment, 5-10 mL of PBS-EDTA were 
added and the cells were centrifuged at 200 x g for 10 min at AT.  The supernatant was 
removed and the resulting pellet diluted with PBS-EDTA to allow accurate cell counting 
and estimation of viability using a benchtop automated cell counter (Countess Automated 
Cell Counter; Invitrogen Life Technologies, Burlington, Ontario, Canada). 
 
3.4 T Lymphocyte Subsets Isolations 
 CD4+ and CD8+ T cells were affinity-purified from total PBMC of healthy donors 
by positive selection using a stepwise approach and an automatic bench-top seperator 
(AutoMACS, Miltenyi Biotech Inc., Auburn, California).  B cells and monocytes were 
also isolated during this process for use in other ongoing experiments not related to this 
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study.  Sequential sorting of cell subsets was performed in a specific order (see Figure 
3.2) and following a protocol developed in this laboratory aiming to maximize cell 
recovery and purity of multiple immune cell types from the same PBMC sample (Corkum 
et al., manuscript in preparation). 
 In the first step, isolation of CD19+ positive cells was performed.  For this 
purpose, total PBMC were centrifuged at 350 x g for 15 min at 4°C, and cells were 
resuspended in 80 μL of precooled MACS running buffer (solution containing PBS, pH 
7.4, 0.5% bovine serum albumin (BSA), and 2 mM EDTA) per 107 cells.  20 μL of CD19 
microbeads (Miltenyi Biotech Inc.) were added and the cells were incubated for 15 min 
on ice.  Then, cells were washed with adding MACS running buffer, bringing total 
volume to 10 mL, and mixed by gently inverting the tube containing cell suspension.  The 
cells were spun down at 350 x g for 15 min at 4°C.  The supernatant was discarded and 
the cell pellet was resuspended in 2 mL of MACS running buffer.  At this point, the cell 
suspension was ready for magnetic separation.  CD19+ cells were isolated using a positive 
selection in standard mode on two subsequent columns.  After isolation was completed 
cells were counted in the CD19+ positive and negative fractions, and cells were 
cryopreserved.  The CD19- fraction was used for subsequent subsets isolations.  Thus, 
CD8+ T cell affinity purification was done next, but using CD8+ microbeads.  After 
obtaining the CD8+ positive fraction, CD8+ T cells were counted, their viability measured, 
and they were immediately used for HCV infection experiments.  After CD8+ positive 
selection, we proceeded to CD14+ isolation prior to CD4+ selection.  We followed this 
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Figure 3.2.  Separation of different immune cell subsets from total PBMC by sequential 
positive selection using macrobeads coated with antibodies against individual immune 
cell markets and autoMACS Myltenyi Pro Separator.  Initially, separation of CD19+-
positive B cells was done that was followed by positive removal of CD8+ T lymphocytes, 
as both of these cell populations represent relatively small percentages of the total PBMC 
population.  Subsequently, positive selection of CD14+ (monocytes) was done prior to 
CD4+ T cell selection to avoid contamination of CD4+ T cells with CD14+ cells since 
some them also express CD4.  * CD19+ and CD14+ cells were not investigated in this 
study (Corkum et al. manuscript in preparation).  
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order of separation since some macrophages are known to express low levels of CD4+ and 
we wanted our CD4+ population to have the highest purity possible.  For positive 
selection of CD14+, we followed the same procedure as for CD19+ and CD8+ cells with 
the only difference being the separation program applied. We used the possel program, 
which performed a positive selection in standard mode for isolation of cell populations 
with frequencies higher than 5%.  The isolated CD14+ cells were cryopreserved and the 
CD19-CD8-CD14- negative fraction was used for positive selection of CD4+ cells.  For 
this purpose, we followed the procedure used for CD14+ isolation.  After isolation of 
CD4+ cells, the cells were counted and used as targets for infection with HCV. 
 
3.4.1 Assessment of Cell Purity by Flow Cytometry 
 Purity of isolated CD4+ and CD8+ T cell subsets was evaluated using flow 
cytometric analysis immediately following isolation.  For each labelling, 5 x 105 cells 
were collected into FACS tubes where MACS running buffer was added to bring volume 
to 100 μL.  Cell subsets were incubated with peridinin chlorophyll protein complex 
(PerCP)-conjugated anti-human CD4, fluorescein isothiocyanate (FITC)-conjugated anti-
human CD8, allophycocyanin (APC)-conjugated anti-human CD14, and phycoerythrin 
(PE)-conjugated anti-human CD20.  Antibodies to CD20 were used instead of CD19 
since, after CD19 microbead labeling of cells, CD19 staining can be weak.  Parallel 
incubations with appropriate isotype controls were performed using PerCP-conjugated 
mouse IgG2a, FITC-conjugated mouse IgG2a, APC-conjugated mouse IgG2a, and PE-
conjugated mouse IgG1. All antibodies and isotype controls were purchased from 
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Miltenyi Biotec.  Incubation took place in the dark at 4°C for 30 min.  The cells were then 
washed with 2 mL of 0.25% Tween-20 (Sigma-Aldrich) in PBS-EDTA by centrifugation 
at 300 x g for 10 min at 4oC, fixed in 2% paraformaldehyde (PFA) in PBS-EDTA, 
washed again, and examined with a FACSCalibur cytometer (Becton Dickinson 
Biosciences, Mountain View, CA).  Analysis of the data was performed using FlowJo 
v.X.0.7 software (Tree Star, Ashland, Oregon).  Using forward versus side scatter, 
lymphocytes were selected.  Gates for determining positivity were established using 
isotype controls so that ~99.0 % of events were negative. 
 
3.5 HCV Infection System 
 For infection experiments with T cell-enriched PBMC as targets, 4-6 x 107 total 
PBMC were placed into flasks with complete AIM-V medium (Invitrogen) and left at 
37°C for 2.5 hours (h) to deplete monocytes via adhesion to plastic.  Subsequently, the 
supernatant from the flask was transferred into 50 mL conical tubes and centrifuged at 
400 x g for 15 min.  After centrifugation, the supernatant was discarded and the cell pellet 
resuspended with appropriate volume of PBS-EDTA to achieve a cell concentration that 
would allow accurate cell counting and measurement of viability using the Countess.  
After counting, monocyte-depleted PBMC were used as targets for infection with HCV 
(MacParland et al., 2006; see Section 3.5).  
 Thus, monocyte-depleted PBMC, or afffinity-purified CD4+ or CD8+ T cells were 
exposed to 5 μg/mL of phytohemagglutinin (PHA; ICN Biomedicals Inc., Aurora, Ohio) 
for 48 h at 37°C, prior to inoculation with HCV (Pham et al., 2004).  PHA-pretreated 
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cells were exposed to HCV infectious plasma at different virus/cell ratios (see Table 4.2).  
Prior to inoculation the HCV infectious plasma was cleared at 400 x g, 4°C for 30 min 
and heat-inactivated at 56°C for 30 min.  After 24 h inoculation the HCV inoculum was 
removed, cells were washed three times, counted and cultured under alternating 
stimulation with PHA and/or interleukin-2 (IL-2; 20 U/mL; Roche Diagnostics, Quebec, 
Canada) for 14 days post-infection (d.p.i.), as described before (MacParland et al., 2006) 
(see Figure 3.3).  More specifically, after removal of the inoculum cells were cultured 
with IL-2 for 72 h (phase A), followed by a 72 h stimulation with IL-2 and PHA (phase 
B).  Then, cells were cultured with IL-2 alone for another 72 h (phase C), and finally with 
IL-2 and PHA for 96 h (phase D).  At the end of each phase, 106 cells/mL were put back 
in culture after being washed three times.  The remaining cells were used for HCV RNA 
positive and negative strand analysis and for identification of NS5A and core proteins by 
confocal microscopy.  Cell culture supernatants were also collected at the end of each 
phase.  Collected supernatants were stored at -80°C until use for characterization of the 
biophysical properties of HCV RNA-reactive particles via buoyant density gradient 
analysis. 
 
3.6 Analysis of HCV Biophysical Properties 
3.6.1 Iodixanol Gradient 
 To examine the buoyant density of the viral particles released from the in vitro 
infected cells and compare it to that of the virions carried in the plasma used as inoculum, 
iodixanol gradient ultracentrifugation was performed.  For this purpose, we used culture
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Figure 3.3.  Schematic representation of HCV-infection cell culture system used in this 
study.  Monocyte-depleted PBMC or affinity-purified CD4+ and CD8+ T cells were 
exposed to 5 μg/mL of PHA for 48 h prior to inoculation with HCV.  PHA-treated cells 
were exposed to HCV inoculum at different virus: cell ratios as shown in Materials and 
Methods and Results.  After 24-h inoculation, the inoculum was removed, cells washed 
and cultured under alternating stimulation with PHA and/or IL-2 for 14 days post-
infection (d).  The 3-day period between 1 d and 4 d was designated as phase A, between 
4 d and 7 d as phase B, between 7 d and 10 d as phase C, and between 10 d and 14 d as 
phase D.  
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supernatants (10 mL) collected from timepoints of experiments where HCV RNA 
negative strand had been detected after infection of CD4+ or CD8+ T cells.  More 
specifically, from experiment III (Table 4.3), we used supernatants collected from 10 
d.p.i. as well as 14 d.p.i. from infected CD4+ T cells, and 7 d.p.i. from CD8+ T cells.  We 
also included the inoculum HCV-11/M used in this experiment.  Thus, 200 μL of HCV-
11/M plasma in 9.8 mL PBS was used as a control.  From experiment VI (Table 4.3), 10 
mL of culture supernatants collected from 14 d.p.i. from CD4+ T cells and 10 d.p.i. from 
CD8+ T cells infected with inoculum HCV-16 were used.  Again, we included 200 μL of 
plasma 16 in 9.8 mL PBS.  All supernatants were initially pre-clarified at 400 x g for 30 
min at 4°C in the presence of a protease inhibitor cocktail (Sigma-Aldrich) in a 1 to 200 
ratio.  Subsequently, they were concentrated by ultracentrifugation at 150,000 x g for 22 h 
at 4°C in a TH-641 rotor using Sorvall Discovery 100SE ultracentrifuge (Mandel 
Scientific Company Inc., Guelph, Canada).  After removal of supernatant, the pellets 
were resuspended in 500 μL of culture medium (AIM-V).  In parallel, 50 μL of plasma 
were diluted in 450 μL of medium (AIM-V).  Resupended pellets and diluted plasma 
were layered separately over a 4.5 mL continuous 10 to 50% iodixanol gradient (prepared 
using OptiPrep Density Gradient Medium [Sigma] and Hanks’ balanced salt solution 
[HBSS; Invitrogen]).  A gradient consisting solely of culture medium (i.e., 500 μL of 
AIM-V medium layered over a 4.5 mL continuous 10 to 50% iodixanol) was also 
prepared following the procedure described above.  After ultracentrifugation at 100,000 x 
g for 16 h at 4°C in a Beckman SW55 Ti rotor (Beckman Coulter Inc, Pasadena, 
California) (Jones et al., 2011), sixteen 300 μL fractions were collected starting from the 
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top of each tube.  The fractions obtained from the gradient consisting only of culture 
medium were used for measuring iodixanol density using a refractometer (UriSystem 
refractometer; Fisher Scientific International Inc., Hampton, New Hampshire). 
 
3.7 RNA Extraction 
 For total RNA extraction from cells, 1 mL of TRIzol Reagent (Invitrogen) was 
added to ~ 1 x 107 cells.  For RNA isolation from plasma or iodixanol gradient fractions, 
250 μL or 300 μL of each aliquot was supplemented with 750 μL or 700 μL, respectively, 
of TRIzol LS (Invitrogen).  In all cases, 200 μL of chloroform were added to each sample 
following 30 min incubation at AT.  After vigorous shaking for 30 seconds (s), samples 
were incubated at ambient temperature for 2 to 3 min and centrifuged at 12,000 x g for 15 
min at 4˚C.  After centrifugation, the aqueous phase of each sample was transferred to a 
fresh tube where 500 μL of isopropanol were added.  Samples were vigorously shaken 
again for 30 s and left at -20 ˚C overnight.  After being retrieved from -20˚C, the samples 
were centrifuged at 12,000 x g for 10 min at 4˚C, the supernatant removed and pellets 
washed with 75% ethanol.  The samples were centrifuged again at 7,500 x g for 5 min, 
the supernatant removed and the resulting RNA pellets left to air dry for no more than 5 
min.  Finally, the pellets were suspended in appropriate volume of RNase-free TE buffer 
(1 mM EDTA in 10 mM Tris-HCl buffer, pH 8.0; Ambion by Life Technologies), and the 
concentration and quality of the RNA was evaluated using spectrophotometric analysis of 
OD260.  1 x 107 PBMC or T cells would yield 20 to 30 μg of RNA. RNA was aliquoted to 
5 μg per vial and stored at -80 ˚C until use.  A mock sample containing UltraPure 
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DNase/RNase-free distilled water (Invitrogen) added in TRIzol in place of in vitro 
infected sample or plasma was always included as a contamination control.  When cell 
numbers allowed, RNA was also extracted from affinity-purified CD4+ (experiments I, III 
and VI) and/or CD8+ T cells (experiment III) exposed to HDP as additional 
contamination and infection controls. 
 
3.8 cDNA Synthesis 
 For cDNA synthesis, 1 to 4 μg of RNA extracted from  HCV-exposed and control 
T-cell enriched PBMC and affinity-purified CD4+ and CD8+ T cells and all RNA 
extracted from 250 μL of plasma or 300 μL of iodixanol fractions were transcribed using 
Moloney murine leukemia virus reverse transcriptase (M-MLV RT) (Invitrogen).  Thus, a 
20 μL volume reaction was assembled on ice by mixing 1-4 μg of RNA template with 4 
μL of 5X First Strand buffer (375 mM KCl, 15 mM MgCl2 and 250 mM Tris-HCl buffer, 
pH 8.3), 1 µl (200 units) of M-MLV RT, 0.25 μL of  RNaseOUT Recombinant 
Ribonuclease Inhibitor (10 units) and 2 μL of each of the following: 0.1 M dithiothreitol 
(DTT), 10 mM dNTP Mix (10 mM each dATP, dGTP, dCTP and dTTP at neutral pH), 
and 100 ng/μL random primers (hexamer oligonucleotides).  If necessary, the volume of 
the reaction was brought up to 20 μL by adding appropriate volume of UltraPure 
DNase/RNase-free distilled water.  All reagents above were purchased from Invitrogen.  
Reaction, which included 1-h incubation at 37°C, followed by 5 min at 95°C took place in 
a PTC-200 thermocycler (MJR Research, Watertown, Massachusetts).  A mock extraction 
was always included as contamination control.  RNA prepared from a mock infection 
 84 
 
(i.e., cells exposed to HDP) was used as negative control. Synthetic RNA positive strand 
at 106 copies/μL (Section 3.10.2.) was always transcribed serving as a positive control. 
 
f3.9 Recombinant HCV 5’-UTR-E2 Plasmid (rHCV UTR-E2) 
 The rHCV UTR-E2 fragment cloned into the dual promoter PCRII plasmid vector 
(Invitrogen) was used as positive control in our real-time and end-point RT-PCR.  The 
excised rHCV UTR-E2 fragment was also used as a template for the synthesis of the 
synthetic HCV RNA positive and negative strand (see Sections 3.10.1 and 3.10.2, 
respectively), and, after labeling with 32P, as a probe for NAH.  
 The rHCV UTR-E2 fragment of 1,821 bp was previously generated in this 
laboratory by transcribing RNA isolated from a patient chronically infected with HCV 
genotype 1a and cloning into the dual promoter PCRII plasmid vector using the TOPO-
TA cloning system (Invitrogen) (Pham et al., 2004) . 
 In order to produce new stock of rHCV 5’-UTR-E2 plasmid for use in this study, 
One Shot TOP10 E. coli cells containing the rUTR-E2 fragment were retrieved from -80 
°C and seeded on Luria-Bertani (LB) agar plates (for reagents and procedures pertaining 
to cloning and sequencing see Section 3.15).  After overnight incubation at 37°C, 10 
single colonies were selected and each colony was cultured in 15 mL conical tubes 
containing 3 mL of LB medium.  After incubation in a rocking incubator at 200 rpm for 
18 h at 37 °C, plasmid DNA was extracted from each colony using the QIAprep Spin 
Miniprep Kit (Qiagen, Venlo, Limburg, Netherlands), as described in detail in Section 
3.15.  Plasmid DNA from each colony was subsequently analyzed by restriction digest 
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using Escherichia coli restriction endonuclease I (EcoRI) and positive colonies were 
sequenced (see Section 3.15).  The sequencing results confirmed the sequence and size of 
the rHCV 5’-UTR-E2 fragment and also revealed that the rHCV UTR-E2 fragment was 
cloned into the vector in a 5’- to 3’- orientation.  We then transferred 20 μL from each of 
the 3 mL LB cultures containing positive colonies into 100 mL of LB.  100 mL cultures 
were placed on a rotating shaker at 200 rpm for 18 h at 37 °C to expand.  The following 
day, plasmid DNA was extracted using the PureLink HiPure Plasmid DNA Maxiprep Kit 
(Invitrogen).  For this purpose, the cultures were centrifuged at 4000 × g for 10 min.  The 
resulting pellet was resuspended with 10 mL of R3 buffer containing 50 mM Tris-HCl 
buffer, pH 8.0, 10 mM EDTA, 20 mg/mL RNase A, until homogeneous.  Then, 10 mL of 
lysis buffer (0.2 M NaOH, 1% [w/v] sodium dodecyl sulfate; SDS) was added.  The 
mixture was gently inverted and incubated at AT for 5 min.  10 mL of precipitation buffer 
containing 3.1 M potassium acetate, pH 5.5, was subsequently added and the tube was 
inverted several times until the mixture became homogeneous.  The mixture was then 
centrifuged at 12,000 × g for 10 min at AT.  The resulting supernatant was loaded onto 
the provided equilibrated column and the column was allowed to drain by gravity flow. 
Then, the column was washed with 60 mL of wash buffer containing 0.1 M sodium 
acetate, pH 5.0, and 825 mM NaCl.  The solution in the column was again allowed to 
drain by gravity flow.  The flow-through was discarded.  15 mL of elution buffer (100 
mM Tris-HCl buffer, pH 8.5, and 1.25 M NaCl) was added to the column and purified 
DNA was eluted into a sterile 30 mL centrifuge tube placed under the column.  10.5 mL 
of isopropanol was added to the elution tube and after mixing well the tube was 
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centrifuged at 12,000 × g for 30 min at 4°C.  After discarding the supernatant, the DNA 
pellet was resuspended in 5 mL 70% ethanol and the elution tube was centrifuged again at 
12,000 × g for 5 min at 4°C.  The supernatant was removed and the pellet was air dried 
for 10 min.  The DNA pellet was resuspended in 200 µL TE buffer and the concentration 
and quality of the purified DNA was evaluated using spectrophotometric analysis and 
stored at -20 °C.   
 
3.10 Preparation of HCV RNA Synthetic Strands 
3.10.1 Synthetic HCV RNA Positive Strand  
   As a template for the synthesis of the HCV RNA positive strand, which was 
routinely used as a positive control for cDNA synthesis and as a specificity control for 
detection of the HCV RNA replicative (negative) strand, we used the dual promoter 
PCRII plasmid vector (Invitrogen) containing the rHCV UTR-E2 1821-bp (see Section 
3.9).  As seen in Figure 3.4, the PCRII vector contains an SP6 RNA polymerase promoter 
site at the 5’-end (upstream) of the cloned sequence that we wanted to transcribe.  As 
mentioned in Section 3.9, sequencing confirmed that the rHCV UTR-E2 fragment was 
cloned into the vector in a 5’- to 3’-end orientation.  To produce sense (positive strand 
RNA), we needed to transcribe, using the RNA polymerase corresponding to the phage 
promoter at the 5’-end of the cloned sequence, using in that case the SP6 RNA 
polymerase. Therefore, for synthesis of the HCV RNA positive strand, we used the 
MEGAscript SP6 transcription kit (Ambion, Life Technologies). 
  In the first step, we linearized the plasmid in the polylinker at the 3’-end 
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Figure 3.4.  Synthesis of HCV RNA positive and negative strands.  (A) Minimal 
promoter sequence requirements of the RNA phage polymerases T7 and SP6 used for in 
vitro synthesis of HCV RNA negative and positive strand, respectively.  (B) Mechanism 
of action of the RNA phage polymerases.  (C) Depending on the orientation of cDNA 
sequence to be transcribed relative to the promoter, the template may produce sense or 
antisense strand RNA.  In this Figure, in order to produce sense RNA, we would have to 
transcribe using RNA polymerase recognizing promoter 1 at the 5’-end of protein coding 
region.  To synthesize antisense RNA, we would have to transcribe using RNA 
polymerase recognising promoter 2 at the 3’-end of protein coding region.  (D) The 
PCRII-TOPO vector containing the rHCV UTR-E2 fragment in a 5’- to 3’-end 
orientation.  The vector contains an SP6 and a T7 RNA polymerase promoter site at the 
5’- and 3’-end of the cloned sequence that we wanted to transcribe, respectively.  
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(downstream) of the cloned sequence.  For this purpose we performed restriction digest 
using Xanthomonas badrii restriction endonuclease I (XbaI). A total of 5 separate 
restriction digest reactions were performed.  Each 50 μL total volume reaction contained 
5 μL of DNA template (1 μg/μL), 5 μL (75 units) of XbaI, 5 μL of 10X Buffer H (100 
mM Tris-HCl buffer, pH 7.5, 500 mM NaCl, 100 mM MgCl2, and 10 mM DTT), 5 μL of 
0.1% BSA, and 30 μL of sterile water. The mixture was incubated at 37°C overnight.  A 
reaction with no added XbaI was included as an “uncut” control.  All reagents required 
for restriction digest were purchased from Invitrogen.  3 μL from each restriction digest 
reaction were analyzed by gel electrophoresis on 1% agarose gel containing ethidium 
bromide (EtBr).  Bands were visualized under UV light. 
 Once successful linearization of plasmids was confirmed, we treated the DNA 
with 200 μg/mL of proteinase K (Invitrogen) and 0.5% SDS for 30 min at 50°C.  
Following proteinase K, we performed DNA extraction.  Thus, an equal volume of 
phenol/chloroform/isoamyl alcohol was added to DNA template and the mixture was left 
on a circular rotator for 10 min at AT.  Thereafter, the mixture was incubated for 3 min at 
AT and span down for 3 min at 17,900 x g.  The aqueous phase was transferred to a new 
Eppendorf tube and sodium acetate and ethanol (1/10 and 2.5-fold of the volume of the 
aqueous phase, respectively) were added and mixed by inverting the tube.  After 
incubation at -20°C for 1 h, the tube was centrifuged at 17,900 x g for 10 min at 4°C.  The 
supernatant was discarded and the pellet air dried for 15 min and resuspended in TE 
buffer.  The concentration and quality of the purified DNA was evaluated by 
spectrophotometric analysis of OD260 and DNA was stored at -20 °C.   
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 Synthesis of the HCV RNA positive sense was done using the MEGAscript SP6 
transcription kit (Invitrogen).  The DNA was diluted to a concentration of 0.8 μg/μL.  A 
20 μL volume reaction was assembled at AT and it contained: 2 μL of each of the rNTPs 
(50mM each), 2 μL of the 10X reaction buffer, 1.25 μg of DNA template, 2 μL of SP6 
enzyme mix, and appropriate volume of nuclease-free water.  The reaction was incubated 
at 37°C for 4 h.  A control reaction including 2 μL of the control template provided with 
the kit (pTRI-Xef, 0.5 mg/mL) was performed in parallel.  After incubation, DNase 
digestion was performed in order to remove residual DNA template.  More specifically, 
one μL of TURBO DNase (2 U/ μL) was added into the newly transcribed RNA, and after 
mixing the reaction was incubated at 37°C for 15 min. All reagents mentioned above 
where provided within the MEGAscript kit. 
 Following DNase treatment, the transcribed RNA was purified using the Ambion 
MEGAclear kit.  Initially, the volume of the newly transcribed RNA was brought to 100 
µL with elution solution (provided with the kit) and mixed gently.  350 µL of binding 
solution concentrate was added and mixed.  Then, 250 µL of 100% ethanol were added 
and the sample was applied to a filter cartridge supplied.  The RNA mixture was pipetted 
onto the filter cartridge and centrifuged for ~15 s to 1 min at 10,000 × g.  The flow-
through was discarded.  The collection/elution tube was reused for the washing steps.  To 
wash the RNA, 500 µL of wash solution in 100% ethanol was applied onto the filter 
cartridge and the wash solution was drawn through the filter as in the previous step.  The 
wash was repeated with a second 500-µL aliquot of wash solution.  Then, the cartridge 
was centrifuged at 10,000 × g for 10–30 s to remove the last traces of wash solution.  To 
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elute the purified RNA, 50 µL of elution solution pre-heated at 95°C was added to the 
center of the filter cartridge applied over a new tube.  The tube was centrifuged for 1 min 
at 10,000 x g at AT.  This elution step was repeated with a second 50 µL aliquot of 
elution solution.  The eluate was collected into the same tube.  To precipitate the RNA, 
0.1 volume of 5 M ammonium acetate and 2.5 volumes of 100% ethanol were added.  
The mixture was incubated at –20°C overnight.  The following day, the tube containing 
RNA was microcentrifuged at 16,000 x g for 15 min at 4°C.  The supernatant was 
carefully removed and the pellet was washed with 500 µL 70% cold ethanol.  After 
repeating centrifugation at 16,000 x g for 15 min at 4°C, the 70% ethanol was discarded.  
To remove the last traces of ethanol, the tube was quickly re-spun and residual fluid was 
aspirated with a very fine tipped pipette.  The pellet was air dried for 5 min at AT and was 
resuspended in DNase/RNase-free distilled water.  Concentration and quality of the 
purified RNA was evaluated using spectrophotometric analysis of OD260 and RNA was 
stored at -80°C.  To confirm that HCV RNA positive strand was produced and that it was 
not contaminated with any residual DNA the following reactions were performed using 
different dilutions of the HCV RNA positive strand as template: (1) Nested endpoint-
PCR/NAH without the reverse transcription step; (2) Nested endpoint-RT-PCR/NAH, and 
(3) HCV RNA negative strand synthesis followed by nested endpoint-PCR/NAH.  
 
3.10.2 Synthetic HCV RNA Negative Strand 
 For the synthesis of the HCV RNA negative (replicative) strand, which was used 
as a positive control for detection of HCV RNA replicative strand, we used the same 
 93 
 
template as for the synthesis of HCV RNA positive strand, i.e., the dual promoter PCRII 
plasmid vector (Invitrogen) containing the  rHCV UTR-E2 fragment (see Section 3.9).  
As shown in Figure 3.4 the PCRII vector contains a T7 RNA polymerase promoter site at 
the 3’-end (downstream) of the cloned sequence that we wanted to transcribe.  To 
produce antisense (negative strand RNA), we needed to transcribe using the RNA 
polymerase corresponding to the phage promoter at the 3’-end of the cloned sequence, in 
that case the T7 RNA polymerase. Therefore, we used the MEGAscript T7 transcription 
kit (Ambion, by Life Technologies). 
 First, we had to linearize the plasmid in the polylinker at the 3’-end (upstream) of 
the cloned 5’-URT-E2 sequence.  For this purpose we performed restriction digest using 
the Haemophilus influenzae restriction endonuclease III (HindIII). A total of 5 separate 
restriction digest reactions were performed.  Each 50 μL total volume reaction contained: 
5 μL of DNA template (1 μg/μL), 5 μL (50 units) of HindIII, 5 μL of 10X Buffer H (100 
mM Tris-HCl buffer, pH 7.5, 500 mM NaCl, 100 mM MgCl2, and 10 mM DTT), and 35 
μL of DNase/RNase-free distilled water.  The mixture was incubated at 37°C overnight.  
A reaction with no added Hind III was included as an “uncut” control.  3 μL from each 
restriction digest reaction were analyzed by gel electrophoresis.  Bands were visualized 
under UV light.  All subsequent steps, i.e., proteinase K treatment, DNA extraction, HCV 
negative strand synthesis using the MEGAscript T7 transcription kit, and RNA 
purification using the Ambion MEGAclear kit were performed exactly as described in 
Section 3.10.1. 
 To confirm that HCV RNA negative strand was produced and not contaminated 
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with any residual DNA, the following reactions using serial dilutions of the newly 
synthesized HCV RNA negative strand as template were performed: (1) Nested endpoint-
PCR/NAH without the reverse transcription step; (2) Nested endpoint-RT-PCR/NAH, and 
(3) HCV RNA negative strand synthesis followed by nested endpoint-PCR/NAH.  
 
3.11 HCV RNA Quantification by Real-Time RT-PCR 
 Enumeration of HCV RNA copy numbers in the plasma and PBMC of patients 
with CHC was performed by real-time RT-PCR, as previously reported (Pham et al., 
2004; Sarhan et al., 2012a; Chen et al., 2013).  For this purpose, 50 ng of cDNA 
transcribed, as described in Section 3.8, from total RNA or from all RNA recovered from 
plasma or gradient fractions was amplified using SsoFast™ EvaGreen Supermix (Bio-
Rad Laboratories, Inc., Hercules, California) in a LightCycler 480 (Roche Diagnostics) 
for 45 cycles (denaturation at 95°C for 10 s, annealing at 55°C for 10 s, and final 
extension at 72°C for 5 s).  Reactions were always performed in triplicates in the final 
volume of 10 μL containing 2 μL of SsoFast EvaGreen Supermix (Bio-Rad; 2x real-time 
PCR mix which contains dNTPs, Sso7d fusion polymerase, MgCl2, EvaGreen dye and 
stabilizers), 2 μL of cDNA at 25 ng/μL and 5 pmoL of each primer: 5'-
GCAGAAAGCGTCTAGCCAT (sense; UTR4) and 5'-CTCGCAAGCACCCTATCAG 
(antisense; RTU3), as described in Pham et al., (2004).  Enumeration of viral load in test 
samples was based on ten-fold serial dilutions of the rUTR-E2 fragment which was 
synthesized as described in Section 3.9.  A mock extraction and a water sample were 
always included as contamination controls, while synthetic HCV RNA positive strand at 
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106 copies/μL was used as positive control.  The sensitivity of the assay ranged between 
10 to 100 vge per reaction.  In some cases, the specificity of the signal detection and 
validity of controls were confirmed by NAH with 32P-labeled rHCV UTR-E2 as a probe, 
as described in Section 3.14.  
 
3.12 Detection of HCV Genome by End-Point RT-PCR 
 HCV RNA positive strand was detected using cDNA transcribed from 1 μg or, in 
case of negative results, from 3 μg of total RNA.  HCV cDNA was amplified employing 
an in house developed PCR technique which consisted of a direct and a subsequent nested 
round of PCR amplification.  Primers designed to amplify the HCV 5’-UTR, cycling 
conditions, and controls used were previously described (Pham et al., 2004).  More 
specifically, for both the direct and nested PCR, amplification took place for 35 cycles 
(denaturation at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 
min) in a PTC-200 thermocycler (MJR Research).  Each reaction had a final volume of 
100 μL containing 10 μL of 10X PCR buffer containing 200 mM Tris-HCl buffer, pH 8.4, 
500 mM KCl, 8 μL of 2.5 mM dNTP mixture, 3 μL of 50 mM MgCl2, 1 μL of each of the 
10 pmol/μL primers (forward and reverse), 0.4 μL of Taq DNA polymerase (2 Units), 
cDNA template, and appropriate volume of sterile bidistilled water.  For the direct PCR, 1 
or 3 μg of cDNA were used as template.  For the nested PCR, 10 μL of direct PCR 
product was used as template.  The following primer pairs were utilized: 5'-
CTGTGAGGAACTACT GTCTTC (sense; UTR1) and 5'-GCGGTTGGTGTTACGTTT 
(antisense; RTU1) for the direct round, and 5'-GCAGAAAGCGTCTAGCCATGGC 
 96 
 
(sense; UTR2) and 5'-CTGCAAGCACCCTATGAGGCAGT (antisense; RTU2) for the 
nested round (Pham et al., 2004).  All reagents used for end-point PCR were purchased 
from Invitrogen apart from the primers that were ordered from Integrated DNA 
Technologies, Inc. (Coralville, Iowa).  The rHCV UTR-E2 fragment at 106 copies/μL was 
used as a positive control.  A mock extraction and a water sample that had undergone 
reverse transcription were always included as contamination controls, while synthetic 
rHCV RNA positive strand at 106 copies/μL was used as positive control.  The specificity 
of amplifications and validity of controls were confirmed by NAH with 32P-labeled rHCV 
UTR-E2 as a probe, as described in Section 3.14.  The sensitivity of this assay was ≤ 10 
vge/mL (≤ 3 IU/mL) or ≤ 5 vge/μg of total RNA (Figure 3.5). 
 
3.13 Detection of HCV RNA Replicative Strand 
 Detection of the HCV RNA negative (replicative) strand was performed by a 
strand-specific RT-PCR/NAH assay (Landford et al., 1999) using rTth DNA polymerase 
(Promega Corp.).  The rTth DNA polymerase is a thermostable enzyme isolated 
from Thermus thermophilus HB-8.  In the presence of manganese, rTth DNA polymerase 
catalyzes the polymerization of nucleotides into DNA using an RNA template in the 
5´→3´ direction.  In the presence of magnesium, the same enzyme catalyzes the 
polymerization of nucleotides into duplex DNA in the 5´→3´ direction (Figure 3.6.). 
The negative strand-specific RT-PCR/NAH assay was performed as previously described 
(Pham et al., 2004; Sarhan et al., 2012a).  More specifically, as RNA template, we used 
1-4 μg of test RNA diluted in UltraPure DNase/RNase-Free distilled water (Invitrogen).
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Figure 3.5.  Assigned levels of HCV RNA positive strand detection by semi-quantitative 
RT-PCR/NAH.  One round of the in-house RT-PCR (direct RT-PCR) detects 
approximately 104 or more vge/reaction when products are analyzed by electrophoresis 
on EtBr-agarose (assigned score: ++++).  When direct RT-PCR is followed by EtBr-
agarose electrophoresis and nucleic acid hybridization (NAH), the sensitivity of the signal 
detection increases by approximately 10-fold, reaching about 103 vge/reaction (assigned 
score: +++).  By using 10 μL of the direct PCR product as a template for a second round 
of amplification (nested RT-PCR), the sensitivity of detection on EtBr-gel after 
electrophoresis further increases to around 102 vge/reaction (assigned score: ++).  Finally, 
when nested RT-PCR is followed by NAH of the amplified products, the sensitivity of 
HCV RNA detection reaches below or equal to 10 vge/reaction (assigned score: +).  
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Figure 3.6.  Assay for HCV RNA negative (replicative) strand detection.  (A) HCV 
replicates via synthesis of a negative-strand HCV RNA which serves as a template for 
HCV RNA positive strand synthesis.  (B) Overall scheme of the HCV RNA negative 
strand detection by a RT-PCR/NAH assay using rTth DNA polymerase (see Materials 
and Methods).  (C) As specificity control for HCV RNA negative strand detection, serial 
dilutions of synthetic HCV RNA positive strand were used (see Materials and Methods).  
As a sensitivity control, serial dilutions of synthetic HCV RNA negative strand were 
utilized.  Using these standards it was shown that the negative-strand RT-PCR/NAH was 
capable of detecting as little as 102 copies/reaction of the correct (negative) strand, while 
nonspecifically identifying positive strand at concentrations ≥106 copies.  Water instead 
of cDNA amplified in direct (D/W) and nested (N/W) reactions were included as 
contamination controls.  Positive signals showed the expected 442-bp (direct RT-
PCR/NAH) or 244-bp (nested RT-PCR/NAH) nucleotide fragments.  The specificity of 
the RT-PCR products was verified using a 32P-labeled rHCV 5’-UTR-E2 fragment as a 
probe. 
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 The amount of template RNA used in this assay depended on the estimated copy 
number of the HCV RNA positive strand in the test sample.  When the copy number of 
the HCV RNA positive strand was estimated to be 10-100 vge/mL, 4 μg of test RNA 
were used as a template, as it is known that the HCV RNA negative strand is 100-1000-
fold less abundant than the positive strand in the infected cells (Komurian-Pradel et al., 
2004).  When the level of HCV RNA positive strand in the test RNA was estimated to be 
> 100 vge/mL, 1-2 μg of test RNA were used for this assay.  It has been previously 
reported in this laboratory that a high concentration of HCV RNA negative strand can 
inhibit its detection by that assay.   
 In the first step, the 10 μL RNA was denaturated at 95°C for 1 min and then 
temperature was lowered to 70°C.  Subsequently, 10 μL of preheated RT mix containing 
2X RT buffer (20 mM Tris-HCl buffer, pH 8.3, with 180 mM KCl, 2 mM MnCl2, 1.6 mM 
deoxynucleoside triphosphate mix, 15 pM sense UTR1 primer, and 5 U of rTth DNA 
polymerase) was added and cycled for 2 min at 60°C and 70°C for 15 min. The 
specificity of this assay derives from the RT step where only the sense UTR1 primer is 
added. After that step, the temperature was held at 70°C and 80 μL of preheated PCR 
mixture which contained a chelating buffer (10 mM Tris-HCl buffer, pH 8.3, with 100 
mM KCl, 750 %M EGTA, 0.05% Tween 20, and 5% glycerol), 2.5 mM MgCl2 and 15 
pM of the antisense RTU1 primer were added.  After 3 min at 94°C, amplification took 
place for 45 cycles (1 min at 94°C, 2 min at 60°C, and 3 min at 72°C), which was 
followed by a final extension step for 7 min at 72°C.  10 μL volumes of the direct PCR 
products were used as templates for the nested PCR, which was performed as described in 
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Section 3.12.  PCR products were analyzed by gel electrophoresis and detected by NAH 
as described below (Section 3.14). 
 Serial dilutions of HCV RNA positive strand synthesized as described in Section 
3.10.1 were used as specificity control for the assay.  Serial dilutions of the synthetic 
HCV RNA negative strand prepared as reported in Section 3.10.2 were used as sensitivity 
control.  Using these standards it was shown that the HCV RNA negative-strand RT-
PCR/NAH was capable of detecting as low as 102 copies per reaction of the negative 
strand and that it maintained specificity of detection for up to 106 copies/reaction as 
shown in Figure 3.6.C.  This was in accordance with previously reported data (Pham et 
al., 2004; Sarhan et al., 2012a).  As negative controls, water samples were included. 
 
3.14 Nucleic Acid Hybridization 
 In order to validate the specificity of the identified amplification signals and to 
enhance by approximately 10-fold the sensitivity of the signals’ detection (Figure 3.6), 
NAH was done using the 32P-labelled HCV UTR-E2 fragment as a probe. 
 
3.14.1 HCV DNA Probe Labelling and Purification  
 To generate the probe, the rHCV UTR-E2 fragment was excised from the PCRII 
plasmid vector by restriction enzyme digestion with EcoRI (as described in Section 3.15).  
The digested products were then separated by electrophoresis in a 0.9% low melting point 
(LMP) agarose gel containing EtBr for approximately 40 min at 80 Volts.  Subsequently, 
bands were visualized with UV light and desired products were excised using a sterile 
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razor blade.  Agarose slices were then transferred into a 1.5 mL sterile microcentrifuge 
tube and incubated at 70 °C until the agarose gel was completely melted.  Purification of 
amplicons was performed via a vacuum manifold using the Wizard PCR Preps DNA 
Purification System (Promega Corp.), as described in Section 3.15.  
 Radioactive labeling of HCV DNA was performed by random primed labeling of 
DNA using the Amersham rediprime II DNA labelling system (GE Healthcare).  In this 
method, random sequence hexanucleotides are annealed to both strands of the denatured 
DNA template and Klenow fragment polymerase is used to extend the oligonucleotides.  
A non-radioactive nucleotide is replaced by the radiolabelled equivalent in the reaction 
mixture and, as a result, a uniformly labelled double-stranded probe is produced.  
More specifically, 25 ng of the purified HCV UTR-E2 fragment was diluted in 45 μL of 
TE buffer.  DNA was denatured by boiling for 5 min and chilled for 2 min.  5 μL of 32P –
dCTP (PerkinElmer, Waltham, Massachusetts) were then added and the mixture was 
transferred to a tube containing an Amersham rediprime II DNA labelling system (GE 
healthcare) random-prime reaction (buffered solution of dATP, dGTP, dTTP, 
exonuclease-free Klenow enzyme and random primers).  After repeated pipetting to 
dissolve the pellet, the mixture was incubated for 1 h at 37°C.  Following 32P labelling of 
the HCV UTR-E2 fragment, the newly synthesized probe was cleaned from the excess of 
32P-dCTP using Illustra nick columns Sephadex G-50 DNA grade (GE healthcare).  Prior 
to use, the “nick column buffer” containing distilled water with 0.15% kathon CG/ICP 
Biocide was removed from the column and 3 mL of TE buffer was added.  After shaking, 
the TE buffer was removed and another 3 mL of TE buffer was added, and left to elute 
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from the column to equilibrate it.  50 μL of the probe were added onto the column and left 
to elute into a 15 mL tube.  400 μL of TE buffer were then added to wash out unbound 
probe into the same 15 mL tube.  The column was then mounted over a new 15 mL tube 
and 450 μL of TE buffer was added to elute the probe.  The probe was transferred to a 1.5 
mL Eppendorf tube and stored at 4°C.  2 μL of the probe was supplemented with 100 mL 
scintillation fluid (Perkin Elmer) and mixed.  The specific activity of the probe was 
determined using the Beckman Coulter LS6500 scintillation counter and expressed as 
counts per minute (cpm). 
 
3.14.2 Southern Blot Hybridization Analysis 
 As previously mentioned, PCR products were analyzed by gel electrophoresis on 
1% agarose gels containing EtBr. Once electrophoresis was completed, the gel was 
soaked in denaturing buffer (1.5 M NaCl, 0.5 M NaOH) for 30 min at ambient 
temperature and then in neutralizing buffer (1.5 M NaCl in 1M Tris-HCl buffer, pH 8.0) 
for another 30 min.  Downword capillary transfer of DNA from the gel to a neutral nylon 
membrane (Hybond-N, GE Healthcare) took place according to Maniatis et al. (1982).  
More specifically, the gel was placed upside down on a bridge which consisted of a sheet 
of 3 MM filter paper (Whatman International Ltd, Maidstone, United Kingdom) placed 
on a glass surface and soaked in 10X standard saline citrate (SSC; diluted from 20X; 3M 
NaCl in 0.3 M sodium citrate dehydrate, pH 7.0).  Parafilm was placed around the edges 
of the gel.  The gel was covered with a nylon membrane, followed by 2 sheets of 3 MM 
filter paper soaked in 10X SSC, one dry sheet of 3 MM filter paper, and a 10-cm high 
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stack of dry paper towels.  The whole set up was reversed and weight was placed over the 
glass surface of the bridge.  After overnight transfer, the nylon membrane was baked at 
80°C for 1 h under vacuum.  The baked membrane was then transferred into a 
hybridization glass tube containing 5 mL of pre-hybridization buffer (4X SSC, 5X 
Denhart’s solution, 0.5 % SDS, 100 μg/mL denatured [boiled and cooled] salmon sperm 
DNA; all from Invitrogen) and incubated at 65 °C for 1 h while constantly being rotated.  
Then, 6 X 106 cpm of probe were added directly into the glass tube that contained the 
hybridization buffer and the membrane was incubated overnight at 65 °C in a 
hybridization oven.  The following day, the membrane was washed twice with 2X SSC 
and 0.1% SDS at AT and twice with 0.1X SSC and 0.05% SDS at 65 °C for 10 min.  
Then, it was air dried, covered with plastic wrap, and placed in a cassette (Bio-Rad 
Laboratories) with a phosphor screen (Kodak) for overnight at AT.  The following day, 
image and density of the signals obtained were analyzed using a Pharos FX plus 
molecular imager system (Bio-Rad Laboratories) and expressed in pixel density units 
(PDU).  
 
3.15 HCV Cloning and Sequencing 
 HCV genome amplicons detected in in vitro infected CD4+ and CD8+ T cells in 
Experiments I, III and V (see Table 4.3), and at time points where HCV replication has 
been confirmed, were analyzed by clonal sequencing.  Those sequences were compared 
with the sequences harbored in the HCV inoculum used for in vitro infection of CD4+ and 
CD8+ T cells and in PBMC of the inoculum donor.   
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 Initially, the amplicons were adenylated by addition of 1 μL of dATP (Invitrogen) 
and incubation at 72 °C for 10 min.  Following 3’-adenylation, PCR products (~40 μL) 
were separated by electrophoresis in a 0.9% LMP agarose gel.  Subsequently, bands were 
visualized with UV light and desired bands excised.  Agarose slices were then transferred 
in a 1.5 mL sterile microcentrifuge tube and incubated at 70 °C until completely melted.  
Purification of amplicons was performed via a vacuum manifold using the Wizard PCR 
Preps DNA Purification System (Promega).  More specifically, using this system, 1 mL 
of resin was mixed with each melted gel slice and subsequently pipetted into a syringe 
barrel.  The syringe barrel was attached to a Wizard Minicolumn and the 
barrel/minicolumn assembly was connected to a vacuum manifold.  Vacuum was applied 
to draw the resin/DNA mixture into the minicolumn.  2 mL of 80% isopropanol were 
added to each minicolumn and vacuum was applied to wash the minicolum.  Vacuum was 
reapplied to dry the resin.  The minicolumn was removed from the barrel, transferred to a 
1.5 mL microcentrifuge tube and centrifuged at 10,000 x g for 2 min to remove residual 
isopropanol.  Each minicolumn was then transferred to a new 1.5 mL microcentrifuge 
tube.  50 μL of water was added to each minicolumn. After 1 min, each minicolumn was 
centrifuged for 20 s at 10,000 x g to elute the DNA fragments.  Eluted DNA was stored in 
the microcentrifuge tube at 4 °C or -20 °C for no more than 24-48 h before used for cell 
transformation. 
 Cloning was performed using the TOPO TA Cloning kit (Invitrogen).  Initially, a 
6 μL TOPO Cloning reaction was set for each PCR product and was left to incubate for 
30 min at AT.  Each reaction contained 4 μL of DNA template, 0.5 μL of TOPO vector 
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and 1 μL of salt solution (1.2 M NaCl and 0.06 M MgCl2).  During incubation, One Shot 
TOP10 chemically competent E. coli cells were thawed on ice.  For transformation of 
One Shot cells, the cloning reaction was added to the cells and kept on ice for 30 min.  
After 30 min, the cells were heat-shocked for 30 s at 42°C and then returned to ice. 
 After transformation, the cells were recovered and plated.  For this purpose, 250 
μL of SOC medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM glucose) was added to each tube.  The tubes were 
then placed in a rocking incubator for 1 h at 37 °C.  After recovery, 100-150 μL of 
transformed cells were spread on prewarmed LB agar plates containing 50 μg/mL 
kanamycin.  The plates were placed in the 37°C incubator for overnight.  The following 
day, at least 20 single colonies were picked from each plate. Each colony was cultured in 
15 mL conical tubes containing 3 mL of LB medium and incubated in a rocking incubator 
at 37°C for ~18 h. 
 After incubation, plasmid DNA was extracted from each colony using the 
QIAprep Spin Miniprep kit (Qiagen).  More specifically, 1.5 mL of each inoculated 
culture was initially transferred to a new tube and spun for 5 min at 17,900 x g in a 
microcentrifuge.  Supernatant was discarded and this process was repeated using the same 
tube until the entire culture had been transferred.  Pelleted bacterial cells were 
resuspended in 250 μL of resuspension buffer (P1; 50 mM Tris-HCl buffer, pH 8.0, 10 
mM EDTA, 100 μg/mL RNase A) and mixed by vortexing.  250 μL of lysis buffer (P2; 
200 mM NaOH, 1% SDS) were then added and each tube was inverted gently 4-6 times 
to mix.  350 μL of neutralization buffer (N3; 3.0 M potassium acetate, pH 5.5) were 
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subsequently added and each tube was again inverted 4-6 times.  Tubes were then 
centrifuged for 10 min at maximum speed in tabletop microcentrifuge.  The supernatant 
(about 850 μL) from each tube was applied to the QIAprep column by pipetting and 
vacuum was applied.  The QIAprep column was washed by adding 750 μL of 
neutralization buffer (PE; 10 mM Tris, pH 7.5, 80% ethanol).  Vacuum was again applied 
to draw the wash solution through the column.  The QIAprep column was transferred to a 
tube and centrifuged for 1 min at 17,900 x g.  Each QIAprep column was then placed in a 
clean 1.5 mL microcentrifuge tube.  To elute DNA, 50 μL of elution buffer (EB; 10 mM 
Tris-HCl buffer, pH 8.5) or water was added to the center of the column.  After 2 min, the 
columns were centrifuged for 1 min and plasmid DNA isolation was completed. 
 Plasmid DNA from each colony was subsequently analyzed after restriction 
digestion with E. coli restriction endonuclease I (EcoRI).  Thus, each 20 μL of reaction 
aliquot contained 10 μL of DNA template, 1 μL (15 units) of EcoRI, 2 μL of 10X Buffer 
H (0.5 M Tris-HCl buffer, pH 7.5, 1 M NaCl, 100 mM MgCl2, 10 mM DTT), 0.25 μL of 
RNaseA (1 mg/mL) and 6.75 μL of sterile water, and was incubated at 37°C for 1 h.  A 
reaction with no added EcoRI was included as an “uncut” control.  All reagents required 
for restriction digest were purchased from Invitrogen.  Each restriction digest product was 
analyzed by gel electrophoresis (120 Volts, 30 min) using 1% agarose gel containing 
EtBr.  Bands were visualized under UV light.  DNA from positive colonies was 
quantitated by Nanodrop.  DNA from 20 clones derived from each 5’-UTR HCV 
amplicon was sent for sequencing at The Centre for Applied Genomics (TCAG) at The 
Hospital for Sick Kids in Toronto.  For this reason, each sample was diluted to 43 ng/μL 
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and was sequenced bidirectionally using universal forward and reverse M13 primers and 
ABI 3730xl DNA Analyzer (Applied Biosystems by Life Technologies).  Sequence 
analysis was performed using Sequencer software version 5.0 (Gene Codes Corp., Ann 
Arbor, Michigan).  
 
3.16 Detection of HCV Proteins in De Novo Infected T Lymphocytes by Confocal 
Microscopy 
3.16.1 Staining of HCV Core and NS5A Proteins 
 To detect HCV NS5A and core proteins, 5x105 to 1x106 B/F cells collected at 10 
and 14 d.p.i., and exposed to HCV-11/M inoculum (experiment V; see Table 4.3) were 
fixed with 200 μL of 4% PFA for 10 min at AT and permeabilized with 200 μL of 0.1% 
saponin in PBS for 10 min at AT.  Blocking of non-specific binding was performed with 
5% normal donkey serum (Jackson ImmunoResearch Laboratories Inc., West Grove, 
Pennsylvania) in PBS (blocking buffer) for 1h at AT.  Then, cells were incubated with 
mouse anti-HCV NS5A mAb (Chemicon International, Temecula, California) at 1:100 
dilution in blocking buffer, or with mouse anti-HCV core mAb (Thermo Scientific by 
Thermo Fisher Scientific, Waltham, Massachusetts) at 1:200 dilution in blocking buffer.  
As controls, cells were exposed to mouse IgG1 K isotype control (eBioscience, 
Affymetrix, Santa Clara, California) at 1:100 dilution in blocking buffer.  Staining with 
the primary antibodies took place overnight in the cold room on a tube rotator.  The 
following day, cells were washed by centrifugation with PBS containing 0.25% Tween-
20 and exposed to Cy3-conjugated donkey antibody to mouse IgG (Jackson 
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ImmunoResearch) at 1:500 dilution in PBS containing 0.25% Tween-20 for 1 h at AT in 
the dark.  After cells were washed by centrifugation, the resulting pellet was resuspended 
with 20% glycerol in PBS.  Cells were then mounted on slides and counterstained with 4’, 
6-diamidino-2-phenylindole (DAPI; 0.1 μg/mL) (Vector Laboratories, Inc., Burlingame, 
California).  All steps, until mounting of cells on slides, were performed with cells being 
in suspension in 1.5 mL Eppendorf tubes (modified from Sarhan et al., 2012a).  Slides 
were examined under an Olympus BX50W1 microscope with a FluoView FV300 
confocal system (Olympus America Inc., Melville, New York).  Approximately 1000 
cells from each preparation were examined and HCV protein positive cells were counted.  
The same procedure was also performed for cells from donor B/F exposed to HDP 
collected at 10 and 14 d.p.i., which served as negative controls.  
 
3.16.2 Double Cell Staining for Detection of HCV NS5A Protein and CD4+ or            
CD8+ T Cell Surface Markers 
 To detect CD4 and CD8 proteins as well as HCV NS5A protein, we used 5x105 to 
1x106 cells from donor A/M collected at 10 and 14 d.p.i., and exposed to inoculum HCV-
16 (experiment VI; see Table 4.3).  For staining with the anti-HCV NS5A mAb and the 
Cy3-conjugated donkey anti-mouse antibody, we followed exactly the same procedure as 
described in Section 3.16.1.  Prior to exposing the cells to the second primary mAb, 
blocking with 5% normal donkey serum in PBS for 1 h at AT was performed.  Once 
blocking was completed, the antibody was added.  Thus, cells were exposed to either 
rabbit anti-human CD4 mAb (Abcam, Cambridge, United Kingdom) at 1:250 dilution in 
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blocking buffer for 30 min on ice or to a rabbit IgG polyclonal isotype control (Abcam) at 
1:100 dilution in blocking buffer.  CD8+ T cells were exposed to rabbit anti-human CD8 
mAb (Abcam) at 1:400 dilution in blocking buffer or to a rabbit IgG polyclonal isotype 
control (Abcam) at 1:100 dilution in blocking buffer for 30 min on ice.  After incubation, 
cells were washed by centrifugation with PBS containing 0.25% Tween-20 and exposed 
to Alexa 488-conjugated donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch) at 
1:400 dilution in PBS containing 0.25% Tween-20 for 1 h in the dark at AT. After that 
step, cells were washed and processed as described in Section 3.16.1. 
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CHAPTER FOUR: RESULTS 
 
4.1 Selection of HCV Inocula for CD4+ and CD8+ T Cell Infection Experiments 
 As previously indicated (Section 3.1), the selection of HCV inocula for the in 
vitro infection of affinity-purified CD4+ and CD8+ T cells was a three-step process 
(Figure 3.1).  At step one, the HCV RNA load in plasma of 16 patients with clinically 
diagnosed CHC was evaluated by real-time RT-PCR.  At the second step, real-time RT-
PCR was used to examine the expression of HCV RNA in the PBMC of patients with the 
highest loads of HCV RNA in their plasma.  In cases where HCV RNA in the PBMC was 
undetectable by real-time RT-PCR, we employed the nested-RT-PCR/NAH assay 
previously established in this laboratory (Pham et al., 2004).  At the final step, plasma 
carrying high HCV RNA load and coming from patients with detectable HCV RNA in 
their PBMC were used for in vitro infectivity experiments of HCV-naïve PBMC-derived 
total T cells using the cell culture system developed in this laboratory (MacParland et al., 
2006).  Plasma found capable of in vitro infecting PBMC-derived total T cells, as 
evidenced by HCV RNA negative strand detection, served as inocula for the in vitro 
infection experiments using affinity-purified CD4+ and CD8+ T cells as targets. 
 
4.1.1 HCV RNA in Plasma of Patients with CHC 
 As the first step in the inocula selection process, the HCV RNA load in plasma of 
16 patients with CHC was evaluated by real-time RT-PCR (see Table 4.1).  It was found 
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that HCV RNA positive strand was detectable in all individuals tested (n=16; 100%) and 
quantifiable in 15 of them.  Thus, HCV RNA loads ranged from 1.34x102 vge/mL (case 
3/M) to 1.6x107 vge/mL (case 16).  HCV RNA load in plasma of patient 5/M was lower 
than 100 vge/mL; which was the assay lowest sensitivity level and, therefore, could not 
be quantified.  
 
4.1.2 HCV RNA in the PBMC of Patients with CHC 
 At the second step in selection of inocula, real-time RT-PCR was used to evaluate 
the presence of HCV RNA in the PBMC (if available) of patients with detectable HCV 
RNA in their plasma.  PBMC samples were available from 12 out of 16 patients 
examined (Table 4.1).  By employing real-time RT-PCR, HCV RNA was detected in 
PBMC of 5 out of these 12 patients (42%) and was quantifiable in two cases (10/M with 
3.57x102 vge/μg and 11/M with 3.07x102 vge/μg).  In cases where HCV RNA in the 
PBMC was undetectable by real-time RT-PCR (n=7), nested-RT-PCR/NAH was 
performed.  HCV RNA was detected in 5 out of 7 individuals (71%) (Figure 4.1 B).  The 
combined results from real-time RT-PCR and nested RT-PCR/NAH assays showed that 
HCV RNA was detected in PBMC of 10 out of 12 patients (83%) (Table 4.1).  It is of 
note, that PBMC were tested without prior stimulation with mitogens which normally 
augments detection of replicating HCV in circulating lymphoid cells (Pham et al., 2004, 
2005; Chen et al., 2013, 2015).  
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Figure 4.1.  Comparison of HCV RNA detection in PBMC from CHC patients who 
provided HCV inocula tested by real-time RT-PCR/NAH and nested RT-PCR/NAH.  
RNA was extracted from PBMC and transcribed to cDNA.  (A) Initially, cDNA 
equivalent of 50 ng of RNA from each sample were amplified by real-time PCR and the 
amplicons separated on agarose gel, transferred onto a nylon membrane and probed by 
NAH, as described in Materials and Methods.  (B) In cases where HCV RNA in the 
PBMC was not detected by real-time RT-PCR/NAH, cDNA equivalent of 1 or 3 μg of 
RNA were amplified by nested-RT-PCR/NAH.  Water added instead of cDNA (RT/W) 
and amplified by direct (D/W) and nested PCR (N/W), as well as RNA/cDNA-free mock 
(Mock) sample were used as negative controls.  The positive controls included serial 
dilutions of the recombinant HCV UTR-E2 fragment (rHCV UTR-E2) as quantitative 
standards (vge) in (A) and a single concentration of HCV UTR-E2 (106 vge) in (B).  
Synthetic HCV RNA positive (sRNA pos) strand at 106 vge was also used as the positive 
and specificity control in (B).  Positive signals showed the expected 244-bp 5’-UTR 
amplicons.  
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4.1.3 HCV RNA Expression and Replication in Total T cells De Novo Infected with 
Selected HCV Inocula                                       
 At the final step of the inocula selection process, plasma carrying high HCV RNA 
load and coming from patients with detectable HCV RNA in their PBMCs were used for 
in vitro infectivity experiments of T cells derived from healthy human PBMC using the 
cell culture system previously developed (MacParland et al., 2006). 
 As shown in Table 4.2, HCV RNA positive strand was detected at variable levels 
in all the experiments where A/M served as donor of PBMC, and at different time points 
post-infection with various inocula tested.  However, HCV RNA negative strand, 
indicative of active HCV replication, was only detected when A/M T lymphocytes were 
exposed to inocula from 11/M and 16 (Table 4.2 and Figure 4.2). 
 Using PBMC from B/F, HCV RNA positive strand was again detected at variable 
levels in all experiments performed, apart from experiments where inocula from 4/M and 
9/M were used.  With regards to HCV RNA negative strand in these experiments, the 
strand was only detected at 7 d.p.i. when plasma from patient 11/M was used as inoculum 
(Table 4.2). 
 Overall, the results showed that plasma from patients 11/M and 16 were capable 
of in vitro infecting PBMC-derived total T cells, as evidenced by HCV RNA negative 
strand detection (Figure 4.2).  Therefore, plasma from these patients were selected as 
inocula for further infection experiments with affinity-purified CD4+ and CD8+ T cells. 
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Figure 4.2.  Detection of HCV RNA positive and negative strands in PBMC-derived total 
T cells after their in vitro infection with authentic, patient-derived HCV.  Monocyte-
depleted PBMC from donor A/M pre-treated with PHA were exposed to HCV-11/M or 
HCV-16 (inocula) and cultured as described in Materials and Methods.  RNA was 
analyzed for expression of (A) HCV RNA positive strand and (B) HCV RNA negative 
strand at different days post-infection (d).  Synthetic HCV RNA (HCV sRNA) positive 
and negative strands were used to confirm specificity of the detections and as quantitative 
standards.  The recombinant HCV UTR-E2 fragment (rHCV UTR-E2) served as 
additional positive control for detection of HCV RNA positive strand.  Water instead of 
cDNA amplified in direct (D/W) and nested (N/W) reactions, as well as a mock-treated 
test RNA (Mock), were included as contaminations controls.  Positive signals showed the 
expected 244-bp fragment.  
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4.2 Purity of CD4+ and CD8+ T Cells Affinity-Purified from Healthy Donors 
 As previously mentioned (Section 3.4.), normal CD4+ and CD8+ T cells used as 
targets for in vitro infection with authentic HCV were isolated from total PBMC via 
positive selection using the autoMACSPro Separator.  In order to evaluate the purity of 
the obtained subsets, flow cytometry analysis was performed, as described in Section 
3.4.1.  The phenotypic analysis of the affinity-purified CD4+ and CD8+ T cells 
demonstrated that the purity of the isolated subsets was higher than 96% and 97%, 
respectively.  As an example, flow cytometry results for affinity purified CD4+ and CD8+ 
T cells used in experiment III are shown in Figure 4.3. 
 
4.3 HCV Genome Expression and Replication in CD4+ and CD8+ T Cells De Dovo 
Infected with Wild-Type, Patient-Derived HCV. 
 As seen in Table 4.3, five experiments were performed where affinity-purified 
CD4+ or CD8+ T cells from donor B/F were separately exposed to inoculum HCV-11/M 
and cultured under conditions described in Section 3.5.  In these experiments, HCV RNA 
positive strand was detected in CD4+ T cells at all time points where RNA was available 
for analysis, apart from experiment I, 14 d.p.i..  Estimated HCV RNA loads in CD4+ T 
cells ranged from 30 to 104 vge per µg of total RNA.  With regards to CD8+ T cells, HCV 
RNA positive strand was detected in all time points where total RNA was examined, 
apart from experiment III, 10 d.p.i.  Estimated HCV RNA loads in CD8+ T cells ranged 
from 25 to 104 vge per µg of total RNA. 
 With regard to expression of HCV RNA negative strand, the strand was detected 
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Figure 4.3.  Purity of affinity-purified CD4+ and CD8+ T cells assessed by flow 
cytometry.  (A) CD4+ cell subset was incubated with PerCP-conjugated rabbit anti-human 
CD4+ mAb or with rabbit IgG polyclonal isotype control, while (B) CD8+ cell subset was 
stained with FITC-conjugated rabbit anti-human CD8+ mAb or with rabbit IgG 
polyclonal isotype control.  The samples were analyzed by flow cytometry (see Materials 
and Methods).  Gates were set up on isotype controls.  
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in both CD4+ and CD8+ T cells in all experiments performed.  More specifically, in CD4+ 
T cells, HCV RNA negative strand was detected at more than one time point in 
experiments III and V at estimated levels between 25 and 5,000 copies per μg of total 
RNA.  In CD8+ T cells, HCV RNA negative strand was also detected in all experiments 
and its loads ranged from 25 to 1,000 copies per μg of total RNA (Figure 4.4 A).  
 When target cells from donor A/M were exposed to inoculum HCV-16, HCV 
RNA positive strand was detected in both CD4+ and CD8+ T cells at all time points where 
total RNA was available for examination. Estimated HCV RNA load was 104 vge/μg of 
total RNA for CD4+ T cells and ranged between 103 and 104 vge/μg of total RNA for 
CD8+ T cells.  In this experiment, HCV RNA negative strand was detected in both 
immune cell subsets; i.e., 2,500 copies per μg at 14 d.p.i. for CD4+ T cells and 25 copies 
per μg at 10 d.p.i. for CD8+ T cells (Figure 4.4 B). 
 In conclusion, HCV RNA positive and negative (replicative) strands were 
detected in CD4+ and CD8+ T cells in all experiments performed.  The positive strand was 
present at a higher percentage (100% at 7 d.p.i., and 92% at 10 and 14 d.p.i.; with 93% 
overall positivity) than the negative strand (33% at 7 d.p.i., 58% at 10 d.p.i., and 42% at 
14 d.p.i.; with 50% overall positivity) (Table 4.3). 
 
4.4 Identification of HCV NS5a and Core Proteins in De Novo Infected CD4+ and 
CD8+ T Cells. 
To determine whether detection of HCV RNA in infected CD4+ and CD8+ T cells was 
accompanied by synthesis of viral proteins, lymphocytes exposed to HCV-11/M
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Figure 4.4.  Detection of HCV RNA positive and negative strands in human CD4+and 
CD8+ T lymphocytes infected in vitro with patient-derived HCV.  Affinity-purified CD4+ 
and CD8+ T cells from B/F and A/M healthy donors treated with PHA were exposed to 
HCV-11/M or HCV-16 or to HDP.  (A) Cells in Experiments I and III infected with 
HCV-11/M.  (B) Cells in Experiment V infected with HCV-11/M and in Experiment VI 
infected with HCV-16.  Cells were cultured as described in Materials and Methods.  RNA 
was analyzed for HCV RNA positive and negative strands (see Materials and Methods).  
Contamination and specificity controls are marked and they were as those outlined in the 
legends to Figures 4.1 and 4.2.  As additional negative control, when the numbers of cells 
recovered allowed (Experiments I, V and VI), affinity-purified CD4+ and CD8+ T cells 
were exposed to healthy donor plasma (HDP) and cultured under the same conditions as 
HCV-infected cells (mock infection).  Positive signals showed the expected 442-bp 
(direct RT-PCR/NAH) or 244-bp (nested RT-PCR/NAH) nucleotide fragments. 
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inoculum (Experiment V, 10 d.p.i. and 14 d.p.i.) were examined for the presence of HCV  
core or NS5A (Figures 4.5 A and B), while cells exposed to HCV-16 inoculum 
(Experiment VI, 10 d.p.i. and 14 d.p.i.) were examined for the presence of NS5A and 
CD4+ or CD8+ by double staining of each cell subtype for NS5A and either CD4 or CD8 
(Figures 4.6. A and B).  As shown in in Figures 4.5 and 4.6, both viral proteins were 
detected in the cytoplasm and close to the plasma membranes of CD4+ and CD8+ T cells.  
The pattern of NS5A or core protein staining was usually homogeneous throughout the 
cytoplasm.  However, granular deposits with tendency to accumulate at the plasma 
membrane were also seen in both CD4+ and CD8+ cells (Figures 4.5 and 4.6).  
Percentages of NS5A and core reactive cells enumerated under a confocal microscope 
were 0.9% and 1.2% for CD4+ and CD8+ cells, respectively, and were comparable at all 
timepoints examined.  CD4+ and CD8+ T cells exposed to HDP and stained for HCV 
NS5A and core proteins (negative controls), as well as CD4+ and CD8+ T cells exposed to 
HCV-11/M inoculum and stained with mouse IgG1 K isotype control showed no staining 
(Figures 4.5 and 4.6). 
In summary, HCV core and NS5A proteins were produced in affinity-purified 
CD4+ and CD8+ T cells infected in vitro with authentic, patient-derived HCV.  In 
addition, NS5A protein was detected in CD4+ or CD8+ T lymphocytes double stained with 
anti-NS5A mAb and respective cell surface markers. 
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Figure 4.5.  Identification of HCV core and NS5A proteins in CD4+ and CD8+ T cells 
infected with authentic HCV by confocal microscopy. (A) Affinity-purified CD4+ T cells 
and (B) CD8+ affinity-purified T cells from B/F healthy donor were exposed to healthy 
donor plasma (HDP) or HCV-11/M inoculum and cultured as described in Materials and 
Methods.  The cells were stained with either anti-HCV core mAb or anti-HCV NS5A 
mAb and counterstained with DAPI (see Materials and Methods). The images were 
captured at X 60 magnification.  Positive cells clearly show cytoplasmic staining of either 
HCV core or NS5A protein, while T cells exposed to HDP were HCV core or NS5A 
negative. 
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Figure 4.6.  Double staining of CD4+ and CD8+ T lymphocytes in vitro infected with 
patient-derived HCV with anti-NS5A and anti-CD4 or anti-CD8 antibodies. (A) Affinity-
purified CD4+ cells and (B) affinity-purified CD8+ T cells from A/M healthy donor were 
exposed to healthy donor plasma (HDP), as a negative control, or HCV-16 inoculum and 
cultured as described in Materials and Methods.  The cells were stained with anti-CD4 or 
anti-CD8 mAb, counterstained with DAPI and subsequently incubated with anti-NS5A 
mAb (see Materials and Methods).  The images were captured at X 60 magnification.  
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4.5 Buoyant Density of HCV RNA-Reactive Particles Released by De Novo Infected 
T Cell Subsets 
 To characterize the biophysical properties of HCV RNA-reactive particles 
released by de novo infected CD4+ and CD8+ T cells and compare them to those of 
virions occurring in the plasma serving as HCV inocula, supernatants collected from the 
infected CD4+ and CD8+ T cells and a sample of respective inoculum used for their 
infection were ultracentrifuged over an iodixanol gradient and 300 μL fractions were 
collected, as described in Section 3.6.1. 
 The analysis of the fractions obtained after density gradient ultracentrifugation of 
HCV-11/M inoculum (Experiment III) showed that HCV RNA-reactive particles 
occurred in fractions 8, 10, 11, 12, 13, 14, 15, and 16, corresponding to iodixanol 
densities of 1.138, 1.104, 1.088, 1.076, 1.060, 1.039, 1.025, and 1.017 g/cm3, respectively 
(Figure 4.7 A).  The peak of HCV RNA positivity was detected in fraction 13 and 14 at 
iodixanol densities of 1.060 and 1.039 g/cm3 with PDU of 4.24 and 3.94, respectively 
(Figure 4.7 A).  In the culture supernatant of CD4+ T cells infected with HCV-11/M 
(Experiment III) and collected at 10 d.p.i., HCV RNA-reactive particles were found in 
fractions 10 and 16 at densities 1.104 and 1.017 g/cm3 with the peak of HCV RNA 
positivity at fraction 16 with 1.00 PDU (Figure 4.7 A).  In the same experiment, culture 
supernatant of CD4+ T cells exposed to HCV-11/M and recovered at 14 d.p.i. 
demonstrated HCV RNA reactivity only in fraction 4 at a density of 1.225 g/cm3 and 0.77 
PDU.  In the supernatant collected from HCV-11/M infected CD8+ T cells obtained at 7 
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Figure 4.7.  Buoyant density in a iodixanol gradient of HCV particles produced by in 
vitro infected CD4+ and CD8+ T cells.  (A) Culture supernatants collected at 10 and 14 
days post-infection (d.p.i.) from CD4+ T cells and at 7 d.p.i. from CD8+ T cells infected 
with HCV-11/M (Experiment III) and (B) at 14 d.p.i. from CD4+ T cells and at 10 d.p.i. 
from CD8+ T cells infected with HCV-16 inoculum (Experiment VI) were concentrated 
by ultracentrifugation (see Materials and Methods).  The resulting pellets were suspended 
in AIM-V culture medium (500 μL) and layered over a 4.5 mL continuous 10-50% 
iodixanol gradient and ultracentrifuged as described in Material and Methods, in parallel 
with 50 μL heat-inactivated HCV-11/M (A) or HCV-16 in (B) diluted with 450 μL AIM-
V medium.  Sixteen 300 μL fractions were collected starting from the top of each gradient 
and all fractions were evaluated for HCV RNA by RT-PCR/NAH.  In parallel iodixanol 
gradients, culture AIM-V medium alone (500 μL) was fractionated under identical 
conditions and collected fractions were used for measuring iodixanol density (g/cm3).  
Contamination and specificity controls are marked and they were the same as those 
outlined in the legends to Figures 4.1 and 4.2. The density of the signals obtained from 
nucleic acid hybridization was enumerated using a Pharos FX plus molecular imager 
system and expressed in pixel density units (PDU).  
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d.p.i., HCV particles were detected at fraction 16 at density 1.017 g/cm3 and 10.16 PDU 
(Figure 4.7.A). 
Analysis of HCV-16 inoculum (Experiment VI), showed that HCV RNA-reactive 
particles were present in fractions 1, 3, and 9 throughout to 16, corresponding to 
iodixanol densities of 1.348, 1.252,  and 1.114 to 1.017 g/cm3 (Figure 4.7 B).  The peaks 
of HCV RNA positivity were detected in fractions 9, 13, and 14 at densities of 1.114, 
1.060 and 1.039 g/cm3, with PDU of 17.04, 17.90, and 19.46, respectively.  In culture 
supernatant of CD4+ T cells exposed to HCV-16 (Experiment VI) and collected at 14 
d.p.i., HCV RNA reactivity was identified in fractions 3 and 9 at densities of 1.252 and 
1.114 g/cm3 with PDU of 1.04 and 1.46, correspondingly.  With regards to culture 
supernatant of CD8+ T cells exposed to the same inoculum (Experiment VI), obtained at 
10 d.p.i., HCV RNA-positive particles were detected in fractions 11 and 16 at densities of 
1.088 and 1.017 g/cm3, and PDU of 0.49 and 1.79, respectively.   
In summary, HCV RNA-reactive particles exhibited variable buoyant densities 
ranging from 1.017 to 1.348 g/cm3 with the HCV RNA-positive particles released by de 
novo infected CD4+ and CD8+ T cells peaking at different densities in comparison to that 
of particles harbored in the plasma serving as HCV inocula.  These differences in 
biophysical properties between HCV particles released by infected T lymphocytes and 
those occurring in inocula used to infect these cells were consistent with the de novo 
production of the virus. 
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4.6 HCV Genome Clonal Sequencing. 
 To determine whether HCV replication in the in vitro infected CD4+ and CD8+ T 
cells led to the emergence of unique HCV variants distinct from those occurring in the 
plasma used as inocula, 5’-UTR amplicons from plasma and PBMC of 11/M patient, and 
from affinity-purified CD4+ and CD8+ T cells infected with HCV 11/M were cloned, and 
20 clones from each amplicon were bidirgenectionally sequenced and compared. 
  Clonal sequencing analysis of the 244-bp 5’-UTR fragment showed that apart 
from an insertion at position 126, which was found in both HCV-11/M (5% of clones) 
and HCV-11/M-infected CD4+ T cells (Experiment I) obtained at 10 d.p.i. (5% of clones), 
the remaining (29) variants identified in infected CD4+ and CD8+ T cells represented 
unique nucleotide changes not found in HCV-11/M (Table 4.4). 
 Among 30 variants identified in infected CD4+ and CD8+ T cells, 17 were 
detected in CD4+ T cells.  Most variants (24 of 30) were identified in only 5% (1 out of 
20) of clones tested, while in some cases, the percentage of clones carrying a unique 
variant (i.e., SNP) was relatively high, e.g., C to T change at position 115 was found in 
40% (8 of 20) clones derived from CD8+ T cells collected at 7 d.p.i. (Experiment III).  
Majority (27 of 30) of variants identified was found in one immune cell subtype with the 
exception of 3 SNPs which were common among CD4+ and CD8+ T cells.  Thus, in 
Experiment V, a T to C change at position 144 was observed in both CD4+ and CD8+ T 
cells at 7 d.p.i., and an A to G substitution at position 252 was identified in both CD4+ T 
cells and CD8+ T cells collected at 7 and 14 d.p.i., respectively.  Furthermore, a T to C  
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substitution at position 282 was detected in CD4+ T cells obtained at 10 d.p.i. 
(Experiment III) and also in CD8+ T cells acquired at 7 d.p.i. (Experiment V). 
 Finally, no variants were identified amongst the clones of the amplicon from the 
in vivo infected PBMC of patient 11/M, as the sequence of all 20 clones was identical to 
the master sequence detected in HCV-11/M inoculum (plasma).    
In summary, unique HCV variants were identified in de novo infected CD4+ and 
CD8+ cells at all timepoints tested and at variable percentages.  Some of these variants 
were common in both CD4+ and CD8+ T cells in the same or different experiments. All of 
these variants, with the exception of an insertion at position 126, were unique to the de 
novo infected cells and not identified in the inoculum used for their in vitro infection. 
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CHAPTHER FIVE: DISCUSSION  
 
 Research on HCV lymphotropism has been ongoing for nearly two decades 
resulting in an accumulating amount of data through various in vivo and in vitro studies.  
As mentioned in Section 1.5.2, several studies have reported the in vivo susceptibility of 
total PBMC to HCV infection.  These works have documented the detection of HCV 
RNA positive and negative strands, and/or HCV proteins in PBMC of patients with AHC 
or CHC (Willems et al., 1994; Lerat et al., 1996; Chang et al., 1996; Gong et al., 2003; 
Pham et al., 2008).  The expression of HCV RNA negative strand was found to be greater 
in PBMC from CHC than ACH (Chang et al., 1996; Gong et al., 2003), implying that 
HCV replication in the lymphoid cells may be involved in supporting chronic infection.  
As previously discussed (Section 1.5.2), HCV infection of the PBMC has also been 
reported in patients with apparent spontaneous or treatment-induced resolution of 
hepatitis C (Pham et al., 2004; Radkowski et al., 2005; Pham et al., 2005, 2008; Callegos-
Orozco et al., 2008; MacParland et al., 2009; Pham et al., 2012; Chen et al., 2013, 2015). 
 With regards to the possible propensity of HCV to preferentially infect certain 
PBMC subsets in vivo, several studies have found HCV replication to be more commonly 
observed in, if not restricted to, CD19+ B cells (Lerat et al., 1998; Morsica et al., 1999; 
Pal et al., 2006).  In other works, in vivo HCV replication extended among various 
immune cell subtypes, including CD4+ and CD8+ T cells, B cells, monocytes and 
dendritic cells (Pham et al., 2004; 2008; Pawełczyk et al., 2013) with levels of viral 
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replication varying among different cell types depending on the clinical status of the 
patients i.e., CHC or OCI (Pham et al., 2008).   
 In vivo infection of immune cells is further supported by findings of numerous 
clonal sequencing analyses and by the results from examination of single-stranded 
conformational polymorphism (SSCP).  Thus, it has been reported that HCV variants 
detected in PBMC were distinct from those in serum or liver of patients with CHC, which 
supports their extrahepatic origin (Maggi et al., 1997; Navas et al., 1998; Laskus et al., 
2002; Ducoulombier et al., 2004; Roque-Afonso et al., 2005; Di Liberto et al., 2006; 
Pham et al., 2008, 2012; MacParland et al., 2009; Durand et al., 2010; Chen et al., 2013, 
2015).  Furthermore, non-random compartmental distribution of HCV quasispecies within 
PBMC subsets has been documented (Roque-Afonso et al., 1999), as well as HCV 
genotypic compartmentalization within immune cell subsets persisting for years, even 
after liver transplantation (Roque-Afonso et al., 2005).  With regards to the effect of 
sequence variations on virus properties, it has been reported that B cells of patients with 
OCI harbor HCV IRES variants that are characterized by a lower translational efficiency 
in hepatocytes than plasma and liver-specific variants (Durand et al., 2010).  Such 
findings not only suggest that the origin of these variants is extrahepatic, but also imply 
that there may be competition between hepatotropic and non-hepatotropic HCV IRES 
variants, which is driven at the translational level.  In this regard, the notion of 
translational control of cellular tropism has been previously described for polioviruses 
(Kauder et al., 2004). 
 In patients with CHC, detection of HCV replication extends beyond the lymphoid 
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cells in circulation.  Thus, HCV negative strand, as well as HCV core and NS3 proteins 
have been detected in biopsy specimens from perihepatic lymph node (LN) in patients 
with chronic HCV infection where  B cells were identified as the main site of HCV 
replication (Pal et al., 2006).  In the same study, quasispecies analyses showed that the 
HCV replication in the LN contributed greatly to the total level of viremia.  In another 
study, HCV RNA presence has been documented in the cerebrospinal fluid (CSF) of 
patients co-infected with HCV and HIV (Bagaglio et al., 2005), as well as in autopsy 
brain tissue from HCV-positive patients with or without HIV coinfection (Radkowski et 
al., 2002).  In the latter study, it was also shown that HCV variants harbored in the brain 
were different than those circulating in the serum and identical to these found in the LN.  
This study also implied that HCV can replicate in the central nervous system (CNS), 
probably in resident-macrophages of blood monocytic origin.  HCV negative strand as 
well as HCV structural and NS proteins have also been detected in pluripotent 
hematopoietic CD34+ cells purified from the bone marrow (BM) of patients with CHC 
(Sansonno et al., 1998).  In the same study, it was observed that when these cells were 
cultured in the absence of growth factors there was a spontaneous increase in viral titers 
in both cell and their culture supernatants, indicating that CD34+ cells and, therefore, BM 
in general can support the full HCV life cycle.   
 Apart from the large body of in vivo experimental and clinical evidence, 
accumulating data from numerous in vitro studies further lend support to the concept of 
HCV lymphotropism.  It was shown that HCV virions released from SB B cell line, 
established from the splenocytes of an HCV-positive patient with type II MC and 
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monocytoid lymphoma, were able to infect  primary human CD4+ T cells (Kondo et al., 
2007) as well as T cell lines (Molt-4 and Jurkat) (Kondo et al., 2009).  In addition, several 
studies reported that serum containing HCV was able to infect T cell lines.  Thus, it was 
shown that authentic, plasma occurring HCV could infect Molt-4 T cells (Shimizu et al., 
1992; Sarhan et al., 2012a, 2012b), HPB-Ma T cells (Shimizu et al., 1993), H9 T cells 
(Nissen et al., 1994), and Jurkat T cells (Sarhan et al., 2012a, 2012b).  As discussed in 
Section 1.10.2.5, research performed in this laboratory has shown that intact, plasma 
occurring HCV can infect PBMC-enriched T cells (MacParlant et al., 2006).  Apart from 
T cells, it has been shown that HCV-positive sera can also infect DC (Navas et al., 2002), 
as well as human primary macrophages/monocytes (Caussin-Schwemlin et al., 2001; 
Laskus et al. 2004; Radkowski et al., 2004).    
 To our knowledge, in vitro infection of primary human CD4+ and CD8+ T 
lymphocytes with authentic, patient-derived HCV has not been documented prior to this 
study.  For our purposes, we adopted the in vitro HCV replication system previously 
established in this laboratory in which mitogen-induced T cell cultures derived from total 
PBMC from healthy donors served as targets for wild-type HCV (MacParland et al., 
2006), as summarized in Section 1.10.2.5.   Instead of monocyte-depleted PBMC we used 
affinity-purified CD4+ and CD8+ T cells as targets aiming to document in vitro infection 
of these immune cell subsets by HCV.  In this culture system, stimulation of target cells 
with PHA prior to exposure to HCV is crucial as data have shown that pre-treatment of 
cells with PHA increases their susceptibility to HCV infection, as well as expression of  
HCV negative strand, implying  increased replication of the virus (Pham et al., 2004, 
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2005; MacParland et al., 2006).  Another critical point in our system was the process 
applied for the identification of the HCV inocula that would be most suitable for in vitro 
infection of lymphoid cells (Section 3.1).  Furthermore, we used highly sensitive assay 
techniques that allowed detection of low levels of HCV infection.  In addition, it is 
noteworthy that we utilized several experimental approaches in order to document 
authentic HCV replication in CD4+ and CD8+ T cells. Thus, we considered the existence 
of productive replication only when HCV RNA negative (replicative) strand, as well as 
HCV structural and/or non-structural proteins, were detected.  In addition, we strived to 
characterize the biophysical properties of HCV RNA-reactive particles produced by the 
de novo-infected CD4+ and CD8+ T cells and to compare them to those of virions 
circulating in the plasma serving as HCV inocula.  Finally, we aimed to assess whether 
HCV variants harbored in the de novo infected CD4+ and CD8+ T cells differ from those 
occurring in the patient plasma used as HCV inocula.   
 In this study, affinity-purified human primary CD4+ and CD8+ T lymphocytes 
exposed to native HCV were found to be susceptible to HCV infection.  In particular, 
HCV RNA vegetative (positive) and negative strands were detected in these in vitro 
infected cells.  Since HCV replicates via synthesis of the HCV RNA negative strand, 
detection of this replicative intermediate accounts for a direct evidence of active viral 
replication in the target cells.  Thus, active replication was documented in both CD4+ and 
CD8+ T cells and in 50% of experimental timepoints (d.p.i.) tested.  On the other hand, 
HCV RNA positive strand was detected in CD4+ and CD8+ T cells in the vast majority 
(93%) of timepoints (d.p.i.) examined.  Such difference in detection of HCV RNA 
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positive and negative strand is expected, as it is known that the HCV RNA positive strand 
could be a 100-1000-fold more abundant than the negative strand in the infected cells 
(Laskus et al., 1998; Komurian-Pradel et al., 2004; Pawelczyk et al., 2013).  These results 
can be further explained by the difference in sensitivity between the assay used for the 
detection of HCV RNA positive strand versus that used for HCV RNA negative strand 
identification, with the latter being approximately 10-100-fold less sensitive.  
 Moreover, the expression of HCV RNA negative strand did not always correlate 
with that of the positive strand at a certain timepoint.  This observation may be reflecting 
virions attached to the cell surface.  For this reason, we do not merely rely on detection of 
HCV RNA positive strand but always employed the negative strand-specific assay, which 
specifically detects this replicative strand.  This assay maintains its specificity for up to 
105 copies per reaction of the correct (negative) strand (Figure 3.5; Pham et al., 2004; 
Sarhan et al., 2012a).  
 It is notable that expression of both strands fluctuated not only between 
experiments, but also amongst timepoints of the same experiment.  Such fluctuation can 
be explained by the low levels of HCV infection coinciding with HCV positive and 
negative strands expression at levels very close to the threshold of detection.  
Furthermore, our in vitro system used freshly isolated primary normal cells and authentic 
virus contained in patient plasma in place of cell line and a cloned virus aiming to reflect, 
as closely as feasible, the in vivo infection of CD4+ and CD8+ T cells.  
 Our finding that de novo infected primary human CD4+ T cells can support active 
replication of HCV, as evidenced by detection of virus RNA positive and negative strands 
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and proteins, has been supported by the findings reported by another group (Kondo et al., 
2007).  As previously mentioned, HCV RNA positive and negative strands have been 
detected in CD4+ T cells isolated from PBMC of healthy donors which were exposed to 
HCV in vitro (Kondo et al., 2007).  In this study, however, HCV virions released in 
culture from SB cells but not authentic, patient-derived virus were used to infect the 
CD4+ T cells.  Our results are also in agreement with previous findings from this 
laboratory (Pham et al., 2008), which showed that HCV RNA positive and negative 
strands and virus proteins were detected in CD4+ and CD8+ T cells which were affinity 
purified from the PBMC of patients with CHC or OCI.  It is evident from these combined 
data that HCV can replicate in CD4+ and CD8+ T cells both in vivo and in vitro.  
 Through our study, we further ascertained that the detection of HCV RNA in 
CD4+ and CD8+ T cells is indicative of active HCV replication by identification of HCV 
core and NS5A proteins via confocal microscopy in the de novo infected cells.  Notably, 
as the NS proteins are not constitutive elements of HCV virions, the detection of the 
NS5A protein within the infected CD4+ and CD8+ T cells provides further compelling 
evidence of ongoing, productive HCV infection.  As previously reported (Pham et al., 
2008; Pawelczyk et al., 2013), no correlation was found between the intracellular display 
of HCV proteins and virus RNA negative strand expression, possibly owing to the low 
level of HCV replication.  Our findings of HCV NS5A protein detection within CD4+ and 
CD8+ T lymphocytes are in accordance with the previous work from this laboratory 
demonstrating that HCV replication takes place in CD4+ and CD8+ T cells of patients 
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chronically infected with HCV or those with OCI (Pham et al., 2008).  This provides 
further evidence that these immune cells constitute sites of persistent HCV propagation. 
 The ability of de novo infected CD4+ and CD8+ T cells to support infection of 
authentic HCV is further demonstrated in our study by comparing the biophysical 
properties of HCV RNA-reactive particles released by the infected cells versus those 
harbored in the inocula used for their infection.  More specifically, ultracentrifugation of 
the inocula HCV-11/M and HCV-16 resulted in recovery of HCV RNA throughout a 
wide variety of densities.  Such variability was expected as it has been extensively 
reported that buoyant densities of HCV RNA-reactive particles can vary greatly among 
patients (Nielsen et al., 2006; 2008).  This heterogeneity can be due to the presence of 
variable ratios of virions and virus cores, and their association to variable degrees with 
immunoglobulins and lipoproteins (Nielsen et al., 2006).  However, we observed a 
different and much less heterogeneous buoyant density profile of HCV RNA-reactive 
particles in the supernatants of the de novo infected cells than that of inocula used for 
their infection.  Thus, most of the HCV RNA-reactive particles present in the inocula 
displayed buoyant densities not observed in T cells supernatants, while particles of other 
densities were more predominant in the supernatants than in plasma serving as inocula.  
Such difference of density profiles may imply that the viral particles released from the de 
novo infected T cells exhibited different biophysical properties compared to HCV 
particles in the plasma.  This might be due to the possibility that HCV in plasma serving 
as inocula originated predominantly from hepatocytes and possibly to the interaction with 
different host protein and lipids.  Similar studies have been previously performed in this 
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laboratory (MacParland et al., 2006, 2009).  These studies came to the same conclusion, 
although they applied different fractionation procedures of HCV RNA-reactive particles.  
Overall, our observation that the HCV RNA-reactive particles released from the de novo 
infected lymphocytes differed in their biophysical profiles compared to those contained in 
inocula is in agreement with the conclusion that new HCV virions were produced.  
 Finally, the emergence of unique HCV variants in the sequence of the highly 
conserved 5’-UTR region of the HCV genomes detected in the de novo infected cells 
lends further support to the fact that primary CD4+ and CD8+ T cells are susceptible to 
infection with authentic HCV.  The evolution in the virus sequence can take place only 
when the virus is replicating.  Therefore, the appearance of unique SNPs in infected cells 
in our study reaffirms that there was active HCV replication.  It is notable that some of 
the SNPs were observed in both T cell subtypes in either the same or different 
experiments, and other SNPs were present at relatively high frequencies.  Our findings 
are in agreement with previous data originating from this laboratory where distinct 
variants appeared in enriched T cells derived from PBMC de novo infected with authentic 
HCV in culture under the same experimental conditions (MacParland et al. 2009).   
 It is notable that some of the variants that we observed have also been identified 
by others.  Thus, the insertion of C at the nucleotide position 126 (126insC), which we 
observed in 5% of the clones derived from inoculum HCV-11/M as well as in 10% of 
clones in CD4+ T cells at 10 d.p.i. in Experiment I, has also been identified in the LNs 
and cerebellum, but not in the serum, of a patient with CHC (Radkowski et al., 2002).  
Similarly to our work, the samples carrying this insertion were HCV RNA negative strand 
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reactive.  Interestingly, 126insC has also been detected in the pretransplant PBMC but not 
serum samples of two patients with CHC (Laskus et al., 2002).  In one of these patients, 
this mutation was seen in the post-transplant serum where it was maintained for up to 2 
weeks post-liver transplantation, suggesting the extrahepatic origin of this variant.  In the 
other patient, this mutation was lost from serum as early as one week post-liver 
transplantation.  Furthermore, the substitution of C by T at nucleotide position 183 
(C183T), which we found in 20% of CD8+ T cell-derived clones at 10 d.p.i. in 
Experiment I, has also been observed in monocytes, but not in the serum, of an HCV-
positive patient with concomitant detection of HCV RNA negative strand in these cells 
(Radkowski et al., 2002).  In another study (Laskus et al., 1998), C183T mutation was 
observed in the PBMC but not the serum of an HCV-infected patient.  In the same study, 
C183T was found in matching serum and PBMC samples from two HCV-positive 
patients.  Taken together, the variants identified both in vivo in the studies mentioned 
above and in our in vitro de novo infection system suggest that these variants may reflect 
evolution of HCV sequence over the course of replication in nonhepatic cells.  Thus, they 
provide further evidence that CD4+ and CD8+ T cells support HCV replication.   
 Overall, we documented in this study that authentic, intact HCV can replicate in 
normal human primary CD4+ and CD8+ T cells by showing: (1) The expression of HCV 
replicative strand in the de novo infected cells, (2) Intracytoplasmic localization of virus-
specific structural and NS proteins, (3) Emergence of new HCV variants in infected cells, 
and (3) Release of HCV RNA-reactive particles by the infected cells with distinct 
biophysical properties. 
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 It would be reasonable to assume that HCV exposure and/or replication in CD4+ 
and CD8+ T cells could have an effect on their function.  Research on the consequences 
of HCV infection on T cell function is very limited.  It has been reported that in vitro 
infection of primary CD4+ T cells with a lymphotropic HCV strain (SB-HCV) affected 
their IFN-γ /STAT-1/T-bet signaling leading to inhibition of IFN-γ production (Kondo et 
al., 2007, 2011).  In the same study, it was shown that the SB-HCV replication in primary 
CD4+ T cells suppressed their proliferation, as well as their development towards Th1 
lineage.  In another study, it was shown that infection of the MOLT-4 T cell line with SB-
HCV inhibited cell proliferation and enhanced Fas-mediated apoptosis (Kondo et al., 
2009).  In addition, work from this laboratory (MacParland et al., 2015b) reported that 
authentic, patient-derived HCV inhibited CD4+ but not CD8+ T cell proliferation in the T 
cell infection model previously described (MacParland et al., 2006), which was also 
applied in the current study (Section 1.10.2.5).  Interestingly, the results of the 
aforementioned study also implied that just exposure to HCV in the absence of detectable 
evidence of its replication was efficient to exert an inhibitory effect on CD4+ T cell 
proliferation.  Finally, it has been shown that HCV core protein upregulated the 
expression of anergy-related genes in Jurkat T cells stably expressing this protein 
(Dominguez-Villar et al., 2007).  This expression profile was accompanied by activation 
of the NFAT transcription factor and suppression of the IL-2 promoter activity. 
 Apart from the studies mentioned, the expected direct effect of HCV replication 
on T cell cytokine profile, cell fate, and functions remains under investigation.  
Nonetheless, in the setting of CHC, HCV-specific CD4+ and CD8+ T cells are 
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characterized by impairment of their effector functions (Rehermann, 2009).  CD4+ T cells 
produce less IL-2 and IFN-γ and this decrease is concomitant with cytotoxicity 
impairment and overall dysfunction of CD8+ T cells (Francavilla et al., 2004).  It has been 
suggested that decreased production of IL-2 by CD4+ T cells may be associated with 
compromised CD8+ T cell cytotoxicity (Golden-Mason et al., 2007).  Furthermore, as 
mentioned in Section 1.7.2.2, HCV-specific T cells express high levels of PD-1 
(Radziewicz et al., 2007; Golden-Mason et al., 2007) with CD8+ T cells also expressing 
increased levels of  Tim-3 (a negative immune regulator), and low levels of CD127 
(Golden-Mason et al., 2009).  Binding of PD-1 to its ligand leads to inhibition of effector 
functions and apoptosis of HCV-specific T cells (Shin et al., 2006).  It has been suggested 
that increased expression of PD-1 on HCV-specific T cells might be a result of chronic 
antigenic stimulation, since it subsides following mutation of virus epitopes recognized 
by T cells (Rutebemberwa et al., 2008).  Functional deregulation of immune cell subtypes 
other than CD4+ and CD8+ T cells coinciding with CHC has been described in Section 
1.9.3.  The relationship between immune cell dysfunctions and HCV replication in these 
cell subsets warrants further investigation. 
 Apart from impairment of functionality, HCV infection of immune cells may have 
significant clinical implications.  In particular, by targeting and establishing a low level 
infection in immune cells, the virus may be impairing the efficiency of immune responses 
preventing viral clearance and favoring chronicity.  Therefore, infected immune cells may 
serve as viral reservoirs from where HCV may continue to replicate and where the 
emergence of distinct variants may be favored.  It is conceivable that these strongholds of 
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infection may play a role in recurrence of symptomatic HCV infection after liver 
transplantation and spontaneous or treatment-induced resolution of hepatitis C (Pham and 
Michalak, 2008; Pham et al., 2010).  Furthermore, HCV infection of immune cells could 
be playing a significant role in the several extrahepatic disorders of autoimmune and/or 
lymphoproliferative nature frequently observed in patients with CHC (Section 1.8).  
 In conclusion, our study lends further support to an increasing body of in vivo and 
in vitro data supporting the propensity of HCV to infect immune cells.  It is of great 
importance to further investigate the molecular mechanisms underlying susceptibility of 
immune cells to HCV, as well as the consequences of HCV infection on functionality of 
these cells.  Such studies could help us elucidate the role of immune cell infection in 
natural progression and pathogenesis of HCV infection.  Furthermore, it would be of 
great value to identify whether elimination of the virus from the lymphoid compartment 
could be conducive to success of long-term outcomes of anti-HCV therapies. 
  
 155 
 
CHAPTER SIX: SYMMARY AND CONCLUSIONS 
 
 In this study, we hypothesized that authentic HCV is capable of in vitro infecting 
primary human CD4+ and CD8+ T lymphocytes, which are the central cells in the 
adaptive, including antiviral, immune responses.  For this purpose, we employed an in 
vitro HCV replication system previously established in this laboratory in which mitogen-
stimulated T cell cultures derived from total PBMC served as targets for native, plasma 
occurring HCV (MacParland et al., 2006, 2009) (Section 1.10.2.5).  In our studies, 
instead of monocyte-depleted PBMC as the source of total T cells, we used affinity-
purified CD4+ and CD8+ T cells as targets of HCV infection. 
 A pivotal point in this culture system employed was the use of PHA to stimulate 
target cells, as it is known that PHA increases susceptibility of lymphocytes to HCV 
infection (Pham et al., 2004, 2005; MacParland et al., 2006, 2009, 2015b).  Another 
crucial parameter in our study was the process of selecting the most suitable HCV inocula 
for our in vitro infection experiments (Section 3.1), as well as the use of highly sensitive 
HCV RNA detection techniques.  
 In our study, we were able to clearly demonstrate that native, molecularly intact 
HCV is capable of establishing infection of both CD4+ and CD8+ T lymphocytes by 
documenting: (1) Presence of HCV RNA positive and negative (replicative) strands in the 
cells from all experiments performed; (2) Expression of HCV core and NS5A proteins in 
the cytoplasm of the de novo infected cells; (3) Identification of HCV variants in the de 
novo infected cells not detected in the inoculum used for their infection (some of these 
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variants have been previously identified in the extrahepatic compartments), and (4) 
Release of HCV RNA-reactive particles from the de novo infected CD4+ and CD8+ 
lymphocytes exhibiting different biophysical properties from the particles contained in 
inocula used to infect the cells.  
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CHAPTER SEVEN: FUTURE DIRECTIONS 
 
 In our study, it was documented that authentic, intact, patient-derived HCV is 
capable of replicating in human primary CD4+ and CD8+ T lymphocytes by using a 
multiparametric detection approach. 
 It would be of great interest to compare the molecular and biophysical properties 
of the virions produced from the de novo infected T cells with that produced by B cells 
and monocytes.  HCV variants emerging in the different immune cell subpopulations 
could be fully sequenced and their sequences compared to each other and to that 
contained in inocula used for their infection in order to identify mutations reflecting virus 
potential adaptation to a given lymphoid cell compartment.  To get a more complete 
picture, these sequences should also be compared to variants isolated from the respective 
fractionated immune cell subtypes isolated from the donors providing these HCV inocula, 
as well as to variants circulating in plasma.  Perhaps ex vivo stimulation of these immune 
cells with mitogens would provide a more relevant comparison, as it would upregulate 
HCV replication in these cells.   
 Furthermore, it would be intriguing to compare the ability of different HCV 
inocula to infect T cells.  In particular, it would be interesting to uncover whether there is 
a difference between various HCV genotypes and subtypes or even between HCV inocula 
carrying different variants and their capacity to infect T cells.  
 Finally, it would be of great value to use our system in order to further study the 
direct effect of HCV replication on CD4+ and CD8+ T cell function.  More specifically, 
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the expression of certain antiviral and functionally important genes could be evaluated via 
real-time RT-PCR or microarray analysis (MacParland et al., 2015a) as it was recently 
initiated in this laboratory.  Similar evaluation should be performed on cells isolated from 
patients naturally infected with different HCV genotypes. 
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Appendix 2.  Location of SNPs in the HCV 5’-UTR sequences detected in CD4+ and CD8+ T 
cells in vitro infected with genotype 1a HCV-11/M. The SNP positions and sequence changes are 
highlighted in orange. The SNPs also identified by others (Laskus et al., 1998, 2002; Radkowski 
et al., 2002) are denoted within red squares. The nucleotide positions numbered according to 
HCV genotype 1a with GenBank accession number M67463. Image modified from Prabhu R. et 
al., 2006. 
 
